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i 
Abstract 
Rare disorders affect less than one in 2000 individuals, placing a huge burden on 
individuals, families and the health care system. Gene discovery is the starting point in 
understanding the molecular mechanisms underlying these diseases. The advent of next-
generation sequencing has accelerated discovery of disease-causing genetic variants and 
is showing numerous benefits for research and medicine. I describe the application of 
next-generation sequencing, namely LipidSeq™ ‒ a targeted resequencing panel for the 
identification of dyslipidemia-associated variants ‒ and whole-exome sequencing, to 
identify genetic determinants of several rare diseases. Utilization of next-generation 
sequencing plus associated bioinformatics led to the discovery of disease-associated 
variants for 71 patients with lipodystrophy, two with early-onset obesity, and families 
with brachydactyly, cerebral atrophy, microcephaly-ichthyosis, and widow’s peak 
syndrome. Understanding these variants and their contribution to disease can increase 
understanding of disease mechanisms and help with the development of therapeutic 
interventions in the future. 
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Chapter 1 – Introduction 
1.1  Rare disease burden in Canada 
In Canada, rare diseases are defined as conditions affecting less than one in every 2000 
individuals1. Rare disorders place a significant burden on individuals, their families and 
the health care system, as there is often a lack of specialized services, social awareness, 
and clinical recognition. Furthermore, Canadian families with rare diseases face 
extraordinary challenges, including countless futile medical tests, unnecessary surgeries, 
financial hardships, social isolation, shortages in treatment options, and early mortality. 
In the case of rare diseases, the term “diagnostic odyssey” describes the burden of these 
diseases on the individual, familial and systemic levels. The diagnostic odyssey details 
the time between the first concerns of a rare disorder to the time when a diagnosis is 
made2. In the diagnostic odyssey, more than half of the affected individuals with rare 
diseases are children, with 30% not living to see their fifth birthday. Further, 40% of 
individuals with rare diseases will receive an incorrect diagnosis, 25% will wait 5‒25 
years for a diagnosis, and 50% will never be diagnosed in the course of their lifetime3. 
Ultra-rare diseases – those limited to a handful of individuals – are often referred to as 
“orphan diseases”. The term orphan disease describes an exceptionally rare disease 
historically neglected by the pharmaceutical industry, due to the assumed low financial 
incentive in devising proper treatments or cures. Because orphan diseases may affect only 
single individuals, families or communities, these individuals face even greater 
challenges than those with more prevalent rare diseases. Furthermore, these diseases are 
often chronically debilitating and life threatening4. With the hardships facing the 
individuals, their families and the health care system, and the lack of treatment options 
available, there is a pressing need to study rare diseases, and develop novel therapeutic 
interventions. 
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1.1.1 Many rare diseases are of genetic origin 
To date, there are an estimated 7000 rare diseases. As most of these 7000 rare diseases 
are predicted to be of genetic origin due to severity and familial recurrence, gene 
discovery is the critical starting point for the understanding of the molecular mechanisms 
underlying these diseases, the development of targeted treatments, and the end of the 
diagnostic odyssey for these patients. Developing therapies is crucial, as fewer than five-
percent of the 7000 rare diseases known-to-date offer effective therapeutic interventions5.  
Previously, rare disease research was limited to standard genetic techniques including 
homozygosity mapping and candidate gene sequencing6. Although these were largely 
successful in identifying the molecular bases of >3500 rare disorders, limitations 
including time requirements and high costs have led to the advent of new and improved 
technologies, and the use of next-generation sequencing (NGS) – deoxyribonucleic acid 
(DNA) sequencing technologies capable of rapidly generating a massive amount of DNA 
sequence data – in rare disease studies7.  
1.1.2 Research problem and motivation 
Although the genetic basis of many rare diseases has been clarified using genetic 
techniques, many rare diseases, rare disease subtypes and orphan diseases remain 
genetically unexplained. With the success of NGS in elucidating the genetic basis of 
numerous rare diseases, I propose the use of NGS technologies in rare disease cases not 
previously subjected to NGS. By using these modern NGS technologies, my goal is to 
identify genetic determinants underlying several genetically unexplained rare diseases. 
Understanding these genetic variants and their contribution to disease can increase 
understanding of disease mechanisms and pave the way for the development of novel 
treatments in the future. 
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1.2  Rare human genetic diseases 
There are many illustrative examples of rare human genetic diseases, notably 
lipodystrophy, extreme early-onset obesity, brachydactyly, and autosomal recessive 
cerebral atrophy. Further, research consortiums such as CARE for RARE 
(CARE4RARE) and Finding of Rare Disease Genes in Canada (FORGE Canada) 
collectively pursue research on the molecular basis of rare diseases.  
1.2.1 Inherited lipodystrophies 
Lipodystrophies are rare disorders characterized by selective and variable loss of adipose 
tissue, with excess accumulation of fat in otherwise unusual sites including the liver and 
muscle8. This results in a generalized muscular appearance with hypertrophy often arising 
in the extremities, more specifically, in the calves and arms. The genetic form of 
lipodystrophy is familial, and includes congenital generalized lipodystrophy (CGL) and 
familial partial lipodystrophy (FPLD). Affected individuals are predisposed to insulin 
resistance, which often progresses to other metabolic complications including diabetes, 
hypertension, metabolic syndrome and hypertriglyceridemia9. Furthermore, individuals 
with lipodystrophy are vulnerable to severe metabolic derangements including acute 
pancreatitis, hepatic cirrhosis and premature cardiovascular disease10. Women with 
severe lipodystrophy often acquire polycystic ovary disease and suffer from infertility, 
highlighting the aggressiveness of the disorder11. Although the global prevalence is less 
than one in a million, milder forms of lipodystrophy are commonly misdiagnosed as 
common central obesity or metabolic syndrome, suggesting that lipodystrophy is an 
underestimated condition12. This is concerning as a clear diagnosis of lipodystrophy can 
allow for earlier care, better management, and improved prognosis. 
1.2.1.1 Congenital generalized lipodystrophy 
First reported by Berardinelli and Seip in 1954 and 1959, CGL, also known as complete 
lipodystrophy or Berardinelli-Seip syndrome, is an extremely rare (less than one in 12 
million people) disorder characterized by the absence of metabolically active adipose 
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tissue from birth13,14. Due to the absence of functioning adipocytes, lipids are stored in 
unusual sites in the body such as the liver and muscle, subsequently leading to a marked 
muscular appearance.  
As the more severe form of the inherited lipodystrophies, individuals with complete 
lipodystrophy generally present with insulin resistance, rapid aging of bones, hepatic 
steatosis, hypertriglyceridemia, early-onset diabetes and high blood pressure, often 
developing into metabolic syndrome. In addition, individuals with CGL acquire 
hepatomegaly and skeletal muscle hypertrophy; hypertrophic cardiomyopathy is also 
reported in 25% of individuals and is a common cause of mortality8. 
To date, there is no cure for CGL. Treatment is through cosmetic procedures, diet, 
hypoglycemic drugs and lipid-lowering drugs. With regards to medication, the 
management of CGL is through the medicated treatment of each symptom. Although 
there has been recent success in CGL treatment with Metreleptin – a leptin replacement 
that aids in the control of metabolic processes in the body, such as triglyceride and blood 
sugar management – this drug has yet to be approved in Canada. 
1.2.1.2 Familial partial lipodystrophy 
The second, milder form of lipodystrophy is FPLD, characterized by the selective loss of 
adipose tissue from the body (most often the limbs) during childhood or puberty. 
Although affected regions may include the face, neck and extremities, the body fat in the 
intra-abdominal or truncal region are often spared, and some individuals present with 
excess fat deposition in the face and neck15. Most individuals presenting with FPLD in 
the clinic are females, with the metabolic complications more severe in women. Most 
women remain fertile; however, some women present with hirsutism and polycystic 
ovary syndrome, leading to fertility issues. Additionally, some patients develop 
cardiomyopathy, myopathy, and features of multisystem dystrophy16,17.  
Similar to CGL, the treatment for FPLD includes lifestyle modifications including diet 
changes and exercise. Again, the treatment revolves around treating each individual 
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symptom (i.e. Metformin for diabetes, statins for high cholesterol) rather than the disease 
as a whole18. 
1.2.2 Extreme early-onset obesity 
Extreme early-onset obesity, or excess adiposity, is defined as a body mass index 
[(weight in kilograms ÷ height in meters)2] greater than or equal to the 85th and 95th 
percentile for gender and age, respectively. In Canada, childhood-onset obesity is a 
pressing health concern with the rates having tripled over the last three decades. 
Currently, approximately one in seven children are obese, with rates depending on factors 
such as age, biological sex, location of residence, and socioeconomic status19. As obesity 
is a significant risk factor for coronary heart disease, high blood pressure, ischemic stroke 
and diabetes, it places a major toll on children and their families. This burden is 
especially apparent in the health care system, as early-onset obesity is associated with 
increased incidence of adult obesity, hepatic steatosis, and cardiovascular disease. For the 
first time in history, the complications associated with obesity are leading to a decrease in 
life expectancy of 2‒5 years20. 
In the past, obesity was mainly attributed to environmental changes, specifically the 
intake of high-energy food in combination with a sedentary lifestyle. In recent years, the 
heritability of obesity has been established, with genetic factors explaining most 
differences between populations21. In fact, obesity risk in children is 10-fold greater when 
both parents are obese than when both parents are of a normal weight21. Aside from 
lifestyle alterations and medications for the management of associated co-morbidities (i.e. 
high blood pressure, diabetes), there is no direct treatment or cure for extreme early-onset 
obesity. 
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1.2.3 Isolated brachydactyly 
Brachydactyly is an inherited malformation characterized by the shortening of the fingers 
and toes due to deficiencies in the development of the phalanges, metacarpals, and/or 
metatarsals. Although brachydactyly can be a common feature in complex malformation 
syndromes, there are many cases of congenital, isolated forms of brachydactyly. These 
isolated brachydactyly syndromes represent one of the ten categories of hand 
malformations as classified by Temtamy and McKusick22. The prevalence of isolated 
brachydactyly is rare, with the exception of types A3 and D, where prevalence varies 
between populations, reportedly averaging around 2%23. Aside from these exceptions, 
most forms of brachydactyly are limited to a few pedigrees. In addition to shortened 
fingers and toes, other features of brachydactyly include short stature, syndactyly (fused 
digits), polydactyly (extra digits), and symphalangism (stiff digits) depending on the 
subtype (Table 1.2.3). Although brachydactyly is best diagnosed using genetic testing, it 
can also be diagnosed using clinical, anthropometric and radiological means. Treatment 
for brachydactyly is strictly cosmetic, through elective surgeries. 
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Table 1.2.3. Clinical features of isolated brachydactyly. 
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1.2.4 Cerebral atrophy 
Neurodegenerative diseases are diseases characterized by the progressive loss of neural 
cells from the brain. Although some neurogenerative diseases are more prevalent, such as 
Alzheimer disease, many neurodegenerative diseases are rare, such as the ataxias or 
spastic paraplegias24,25. Cerebral atrophy, the loss of neurons and neuronal connections in 
the brain, is a common feature of many rare neurodegenerative diseases. In 2013, my 
laboratory described a case of autosomal recessive cerebral atrophy, a novel 
neurodegenerative disorder in an Old Order Amish family. In this specific case of 
cerebral atrophy, the affected individuals featured additional symptoms including 
microcephaly, seizures and psychomotor retardation26. Cerebral atrophy is diagnosed 
through radiological imaging of the brain. 
1.2.5 FORGE Canada and CARE for RARE 
In Canada, two Consortiums study the genetic basis of over 200 rare diseases with 
pediatric onset. These coalitions, FORGE Canada and CARE4RARE, represent the first 
and second phases of a nationwide project led by Dr. Kym Boycott and Dr. Alex 
MacKenzie of the Children’s Hospital of Eastern Ontario Research Institute.  
1.2.5.1 Project overview 
The goal of the previous FORGE Canada and current CARE4RARE project was to study 
the genetic causes of over 200 rare diseases affecting children. In order to do this, the 
organizers formed a consortium composed of 21 research sites and hospitals, 80 
physicians, and 50 scientists. The approach of the project was to use high power DNA 
sequencing in order to identify novel disease genes. The recruitment of this project, 
which ended in March 2017, included over 4000 patients with 950 different rare 
diseases27.  
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Several criteria required satisfaction in order to qualify for either the FORGE Canada or 
CARE4RARE Projects. These criteria included the following: 
1) Unrelated patients and/or families with the same disorder OR, 
2) Single families with multiple affected family members (+/‒ consanguinity) AND, 
3) Meet the following inclusion sub-criteria: 
a. Onset is in childhood or adolescence 
b. The disease is most likely due to a single gene (monogenic) 
c. DNA is accessible for the proband and available family members 
d. Clinical material is of high quality 
1.2.5.2 Project significance 
In sum, the FORGE Canada Project has identified mutations in disease genes for 105 of 
362 families. Further, since 2011, the CARE4RARE Project has successfully resulted in 
the publication of 139 manuscripts on the discovery of 135 novel disease-causing 
genes27. These results have provided closure and ended the diagnostic odyssey for the 
individuals and the families through the provision of a diagnosis.  
1.2.5.3 FORGE Canada and CARE for RARE cases 
The Blackburn Cardiovascular Genetics Laboratory has been involved in several FORGE 
Canada and CARE4RARE Projects. There are currently 11 projects in progress, namely: 
FORGE 214 (Angelman-like syndrome), FORGE 122 (Dystonia, ataxia and intellectual 
disability), FORGE 11 (Osteopetrosis), FORGE 352 (Microcephaly-ichthyosis), C4R 572 
(Autosomal dominant isolated cryptophthalmos), C4R 573 (Widow’s peak syndrome), 
C4R 575 (Amyoplasia), C4R 592 (Metaphyseal chondrodysplasia), C4R 664 
(Craniosynostosis), C4R 907 (Heterotaxy disorder), and C4R 924 (Craniorachischisis). 
The details of each case are listed in Table 1.2.5.3. 
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Table 1.2.5.3. Clinical description and pedigrees for all CARE for RARE and 
FORGE Canada cases. 
Case Clinical Description Pedigree 
FORGE 214, 
Angelman-like 
syndrome 
 Three children equally 
affected, parents are 
healthy first cousins with 
Iraqi ancestry 
 Features include: 
significant global 
developmental delay, 
delayed speech, 
repetitive behaviour and 
similar physical features 
such as triangular face, 
wide mouth, pointed 
chin and fifth finger 
clinodactyly 
 
 
FORGE 122, 
Dystonia, ataxia and 
intellectual 
disability* 
 Three affected siblings 
with a progressive, 
childhood-onset ataxia 
syndrome 
 Not known to be 
consanguineous 
 Features include: 
progressive gate ataxia 
beginning between ages 
2-5, wheelchair-bound 
by early adolescence and 
dysarthria 
 Two oldest siblings are 
non-verbal with limited 
responsiveness and 
minimal spontaneous 
movement 
 
FORGE 11, 
Osteopetrosis 
 Old Order Mennonite 
and Low-German 
Speaking Mennonite 
families 
 Features include: optic 
atrophy, macrocephaly, 
mid-facial hypoplasia, 
micrognathia, abnormal 
eruption of teeth, broad 
halluces and short stature 
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FORGE 352, 
Microcephaly-
ichthyosis*A  
 Old Order Amish 
families 
 Additional features 
include: failure to thrive, 
feeding difficulties, 
developmental delay, 
lethality in the first year 
of life, enlarged 
ventricles and early 
delivery around 33 
weeks gestation 
 Recurrence in the family  
 
C4R 572, Autosomal 
dominant isolated 
cryptophthalmos  
 Female child born to 
term to non-
consanguineous parents 
 Female displays 
complete bilateral 
isolated 
cryptophthalmos, a 
condition resulting in the 
overgrowth of skin over 
the eye  
 
C4R 573, Widow’s 
peak syndrome* 
 Non-consanguineous 
family 
 Widow’s peak syndrome 
features: a characteristic 
widow’s peak hairline, 
delayed development, 
inability to touch the 
shoulders, dysmorphic 
face and the inability to 
supinate the arms 
 
C4R 575, 
Amyoplasia 
 Three unrelated families 
with amyoplasia, 
characterized by a 
generalized lack of 
muscular development 
and growth in newborns 
 Both probands present 
with severe muscle 
hypoplasia  
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C4R 592, 
Metaphyseal 
chondrodysplasia 
 Metaphyseal 
chondrodysplasia 
features short stature 
with abnormally short 
arms and legs 
 No abnormal facial 
features were present in 
the patients of interest 
 
 
C4R 664, 
Craniosynostosis* 
 Non-consanguineous 
family 
 Craniosynostosis is a 
birth defect resulting in 
the abnormal 
development of the skull 
 Digital anomalies also 
present 
 
C4R 907, Heterotaxy 
disorder 
 Two affected children 
born to consanguineous 
parents of Lebanese 
descent 
 Disorder features: 
heterotaxy with 
holoprosencephaly, 
bilateral ectopic thymus, 
fused kidneys, annular 
pancreas, bi-lobed right 
lung, absent olfactory 
nerves, dysplastic optic 
nerves and chiasm and a 
single umbilical artery 
 
C4R 924, 
Craniorachischisis* 
 Stillborn baby presented 
with craniorachischisis, a 
severe neural tube defect 
with anencephaly and 
spina bifida 
 
  
 
 
 
 
 
 
For each pedigree, biological males are represented as squares and biological females as circles. Shaded shapes indicate the individual is affected with the disorder. 
Double lines indicate consanguineous relationships. In some pedigrees, hashed lines represent individuals in which sequencing has been performed. When shown, 
asterisks represent patients in which DNA is available.  
Abbreviations are as follows: FORGE, Finding of Rare Disease Genes Canada project. 
*The red asterisk represents the projects I was directly involved in or was working with undergraduate students on. The remaining cases without an asterisk are those 
in which I assume an administrative role. 
ANote: for the microcephaly-ichthyosis pedigree, the shaded shapes are individuals clinically diagnosed with microcephaly-ichthyosis, the shapes with vertical curved 
lines are those with histidyl-tRNA synthetase disorder, the horizontal curved lines are individuals with congenital hypoventilation syndrome, and the shape filled with 
the plus sign is an individual clinically diagnosed with cystinosis. 
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1.3  The human genome sequence 
In the year 1990, the International Human Genome Sequencing Consortium, composed of 
public and private researchers, began the publically funded Human Genome Project, a 
13-year project with the goal of determining the DNA sequence of the human genome. 
With the sequencing of over three billion base pairs and approximately 21,000 genes, the 
group of researchers began a revolution in the fight against human disease by introducing 
a trove of genetic information applicable for numerous fields including developmental 
biology, physiology, evolution and medicine28,29.  
1.3.1 Variation within the human genome 
Human genetic variation refers to the genetic differences within and among populations. 
A variant form of a gene is an allele, where humans inherit one allele from each parent at 
each genetic locus, or position. Each pair of alleles represent the genotype of a gene, 
which can be classified as homozygous or heterozygous, referring to two identical alleles 
or two different alleles, respectively. Genetic variation is manifested as single nucleotide 
changes, insertions and deletions, repetitive elements and structural rearrangements of the 
DNA sequence30. A mutation is a permanent change in the DNA sequence. The term 
genetic “variant” has been gaining popularity over the term “mutation” in the field, and 
refers to a benign or pathogenic alteration, or one of unknown significance.  
Many decades prior to the availability of DNA sequencing technology or the sequence of 
the human genome, researchers first became aware of differences in the genome through 
the study of chromosome number and structure31. This led to the advent of molecular 
biology, a multifaceted field in biology with one branch focused on the structure and 
function of nucleic acids and proteins essential for life. Research into molecular biology 
gave way to the understanding of the variation present in the human genome, notably the 
implications of this variation and relationship to disease. Now, with the sequence of the 
human genome available, researchers are able to study the impact of variation in the 
genome, where the variation is composed of single nucleotide changes, insertions and 
deletions, copy-number variations, repeat variations, and structural variations, all with 
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potential disruptive effects on the genome. Although some variation can be benign, some 
defects in the genome can cause genetic diseases, health conditions caused by variation in 
the genome.  
1.3.1.1 Single nucleotide variation 
Single nucleotide variations (SNVs) are the most common class of genome variation, 
with single nucleotide changes occurring approximately once every 500–1000 nucleotide 
bases in the human genome sequence32. Each SNV represents a change in a single DNA 
building block or a nucleotide base – composed of Thymine, Adenine, Cytosine and 
Guanine, often shortened to T, A, C and G – commonly referred to as point mutations. 
An example of a SNV may be a replacement of a Thymine with a Cytosine (T>C) in a 
specific stretch of DNA. When these SNVs occur in a region coding for an amino acid 
(three nucleotides, also referred to as a codon), these SNVs can result in either 
synonymous (no change in amino acid) or non-synonymous changes (change from one 
amino acid to another).  
The wobble effect is the effect caused by the redundancy of the genetic code. More 
specifically, each amino acid (with the exception of methionine and tryptophan) may be 
coded by multiple codons, or multiple three letter codes composed of A, T, C or G. As 
there are more codons than amino acids, the third base is not as discriminatory for the 
amino acid as the first two bases. Due to the redundancy in the DNA code, many SNV 
changes are tolerated or inconsequential. However, in certain cases, these changes can 
lead to pathogenic missense or nonsense changes, referring to a change in one amino acid 
to another, or a change in one amino acid to one coding for the truncation of a protein 
downstream. 
Due to the high frequency of these SNVs in the genome and the fact that some SNVs are 
seen in approximately 1% of the population, SNVs often act as biological markers or 
contribute to phenotypic traits (observable and measurable features)33. For example, 
personal differences in SNPs may cause alterations at the level of the cell, or influence 
drug metabolism. In some circumstances, SNVs are associated with disease and act by 
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driving a disease phenotype (the observable characteristics of an individual) or 
contributing to phenotypic traits. These disease-causing SNVs are most often exonic, 
non-synonymous SNVs – those in the coding region causing a substitution in amino acid. 
1.3.1.1.1 Splicing variation 
Splicing is the editing of precursor messenger ribonucleic acid (mRNA) to mature 
mRNA. During splicing, introns (nucleotide sequences in a gene discarded during 
splicing) are removed, and exons (the part of the gene that codes for the final mRNA, 
which is translated into protein) are ligated together. Splice site mutations refer to genetic 
variants that insert, delete or change the nucleotides in the specific region where splicing 
takes place. As these variants can result in the retention of intronic DNA in the mRNA or 
result in the loss of exons from mature mRNA, variants in the splice site can have large 
effects on human health and disease. In fact, an estimated 15-50% of human disease 
variants are those that alter splicing elements34. An example of a mutation in a splice site 
leading to disease is seen in hypoparathyroidism, where a G to C substitution in the first 
nucleotide base of intron 2 in the parathyroid hormone gene (PTH) causes exon skipping 
(the loss of an exon), and parathyroid hormone deficiency35. 
1.3.1.1.2 Insertions and deletions 
Another form of variation present at the nucleotide level are micro insertions or deletions 
affecting 1‒50 base pairs, collectively known as “INDELs”. In terms of occurrence, 
INDELs represent a common alteration in the genome, second only to SNVs36. These 
INDELs alter the number of DNA bases in a gene by either adding or removing a piece 
of DNA. When occurring in functionally important sites in the human genome, these 
INDELs are likely to influence human traits or drive disease36. A notable example is Tay-
Sachs disease in the Ashkenazi Jewish, where a four base pair insertion (c.1278insTATC) 
alters the reading frame of the hexosaminidase A gene (HEXA)37. This mutation leads to 
an infantile form of Tay-Sachs disease where the most common features include 
deterioration of both mental and physical abilities, and mortality approximately at the age 
of four. INDELs can either occur inframe when in a multiple of three (deletion or gain in 
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amino acids) or out-of-frame, where there is a change in amino acids downstream of the 
insertion or deletion, with a possible inframe occurrence of a stop codon. This is referred 
to as a frameshift and may alter or abolish the function of the resulting protein. Further, 
INDELs can result in aberrant splicing when occurring in splice sites. 
1.3.1.2 Repetitive elements 
The human genome consists of millions of copies of transposable elements (TE) and 
other repetitive sequences, altogether contributing up to two-thirds of the human 
genome38. These repetitive elements – most commonly tandem repetitive elements or 
interspersed repetitive elements that do not encode proteins – are labelled “junk” DNA. 
Although considered junk or inconsequential, a growing body of evidence has been 
accumulating in recent years clarifying the role of these repetitive regions in the 
regulation of gene expression39. Continued research into these repeat sequences is 
exploiting the role of these elements in gene expression. 
Although most repetitive elements in the genome are harboured outside of the coding 
region, some repeat sequences lie within genes and are subject to mutation. For example, 
triplet repeat expansions (TREs) – trinucleotide repeats (i.e. CAGCAGCAG) abnormally 
expanded in certain genes or introns – are dynamic mutations that occur in regions with 
trinucleotide repeats. These TREs are the cause of TRE disorders such as Fragile X 
syndrome or Huntington’s disease.   
1.3.1.3 Structural variation 
Structural variation (SV) affects a region of DNA approximately one kilo base (1-kb) or 
larger40. SVs, including inversions, balanced translocations or genomic imbalances, have 
long been associated with chromosomal rearrangements and genetic disorders. SVs can 
arise through various mechanisms including non-allelic homologous recombination (HR), 
non-homologous end joining (NHEJ), or replication-error41.  
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1.3.1.3.1 Copy-number variation 
Copy-number variation (CNV) is a form of structural variation where there is a change in 
copy-number involving a DNA fragment over 1-kb40. CNVs can include deletions, 
insertions or duplications present in variable copy-number in comparison to the reference 
genome. As CNVs are regions of variable copy number, they may change gene 
expression levels, and alter transcription levels to values higher or lower than expected in 
a reference genome. Due to the change in gene expression, CNVs may play a large role in 
phenotypic variation. Further, since CNVs encompass significantly more nucleotide 
content per genome than single nucleotide polymorphisms (SNPs; up to 10-fold greater 
or up to 12% of the genome), CNVs play an important role in genetic diversity, disease 
and evolution42,43. 
1.3.2 Germline versus somatic variation 
Germline variation is defined as variation present in the germline, or the tissue involved 
in forming sex cells. As a mutant sex cell may participate in fertilization, germline 
variation may be passed on from parent to offspring44. In contrast, somatic variation 
occurs in a single cell in developing somatic tissue. By definition, somatic cells are those 
that are never transmitted from parent to progeny44. As cells are constantly dividing and 
genetic material is continually replicated over the course of a lifespan, mistakes in 
replication can accumulate in somatic cells through a lifetime45. Although many of these 
variants do not have a phenotypic effect, some may alter key cellular functions by 
affecting normal protein function and drive certain human diseases. Early somatic 
variants – those occurring during embryogenesis – can also contribute to developmental 
disorders, cancer or aging.  
1.3.3 Inherited versus de novo variation 
Variation can arise in the genome through two mechanisms. Inherited variation are DNA 
changes transmitted from parent to offspring. Specifically, each egg and sperm cell 
contribute half of the genetic information needed to produce an offspring. When the egg 
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and sperm join during fertilization, a new cell is formed, composed of all the necessary 
genetic information needed to form an individual. This leads to variation passed on from 
parent to progeny.  
On the other hand, de novo variation are DNA changes that are spontaneous (through 
DNA replication errors or spontaneous lesions) or induced (caused by mutagens such as 
radiation or chemical substances) in an offspring’s genome, not inherited from either 
parent. These de novo genetic alterations may be acquired any time post-zygotically 
(during the lifespan). This variation is de novo as the variation is not present in either 
parental genome.  
Both inherited and de novo variation may provide meaningful contributions to disease. 
More specifically, diseases may be caused by inherited variation, or de novo variation. 
An example of inherited variation causing disease is hemophilia A, where multiple 
generations in a family inherit a variant in the coagulation factor VIII gene (F8) and 
present with a severe bleeding disorder. In contrast, de novo variation is best exemplified 
in severe early-onset pediatric diseases, where the causative mutations only arise post-
zygotically given that they are lethal in the germline and/or individuals with these 
mutations do not reproduce46. 
1.4   Human genetic diseases 
Although there are diseases that occur through bacterial infection or exposure to viruses, 
it is estimated that most human diseases have a genetic component. A genetic disease is 
any disease attributed to abnormality in the human genome. These genetic diseases can 
range from minor to severe and can be due to any of the aforementioned variation. In this 
section, I describe the heritability of human genetic diseases. 
1.4.1 Heritability of genetic diseases 
Heritability refers to the ratio of genetic variation (VG) to phenotypic variation (VP); a 
fundamental tool used in the study of the inheritance of human disease that is able to 
partition the phenotypic variation into both genetic and environmental components47. Put 
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simply, heritability is a statistic that is used to determine the proportion of variation in a 
trait within a population that can be explained by genetics (rather than environment or 
random chance). This is modelled through the following equation: 
Phenotype (𝑃) = Genotype (𝐺) + Environment (𝐸) 
There are two definitions of heritability48. The first, H2 or broad-sense, refers to the 
genetic contributions to phenotypic variance through additive (phenotypic contributions 
from more than one gene or alleles of a single gene, where the sum of the effects of both 
alleles is equal to the sum of their effect individually), dominance (the relationship 
between alleles of one gene where the effect of one allele masks the other, leading to a 
phenotypic effect) and epistatic genetic effects (the phenomenon where one gene relies 
on other modifier genes, where the sum of the effects in combination do not equal the 
sum of the effects individually). 
𝐻2 =
Var(𝐺)
Var(𝑃)
 
The second definition, h2 or narrow sense, captures the proportion of genetic variation 
due to additive genetic effects (A; contributions from more than one gene or alleles of a 
single gene acting synergistically). 
ℎ2 =
Var(𝐴)
Var(𝑃)
 
Heritability of disease can also refer to the mode in which transmission occurs. Diseases 
can be monogenic, digenic or polygenic, and involve variable penetrance, each defined in 
the following sections. 
1.4.1.1 Monogenic diseases 
Monogenic diseases, or single gene disorders, are those caused by variants within a single 
gene. These variants can be inherited in a family; can be dominant or recessive, and 
autosomal or sex-linked. These modes of inheritance refer to the manner in which genetic 
traits are passed from one generation to the next. The modes of inheritance include: 1) 
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autosomal dominant; 2) autosomal recessive; 3) X-linked; 4) Y-linked; 5) codominant or; 
6) mitochondrial. Their definitions are as follows: 
1) Autosomal dominant: when one copy of a gene in a cell harbours a variant. This 
may be transmitted from one parent to an offspring or inherited de novo. 
2) Autosomal recessive: when both copies of a gene in a cell carry variants. One 
copy is transmitted paternally and one copy is transmitted maternally to the 
offspring. 
3) X-linked: when variants are harboured in genes on the X chromosome(s), one of 
the two sex chromosomes that can be present in the genome. Note that normally 
biological males have one X and one Y chromosome, and biological females have 
two X chromosomes. 
4) Y-linked: when variants are harboured on the Y chromosome, with transmission 
only possible from the paternal parent to a male offspring. 
5) Codominant: when two different alleles of a gene are expressed and each 
influence the genetic trait. 
6) Mitochondrial: when genes in mitochondrial DNA carry variants and are 
transmitted through maternal inheritance. 
Monogenic diseases can also be considered Mendelian diseases, defined as diseases 
where alternative genotypes fall into distinct phenotypic classes, according to Gregor 
Mendel’s laws of inheritance49. One example of a monogenic disease is cystic fibrosis, 
caused by a variant in the cystic fibrosis transmembrane conductance regulator gene 
(CFTR) with an autosomal recessive mode of inheritance. 
1.4.1.2 Digenic diseases 
Digenic diseases are those where the disease phenotypes are caused by a combination of 
variants in two genes, or two separate phenotypes caused by variants in two different 
genes acting synergistically50. To cause disease, these genes may interact directly, 
21 
 
 
indirectly, through a common pathway, through co-expression, or through similar 
function. Due to the prevalence of digenic diseases, a common resource known as the 
Digenic Diseases Database (DIDA) is accessible, containing information on over 40 
digenic diseases and over 200 digenic combinations51. The first reported example of a 
digenic disease was retinitis pigmentosa, where double heterozygotes with variants in the 
peripherin 2 (RDS) and retinal outer segment membrane protein 1 (ROM1) loci displayed 
the disorder52. 
1.4.1.3 Polygenic diseases 
Polygenic diseases are defined as genetic disorders caused by a combination of 
abnormalities in more than one gene. Due to the fact that they are attributed to variants in 
more than a single gene, they are inherited differently than monogenic disorders (as 
described in Section 1.4.1.1). In humans, polygenic diseases are more frequent than 
monogenic disorders, and have a greater economic burden. Due to the multiple gene 
(multigenic) nature of these diseases, different methods have been developed to study 
these diseases. These approaches include: 1) the use of a priori data or a set number of 
genetic loci, or 2) the complete analysis of all available loci53. These may take the form 
of case-control studies or genome-wide association studies (GWASs), respectively, 
where case-control studies refer to the comparison of affected and healthy subgroups, and 
GWASs refer the analysis and determination of similarities in genome-wide data of an 
affected cohort. Association studies require the selection of several candidate genes in 
order to carry out association analysis53. Illustrative examples of polygenic disease are 
the familial dyslipidemias, such as coronary heart disease and diabetes. These are 
polygenic as they are associated with multiple genes, and are not inherited as simply as 
single gene disorders54. 
1.4.1.4 Disease penetrance and expressivity 
Disease penetrance and expressivity refer to factors that influence genetic changes. 
Explicitly, penetrance refers to the proportion of individuals with a genetic change who 
phenotypically exhibit a genetic disorder. When some individuals with the genetic variant 
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do not display all or some of the features of a disorder, the condition is said to have 
incomplete or reduced penetrance. Incomplete penetrance is demonstrated in cases of 
breast cancer, where variants in the breast cancer, DNA repair associated 1 or 2 genes 
(BRCA1 or BRCA2) may cause cancer in some individuals over the course of a lifetime, 
but not others55.  
On the other hand, expressivity is defined as the degree in which the expression of a trait 
differs among individuals. This is exhibited when individuals with the same phenotype 
display varying severity of a disease; or in other words, the disease exists on a spectrum. 
For example, variable expressivity is seen in Marfan syndrome where some individuals 
have mild symptoms (tall and thin features with slender fingers), while some experience 
additional features such as life-threatening heart and blood vessel complications. 
Although this disorder displays variable expressivity, most individuals with Marfan 
syndrome carry variants in the fibrillin 1 gene (FBN1)56. 
1.5  Genetic variation and rare diseases 
For the rare genetic diseases described earlier – namely, lipodystrophy, extreme early-
onset obesity, brachydactyly, autosomal recessive cerebral atrophy, and those ascertained 
from the CARE4RARE and FORGE Canada consortiums – although many cases of these 
diseases have been genetically explained with causative variants identified, the genetic 
etiology of many remain unknown. In this section, I describe the known genetics of these 
diseases and unexplained cases in my laboratory.  
1.5.1 The genetics of lipodystrophy 
Over the years, many genetic variants have been associated with lipodystrophy. As the 
defective gene often causes a distinct lipodystrophy phenotype, both CGL and FPLD 
have been divided into subtypes. 
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1.5.1.1 Congenital generalized lipodystrophy 
There are four subtypes of CGL based on previously identified genes; denoted as CGL1‒
4. CGL commonly follows an autosomal recessive mode of inheritance. Although each 
subtype features the complete loss of adipose tissue, different subtypes present with 
distinct characteristics57: 
1) CGL1: characterized by the absence of metabolically active adipose tissue from 
birth, CGL1 is associated with variants in the 1-acylglycerol-3-phosphate O-
acyltransferase 2 gene (AGPAT2), a gene encoding an enzyme required for 
phospholipid and triglyceride biosynthesis. 
2) CGL2: featuring the lack of adipose tissue from birth, mild mental disability and 
cardiomyopathy, CGL2 is associated with variants in the seipin lipid droplet 
biogenesis associated gene (BSCL2) encoding seipin, a protein that may play a 
role in adipocyte differentiation. 
3) CGL3: reported in a single patient, CGL3 features the absence of body fat, 
shortened stature and vitamin D resistance. CGL3 is correlated with variants in 
the caveolin 1 gene (CAV1) encoding the caveolin 1 protein, an integral 
component of caveolae on adipocyte membranes. 
4) CGL4: featuring the absence of body fat with congenital myopathy and 
cardiomyopathy, CGL4 is associated with variants in the polymerase I and 
transcript release factor gene (PTRF; also referred to as cavin) associated with the 
biogenesis of caveolae. 
Lipid droplets are defined as organelles responsible for the storage of triglycerides. 
Playing a fundamental role in metabolism, the reduction or lack of lipid droplets cause 
the lipodystrophies58. With each form of CGL, although each are attributed to distinct 
genes, all gene products are involved in adipocyte lipid droplet formation. Further, each 
form of CGL is associated with low leptin (the hormone of energy balance) as a result of 
the lack of adipose tissue. This results in excess triglycerides and high blood sugar. 
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1.5.1.2 Familial partial lipodystrophy 
As in the case of CGL, FPLD also exists in various forms (FPLD1–5) with subtypes 
defined based on their associated gene(s). Generally, FPLD follows an autosomal 
dominant mode of inheritance. Similar to CGL, each subtype features a similar pattern in 
adipose tissue loss but various additional characteristics57: 
1) FPLD1: a genetically unexplained form of FPLD, characterized by the loss of 
subcutaneous fat from the extremities. 
2) FPLD2: a form of FPLD featuring the loss of subcutaneous fat from the 
extremities and truncal region from puberty. FPLD2, or Dunnigan variety, is 
associated with variants in the lamin A gene (LMNA) encoding the lamin A 
protein, where deleterious mutations result in the premature death of adipocytes.  
3) FPLD3: characterized by the loss of subcutaneous fat from the extremities, 
principally from the distal regions. FPLD3 is associated with variants in the 
peroxisome proliferator-activated receptor gamma gene (PPARɣ), encoding a 
transcription factor required for adipogenesis.  
4) FPLD4: reported in a single family, FPLD4 features the loss of subcutaneous fat 
from the extremities. This subtype of FPLD4 is associated with variants in the 
AKT serine/threonine kinase 2 gene (AKT2) encoding protein kinase B, involved 
in adipocyte differentiation and insulin receptor signaling. 
5) FPLD5: a subtype of FPLD featuring fibrosis of adipose tissue and the loss of 
subcutaneous fat from the extremities. FPLD5 is attributed to variants in the 
perilipin 1 gene (PLIN1) encoding an integral constituent of lipid droplet 
membranes, involved in lipid storage. FPLD5 has also been associated with 
homozygous variants the cell death inducing DFFA-like effector C gene 
(CIDEC), encoding a protein required for lipid droplet formation and energy 
storage in adipose tissue. 
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1.5.1.3 Unexplained cases of lipodystrophy 
With the familial lipodystrophies, although many causative gene mutations have been 
identified in affected individuals as described (i.e. LMNA, PPARG, AGPAT2 and BSCL2 
variants), many individuals remain genetically unexplained59,60. Over the years, the 
Blackburn Cardiovascular Genetics Laboratory (Robarts Research Institute, London ON, 
Canada) has been successful in identifying the genetic basis of 120 lipodystrophy-
affected patients using Sanger sequencing. Although this resulted in 44% of 267 
lipodystrophy patients characterized by mutations in lipodystrophy-causing genes, 56% 
of patients remained genetically unexplained after Sanger sequencing.  
1.5.2 The genetics of obesity 
To date, there have been many genes identified that underlie monogenic and polygenic 
obesity. The rare, monogenic forms of human obesity have been critical in the elucidation 
of the pathogenic mechanisms causing obesity. These rare forms of monogenic obesity 
are associated with the following genes: LEP, LEPR, POMC, PCSK1, MC4R, BDNF, and 
NTRK2, where all aforementioned genes and protein products are involved in body 
weight management (described in detail in Table 1.5.2)61-67. Further, all genes encode 
either hormones or neurotransmitters/receptors belonging to the highly conserved leptin-
melanocortin pathway, a critical pathway in the regulation of food intake and body 
weight. 
In contrast to the monogenic forms of obesity where obesity is the main feature, the 
syndromic forms of early-onset obesity are Mendelian disorders with obesity as one 
clinical feature. The additional clinical features may include intellectual disability, 
dysmorphic countenances and developmental abnormalities, generally organ-specific. To 
date, over 30 syndromes have been identified, with Prader-Willi, Bardet-Biedl, Cohen, 
and Alström syndrome as classic examples68-71.  
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Table 1.5.2. Genes involved in the pathophysiology of obesity. 
Gene name Symbol Function 
Leptin LEP Encoding the hormone leptin, this hormone is 
involved in the regulation of body weight. Leptin 
works by attaching to the leptin receptor on the 
surface of organs and tissues, including the 
hypothalamus. The hypothalamus controls states 
including hunger and thirst, and the release of 
hormones through the body. The binding of leptin 
in the hypothalamus triggers a feeling of satiety.  
Leptin receptor LEPR The leptin receptor is a Type I cytokine receptor 
that binds with the hormone leptin. The leptin 
receptor is responsible for the regulation of energy 
metabolism and body weight through interactions 
with gangliosides in the cell membrane. 
Proopiomelanocortin POMC The POMC gene encodes the 
proopiomelanocortin protein, which is cleaved 
into small peptides in the body. These peptides 
then bind to several proteins in the body to trigger 
signaling pathways responsible for functions 
including energy homeostasis, melanocyte 
stimulation and immune modulation. 
Prohormone convertase 1 PCSK1 Encoding a member of the subtilisin-like 
proprotein convertase family, this protein is 
involved in the secretory pathway. More 
specifically, it functions in the proteolytic 
activation of polypeptide hormones and 
neuropeptide precursors. 
Melanocortin 4 receptor MC4R The MC4R gene encodes a membrane-bound 
receptor belonging to the melanocortin receptor 
family. This protein interacts with melanocyte-
stimulating hormones and adrenocorticotrophic 
hormones and plays a role in energy homeostasis 
and somatic growth. 
Brain-derived 
neurotrophic factor 
BDNF This gene encodes a protein found in the brain and 
spinal cord that plays a role in growth, 
differentiation, and maintenance of nerve cells. 
The BDNF protein is localized in brain regions 
responsible for controlling eating, drinking and 
body weight. 
Neurotrophic tyrosine 
kinase receptor type 2 
NTRK2 The NTRK2 gene encodes a membrane-bound 
receptor kinase that phosphorylates both itself and 
members of the mitogen-activated protein kinase 
pathway. Signaling through NTRK2 results in cell 
differentiation.  
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1.5.2.1 Unexplained cases of early-onset obesity 
As in the case of the lipodystrophy patients in the laboratory, the prevalence of 
genetically unexplained cases is also reflected in the early-onset obesity cohort, where 
known obesity-causing genes, POMC, LEP, LEPR, PCSK1 and MC4R, cannot explain 
the phenotype of five patients and/or families with extreme early-onset obesity 
ascertained in the Blackburn Cardiovascular Genetics Laboratory (Robarts Research 
Institute, London ON, Canada)20. In some instances, these patients display variable co-
morbidities (i.e. hyperphagia, intellectual disability) in addition to extreme early-onset 
obesity. 
1.5.3 The genetics of brachydactyly 
Most isolated brachydactyly syndromes display an autosomal dominant mode of 
inheritance, with variable penetrance. To date, several gene mutations have been 
designated as causative for each subtype (Table 1.5.3). Here, I describe subtype 
brachydactyly type A. 
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Table 1.5.3. The genetics of isolated brachydactyly. 
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1.5.3.1 Brachydactyly type A 
As described by Bell in 1951, the hallmark feature of brachydactyly type A is the 
shortening of the middle phalanges72. Type A has been further divided into four subtypes, 
A1 to A4, with each subtype further subdivided into types A to D. 
1.5.3.1.1 Brachydactyly type A1 (BDA1) 
In the early 1900s, Farabee and Drinkwater characterized the first disorder that could be 
explained by Mendelian autosomal dominant inheritance – brachydactyly. In 1963, Haws 
and McKusick continued the analysis on Farabee’s family and associated the condition to 
BDA173. In BDA1, the middle phalanges of all the digits are absent or shortened, with 
shortening of the thumb and big toe. In some instances, the middle and terminal 
phalanges are fused (terminal symphalangism, or fusion of the terminal phalanges), with 
shortening of the metacarpals. Drinkwater found that the shortened phalanges were due to 
the absence of the epiphyses, which subsequently lead to overall shortened stature in 
adulthood22,74,75. BDA1 has been attributed to mutations in the Indian Hedgehog gene 
(IHH), where mutations affect endochondral ossification of the developing bones76-83. 
1.5.3.1.2 Brachydactyly type A1, B (BDA1B) 
Armour et al. described a family with a mild form of brachydactyly that did not fit the 
clinical findings of other families with BDA184. In their family, Armour and colleagues 
described shortened middle and terminal phalanges, with all the digits slightly shortened. 
The feet of this family were also affected, with the children displaying multiple coned 
epiphyses. From this research, Armour et al. highlighted the benefits of using a 
metacarpophalangeal profile in designating clinical status. In 2002, Armour et al. 
performed a linkage study, and mapped the condition to the cytogenetic bands 5p13.3-
p13.285. However, the causative gene and putative mutations have not yet been identified. 
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1.5.3.1.3 Brachydactyly type A1, C (BDA1C) 
 Type A1C was first described by Byrnes and colleagues in a consanguineous French-
Canadian family86. In this subtype of BDA1, individuals displayed markedly shortened 
middle phalanges of the second through fifth digits, and the first terminal phalanx. There 
was also shortening in the first metacarpals resulting in the appearance of a shortened 
thumb. The third to fifth metacarpals were slightly affected, and the feet were affected in 
this family. BDA1C is attributed to a mutation in Growth Differentiation Factor 5 
(GDF5), associated with a decreased effectiveness of chondrogenesis and abnormal 
skeletal morphogenesis87. BDA1C is inherited in an autosomal recessive or dominant 
manner, with recessive mutations causing a more severe phenotype86. 
1.5.3.1.4 Brachydactyly type A1, D (BDA1D) 
In 2015, Racacho et al. described patients with BDA1D, a “BDA1-like” brachydactyly88. 
In the first proband, features included short second digits, curved fifth digits, and 
shortened first and second toes. Upon radiographic analysis, it was found that there was 
absence of the middle phalanges in the index fingers, with shortened middle phalanges in 
the fifth digits. The terminal phalanges of the thumbs were also affected. In the second 
proband, brachydactyly and clinodactyly of the fifth digits and right thumb were reported, 
with abnormally-shaped middle phalanges of the second digit and fifth digit. This 
condition was designated as BDA1-arachnodactyly. Type BDA1D has been associated 
with mutations in Bone Morphogenetic Protein Receptor Type 1B (BMPR1B)88. Where 
the p.K325N mutation acts in a dominant-negative manner. Mutations in BMPR1B result 
in brachydactyly by affecting normal chondrogenesis.  
1.5.3.1.5 Brachydactyly type A2 (BDA2) 
BDA2 is characterized by the absence or shortening of the middle phalanx of the index 
finger and second toe. Rarely, this feature can extend to the fifth digit. In severe cases, 
the middle phalanx is a rhomboid or triangular shape causing the index finger to deviate 
radially. BDA2 is inherited in an autosomal dominant manner, with mutations identified 
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in Bone Morphogenetic Protein 2 (BMP2), BMPR1B, and GDF589-94. The reported 
families are of German, Norwegian, Swiss, Chinese and Polish descent22.   
1.5.3.1.6 Brachydactyly type A3 (BDA3) 
In BDA3, the most common features include the shortening and slanting of the middle 
phalanx of the fifth digit. Due to the characteristic rhomboid or triangular shape of the 
middle phalanx, clinodactyly of the fifth finger is present22. The prevalence of BDA3 is 
quite common, often seen in syndromic forms. The frequency of BDA3 can vary from 
3.4% to 21% in various, isolated ethnic populations22. Although there are multiple 
definitions of BDA3, Hertzog defined BDA3 as requiring the middle phalanx of the fifth 
finger to be less than half the size of the middle phalanx of the fourth digit95.  Williams et 
al. also found that cone-shaped epiphyses in BDA3 are twice as likely in females than 
males, suggesting a strong sex-bias in BDA3 inheritance96. Although there is no 
candidate locus or gene identified to date, BDA3 is inherited in an autosomal dominant 
manner with variable penetrance22.    
1.5.3.1.7 Brachydactyly type A4 (BDA4) 
In 1978, Temtamy and McKusick studied a family with four generations of BDA422. The 
features of this family included the shortening of the second and fifth digits due to 
brachymesophalangy – an abnormal shortening of the middle phalanges. Although the 
fourth finger was not always affected, it displayed an irregularly shaped middle phalanx 
resulting in radial deviation of the terminal phalanx when afflicted. The feet were also 
affected22. BDA4 has been reported multiple times in the literature with added features 
including nail dysplasia, clinodactyly, short stature, and a bifid appearance of the 
thumb97-99. No causative locus or gene for this sub-phenotype has been identified. 
1.5.3.1.8 Unexplained cases of brachydactyly 
To date, various forms of brachydactyly have been characterized and numerous causative 
genes have been found (Table 1.5.3). Although there is much known about 
brachydactyly, many subtypes remain genetically undefined. We introduce a 31-year-old 
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female from Ontario referred to Dr. Hegele’s Endocrinology Clinic (London Health 
Sciences Centre, University Hospital, London ON, Canada) for medical consultation for a 
lifelong history of short stature and shortening of all digits of the upper and lower 
extremities. There was no history of other medical conditions, specifically no nystagmus, 
musculoskeletal abnormalities, developmental delay, or scoliosis. Upon examination, all 
digits of upper and lower extremities were noted to be short, with missing middle 
phalanges and splayed fingers, similar to a brachydactyly type A phenotype. The 
proband’s parents were both of short stature, but only her mother shared identical features 
including very short fingers and toes. Eight maternal aunts and one uncle had all reported 
abnormally shortened fingers of variable severity. One brother and her daughter had 
similarly shortened digits (Figure 1.5.3.1.8). 
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Figure 1.5.3.1.8. Pedigree of a Canadian autosomal dominant brachydactyly-affected family. The black arrow indicates the 
proband. All shaded shapes represent those clinically affected. Biological females are represented by circles and biological males are 
represented by squares.  
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1.5.4 The genetics of autosomal recessive cerebral 
atrophy 
In 2013, our laboratory (Blackburn Cardiovascular Genetics Laboratory) elucidated the 
genetic basis of a novel pediatric neurodegenerative disorder deemed, autosomal 
recessive cerebral atrophy26. Using a combination of homozygosity mapping and exome 
sequencing, Lahiry et al. identified four individuals with a c.995C>T (p.Thr332Met) 
variant in the TMPRSS4 gene encoding transmembrane protease, serine 4, a protein 
involved in numerous biological processes26. 
1.5.4.1 Unexplained cerebral atrophy 
Recently, a second family with a history of disease resembling autosomal recessive 
cerebral atrophy was referred to the Blackburn Cardiovascular Genetics Laboratory from 
India (Figure 1.5.4.1). In this case, the proband presented with microcephaly, severe 
cortical atrophy and widened lateral ventricles. The parents were both clinically 
unaffected with normal brain structure and function. The sister of the proband was also 
affected but passed away prior to genetic testing. 
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Figure 1.5.4.1. Pedigree of a family with cerebral atrophy. Biological males are 
squares and biological females are circles. The arrow indicates the proband, whereas the 
shaded shapes represent those affected by the cerebral atrophy, microcephaly and 
widened lateral ventricles. 
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1.5.5 Genetically unexplained consortium cases 
The Blackburn Cardiovascular Genetics Laboratory is actively working on 11 FORGE 
Canada and CARE4RARE Projects. The rare diseases in the 11 families previously listed 
are all genetically unexplained and require a genetic diagnosis. By using NGS 
technologies, I seek to identify genetic determinants underlying all the genetically 
unexplained rare disease cases ascertained in the Blackburn Cardiovascular Genetics 
Laboratory. 
1.6  Next-generation sequencing and rare diseases 
Since the 1970s, Sanger sequencing has been the gold standard in genetic studies with 
several historical accomplishments, notably the sequencing of the first human genome29. 
However, limitations including time requirements and high costs have led to the advent 
of new and improved technologies, designating Sanger sequencing as first generation 
sequencing100. Over the past five years, we have been in a new era of genomics, where 
NGS methods have become mainstay in genomic research. NGS is an umbrella term used 
to describe all the newer methods, capable of generating a colossal amount of data 
rapidly and efficiently100. It includes three dominant methods used to identify genetic 
variants, namely targeted resequencing, whole-exome sequencing (WES), and whole-
genome sequencing (WGS). 
Today, many platforms exist to perform NGS. Although each company offers a distinct 
method, the general workflow is as follows: 1) template preparation, 2) sequencing and 
imaging, 3) genome alignment and assembly, and 4) genome enrichment. Regardless of 
the company chosen, each method provides a rapid and inexpensive genome-wide 
sequence readout as an output, and allows for characterization of evolutionary 
relationships and the elucidation of the DNA sequence for studies in health and 
disease101. 
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1.6.1 Targeted resequencing 
Targeted resequencing is a method of NGS that works by using NGS chemistry to isolate 
and sequence any number of pre-selected genes from a sample library. With the ability to 
rapidly sequence target genes, these targeted gene panels are able to identify causative 
variants in genomic loci. Targeted resequencing is one of the fastest growing applications 
for NGS technologies. 
1.6.1.1 LipidSeq™ 
An excellent example of a NGS clinical resequencing panel is LipidSeq™, a targeted 
gene panel designed by, and used in, the Blackburn Cardiovascular Genetics 
Laboratory102. The objective of the pilot LipidSeq™ project was to develop a NGS-based 
method to facilitate in the clinical diagnosis of dyslipidemias. Using Illumina 
technologies, this pilot study on LipidSeq™ demonstrated a 95% concordance rate with 
the gold standard, Sanger sequencing, highlighting its diagnostic utility in the clinic. To 
date, over 3,000 DNA samples have been processed using LipidSeq™. 
Currently, the LipidSeq™ panel targets ~73 genes and >180 SNPs associated with 
monogenic dyslipidemias. The LipidSeq™ targets genes involved in lipid metabolism as 
well as genes associated with lipodystrophy and its associated metabolic comorbidities 
(Table 1.6.1.1).  
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Table 1.6.1.1. Details regarding the genes targeted by the LipidSeq™ gene panel 
relating to lipodystrophy and associated metabolic comorbidities.  
Phenotype Gene Function RefSeq 
(NM_) 
Chromosome: 
Start-Stop/ 
Location 
Lipodystrophy LMNA LMNA encodes lamin A and lamin 
C proteins, which contribute to the 
structural network of the inner 
nuclear membrane of cells. 
170707 1:156052369-
156109880/ 
1q22 
PPARG The PPARG gene encodes 
peroxisome proliferator-activated 
receptor-gamma (PPARɣ). This is a 
nuclear receptor, which regulates 
adipocyte differentiation. 
015869 3:12329349-
12475855/ 
3p25.2 
LMNB2 LMNB2 encodes lamin B, a 
component of the structural network 
of nuclear membranes in 
vertebrates. It is important for 
mitotic processes, nuclear stability, 
chromatin structure, and gene 
expression. 
032737 19:2428163-
2456966/ 
19p13.3 
CIDEC CIDEC is a DNA fragmentation 
factor (DFF). In adipocytes, the 
encoded protein contributes to lipid 
droplet formation and plays a major 
role in promoting apoptosis.  
0011996
23 
3:9908394-
9921938/ 
3p25.3 
AKT2 AKT2, an oncogene, encodes a 
serine/threonine kinase with Src 
Homology 2-like domains. It is 
highly expressed in insulin-sensitive 
tissues and regulates hepatic 
metabolism during fasting. 
001626 19:40736224-
40791443/ 
19q13.2 
CAV1 CAV1 encodes caveolin-1, the main 
component in the cavaolae plasma 
membranes of most cell types. 
Caveolin-1 is an integral membrane 
protein, which links integrin 
subunits to proto-oncogene tyrosine 
kinase, FYN, promoting cell cycle 
progression. 
001753 7:116164839-
116201239/ 
7q31.2 
AGPAT2 AGPAT2 encodes a 1-acylglycerol-
3-phosphate O-acyltransferase 
protein, which converts 
lysophosphatidic acid to 
phosphatidic acid during 
phospholipid biosynthesis. This 
protein is localized to the ER. 
006412 9:139567595-
139581911/ 
9q34.3 
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BSCL2 BSCL2 encodes seipin, a 
transmembrane protein that is 
activated during pre-adipocyte 
differentiation and contributes to 
lipid droplet morphology. Seipin is 
localized to the ER. 
0011229
55 
11:62457734-
62477091/ 
11q12.3 
PTRF PTRF encodes cavin, a protein that 
regulates rRNA transcription and 
plays an essential role in caveolae 
biogenesis. Cavaolae, in turn, are 
crucial for signal transduction and 
lipid transport in many cell types. 
012232 17:40554467-
40575506/ 
17q21.2 
LIPE LIPE encodes a hormone-sensitive 
lipase, which exists in two forms, 
depending on the translational start 
codon. Present in steroidogenic 
tissues, the longer form contributes 
to cholesterol processing for steroid 
hormone production. Expressed in 
adipose, the shorter form hydrolyzes 
TGs, thereby regulating the 
mobilization of free fatty acids. 
005357 19:42905664-
42931578/ 
19q13.2 
Werner’s 
Syndrome 
WRN The WRN gene encodes the Werner 
protein, which shows dominant 
nucleolar localization, possesses 
DNA helicase activity (3’ to 5’) and 
also acts as an exonuclease (3’ to 
5’). This protein may also be 
involved with DNA double strand 
break repair. 
000553 8:30890778-
31031277/ 
8p12 
Mature Onset 
Diabetes of the 
Young (MODY) 
HNF4A Hepatocyte nuclear factor-4-alpha 
(HNF4A) is a transcription factor 
belonging to the nuclear receptor 
family. HNF4A is the most 
prominent DNA-binding protein in 
the liver, where it is known to 
regulate genes involved in lipid 
metabolism. The encoded protein 
also controls the expression of 
genes including hepatocyte nuclear 
factor 1 alpha. This gene may also 
play a role in liver, kidney and 
intestine development. 
000457 20:42984441-
43061485/ 
20q13.12 
GCK GCK is expressed in the liver and 
pancreatic islet beta cells and plays 
a significant role in glucose 
metabolism. Glucokinase (GCK) is 
a unique member of the hexokinase 
family where, in metabolic 
pathways, hexokinases 
033508 7:44183870-
44229022/ 
7p13 
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phosphorylate glucose to produce 
glucose-6-phosphate. 
HNF1A Hepatocyte nuclear factor-1-alpha 
(HNF1A) or HNF1 homeobox A is 
thought to aid in the orderly and 
sequential activation of genes 
during development at the level of 
transcription. HNF1 protein is a 
transcription factor that binds to a 
variety of promoters in the liver and 
is required for the expression of 
several liver-specific genes.   
000545 12:121415861-
121440315/ 
12q24.31 
PDX1 Pancreatic and duodenal homeobox 
1 (PDX1) acts as a transactivator 
that binds the TAAT element in the 
promoter region of target genes 
involved in pancreas development. 
The protein encoded by PDX1 is a 
transcriptional activator of several 
genes and plays a significant role in 
glucose-dependent regulation of 
insulin gene expression. 
000209 13:28494168-
28500451/ 
13q12.2 
HNF1B Hepatocyte nuclear factor-1-beta 
(HNF1B) is a transcription factor 
(otherwise known as transcription 
factor-2) that is a member of the 
homeodomain-containing 
superfamily of transcription factors. 
This protein can bind as either a 
homodimer or a heterodimer in 
conjunction with HNF1A. This gene 
has been shown to take part in 
nephron development and regulates 
the development of the embryonic 
pancreas. 
000458 17:36046434-
36105096/ 
17q12 
NEUROD1 Neurogenic differentiation 1 
(NEUROD1) is a basic helix-loop-
helix (bHLH) protein, which acts as 
a transcription factor involved in 
determining cell type during 
development. NEUROD1 (after 
heterodimerization with the 
ubiquitous helix-loop-helix protein 
E47, regulates insulin gene 
expression by binding to a critical 
E-box motif on the insulin 
promoter. 
002500 2:182540833-
182545392/ 
2q31.3 
KLF11 Kruppel-like factor 11 (KFL11) 
encodes a zinc finger transcription 
factor that binds to specificity 
protein 1-like sequences in both 
epsilon- and gamma-globin gene 
003597 2:10170776-
10194963/ 
2q25.1 
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promoters. Their binding inhibits 
cell growth and results in apoptosis. 
CEL Carboxyl-ester lipase (CEL) is a 
major component of pancreatic juice 
and is in charge of the hydrolysis of 
cholesterol and other dietary esters. 
The protein encoded by CEL 
promotes large chylomicron 
production in the intestine and is 
also thought to interact with 
cholesterol and oxidized 
lipoproteins to modulate the 
progression of atherosclerosis.  
001807 9:135936741-
135947250/ 
9q34.2 
 
PAX4 Paired box gene 4 (PAX4) is a 
member of the PAX family of 
transcription factors. This gene 
plays an important role during fetal 
development and cancer growth. In 
addition, it has been found that 
PAX4 is essential for the 
differentiation of insulin-producing 
beta cells in the mammalian 
pancreas. 
006193 7:127250346-
127255982/ 
7q32.1 
INS Consisting of two dissimilar 
polypeptide chains, A and B, and 
linked by two disulfide bonds, 
insulin is synthesized by beta cells 
of the islets of Langerhans. Insulin 
is under the control of a single gene 
locus and binds the insulin receptor, 
stimulating glucose uptake. 
0011850
97 
11:2181009-
2182439/ 
11p15.5 
BLK B-lymphocyte specific kinase (BLK) 
encodes a non-receptor tyrosine 
kinase. These genes are typically 
involved in cell proliferation and 
differentiation. This protein 
stimulates insulin synthesis and 
secretion in response to glucose 
levels and enhances expression 
levels of several pancreatic beta-cell 
transcription factors. 
001715 8:11351521-
11422108/ 
8p23.1 
Hypertriglyceri-
demia (HTG) 
LPL LPL is responsible for the 
breakdown of chylomicron 
triglycerides into two fatty acids and 
a monoacylglycerol along the 
luminal surface of capillaries in the 
heart, skeletal muscle, and adipose 
tissue. It functions as a homodimer 
and requires APOC2 as a cofactor. 
000237 8:19796582-
19824770/ 
8p22 
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APOC2 APOC2 is a lipid-binding protein 
secreted in the plasma as a 
component of chylomicrons and 
VLDLs. It is essential for 
lipoprotein lipase activation and TG 
breakdown activity. 
000483 19:45449239-
45452822/ 
19q13.2 
APOC3 Apolipoprotein C-III is a component 
of HDL and ApoB containing 
lipoprotein particles. It impairs 
hepatic uptake and catabolism of 
ApoB-containing lipoproteins. 
000040 11:116700624-
116703787/ 
11q23.3 
APOA5 APOA5 is secreted in the plasma as 
a component of HDL, and to a 
lesser extent, VLDL and 
chylomicrons. It is a strong 
stimulator of LPL-mediated TG 
hydrolysis and an activator of LPL. 
052968 11:116660086-
116663136/ 
11q23 
LMF1 The LMF1 protein resides in the ER 
and is vital for LPL maturation and 
transport through the secretory 
pathway. It is therefore essential for 
functioning circulating LPL in the 
blood.  
022773 16:903634-
1031318/ 
16q13.3 
GPIHBP1 LPL and chylomicrons bind to 
GPIHBP1 in the capillary 
endothelial cells of the heart, 
skeletal muscle and adipose tissue, 
making it an important component 
of chylomicron TG catabolism. 
178172 8:144295068-
144299044/ 
8q24.3 
GCKR GCK is expressed in the liver and 
pancreatic islet beta cells and plays 
a significant role in glucose 
metabolism. It is a unique member 
of the hexokinase family where, in 
metabolic pathways, hexokinases 
phosphorylate glucose to produce 
glucose-6-phosphate. 
033508 7:44183870-
44229022/ 
7p13 
CREB3L3 cAMP responsive element-binding 
protein 3-like 3 (CREB3L3) is a 
transcription factor specific to the 
liver. The encoded protein is 
localized to the ER and is activated 
by cyclic AMP stimulation. The 
encoded protein binds the cyclic 
AMP response element (CRE) and 
box-B element. 
032607 19:4153598-
4173051/ 
19p13.3 
TRIB1 By controlling the differentiation of 
tissue-resident M2-like 
macrophages, TRIB1 is considered 
critical for adipose tissue 
025195 8:126442563-
126450647/ 
8q24.13 
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maintenance and the suppression of 
metabolic disorders. 
GPD1 GPD1 encodes an important protein 
involved in lipid metabolism. The 
encoded protein catalyzes the 
conversion of dihydroxyacetone 
phosphate (DHAP) and reduced 
nicotine adenine dinucleotide 
(NADH) to glycerol-3-phosphate 
(G3P) and NAD+. 
005276 12:50497602-
50505103/ 
12q13.12 
GALNT2 GALNT2 encodes a membrane-
bound glycosyltransferase protein 
that catalyzes the first step of O-
glycosylation of peptides in the 
Golgi. 
004481 1:230202956-
230417875/ 
1q42.13 
MLXIPL MLXIPL encodes a leucine zipper 
transcription factor, which belongs 
to the Myc/Max/Mad family. In a 
glucose-dependent manner, it 
activates the promoters of genes 
coding for TG synthesis. 
032951 7:73007524-
73038903/ 
7q11.23 
Low high-
density 
lipoprotein 
(LHDL) 
ABCA1 ABCA1 is part of the ATP-binding 
cassette (ABC) superfamily of 
transporters. ABCA1 is a cholesterol 
efflux pump, which removes 
cholesterol from cells. 
005502 9:107543283-
107690527/ 
9q31.1 
APOA1 Apolipoprotein 1 is synthesized in 
the liver and small intestines. It is 
the main protein of plasma HDL, 
promotes cholesterol efflux for 
excretion and acts as a cofactor to 
LCAT. 
000039 11:116706467-
116708338/ 
11q23-q24 
LCAT Lecithin-cholesterol acyltransferase 
(LCAT) esterifies cholesterol with a 
lecithin molecule, reducing its 
solubility and aiding in the 
formation of pseudo-
HDL/LDL/VLDL. LCAT has a high 
affinity for HDL and plays an 
important role in the formation of 
HDL cholesterol. 
000229 16:67973787-
67978656/ 
16q22.1 
ANGPTL3 Angiopoietin-like 3, expressed 
predominantly in the liver, is in a 
class of lipid metabolism 
modulators that regulate VLDL 
levels in the plasma. It acts as a dual 
inhibitor of both lipoprotein lipase 
and endothelial lipase. 
014495 1:63063158-
63071976/ 
1p31.1-p22.3 
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ABCG1 ABCG1 encodes an ATP-binding 
cassette transporter protein which 
regulates macrophage cholesterol 
and phospholipid transport. It also 
contributes to cholesterol 
homeostasis in several cell types. 
004915 21:43619799-
43724497/ 
21q22.3 
High low-
density 
lipoprotein 
(HLDL) 
APOB Apolipoprotein B is a hydrophilic 
protein on chylomicrons, thereby 
allowing for transport of LDL to the 
tissues of the body. ApoB-48 is 
synthesized in the intestines and 
ApoB-100 is synthesized in the 
liver. 
000384 2:21224301-
21266945/ 
2p24-23 
Abbreviations: HDL, high density lipoprotein; VLDL, very low density lipoprotein; LPL, lipoprotein lipase; TG, 
triglyceride; ER, endoplasmic reticulum; LDL, low density lipoprotein; rRNA, ribosomal RNA. 
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1.6.2 Whole-exome sequencing 
WES is a method of NGS capable of sequencing all protein-coding regions of the genome 
(approximately 1‒2%). Using a library preparation kit that captures all exonic content of 
the genome (known as the exome); WES allows identification of all gene variants, rather 
than the select few possible in the scaled-down approach of targeted resequencing. WES 
is a feasible and rapid approach to sequencing a large amount of DNA, and a valuable 
tool for rare disease research. 
1.6.2.1 Whole-exome sequencing successes 
WES has had momentous success as a tool for rare disease variant discovery. Although it 
only targets a significantly small proportion of the human genome, it stands as the 
method-of-choice for rare disease research because 85% of disease causing mutations 
found-to-date have been harboured in exons103. Further, the use of WES has had much 
success in identifying the genetic basis of rare diseases, with the identification of 
causative genes for both Schinzel-Giedion syndrome and Miller syndrome as notable 
examples of the first cases of WES success104,105. In sum, the genetic basis of >200 
disorders have been identified using WES, making the success and efficiency of WES 
preferred over WGS100,106. Moreover, due to the declining cost of WES, the high 
diagnostic yield, and the general acceptance of WES in the health marketplace, it has 
become the preferred diagnostic method for rare disease patients on the diagnostic 
odyssey who have not been genetically explained using standard genetic techniques107. 
1.6.3 Whole-genome sequencing 
The third and most comprehensive form of NGS is WGS, a method reporting almost 
every nucleotide (~85%) in the human genome. As WGS targets most nucleotides, it is 
capable of determining variations in any part of the genome, including regulatory regions. 
These variations detected through WGS have significant implications on an individual’s 
phenotype, ranging from protective against disease, to causative of disease, to neutral or 
benign. In recent years, WGS has become a widely used tool in cancer research and the 
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analysis of somatically acquired variants in tumour tissues108. Despite the utility of WGS, 
there are many caveats to the widespread implementation of WGS. For example, factors 
including misdiagnosis, risk of incidental findings, and the gap in literature on non-
exonic regions are all major considerations108. Because of these drawbacks, WES remains 
the preferred sequencing method for rare disease research.  
1.7  Thesis project outline 
With a staggering number of rare diseases without a genetic explanation, there is a 
substantial need to investigate these rare disorders and end the diagnostic odyssey for 
these individuals and their families. In the Blackburn Cardiovascular Genetics 
Laboratory, we have been referred patients with a variety of rare diseases including 
lipodystrophy, extreme-early onset obesity, brachydactyly, cerebral atrophy, and those 
through the FORGE Canada and CARE4RARE Projects. Generally, when familial 
recurrence of a rare phenotype is present, the likelihood that the disease is monogenic is 
high. Further, extreme severity of a disease with high penetrance also suggests the 
possibility of a single gene explanation. Therefore, it is predicted that these rare diseases 
are attributed to novel, single gene, genetic variations. Through NGS methods such as 
LipidSeq™ and WES, I seek to identify the molecular basis of each rare disorder. 
1.7.1  Project overview 
Overall, we enrolled 153 patients with lipodystrophy, 5 patients with extreme early-onset 
obesity, one family with brachydactyly, one family with cerebral atrophy, and 11 families 
associated with FORGE Canada or CARE4RARE. To start, I began by using the 
LipidSeq™ targeted gene panel for the lipodystrophy cohort, and Sanger sequencing for 
all other rare disease samples to determine if known genes could explain these disorders. 
In the cases where no mutations were found from Sanger sequencing or LipidSeq™, I 
sought to determine the genetic basis of these unexplained diseases using WES and 
subsequent bioinformatics analysis. In the event that candidate variants were identified, I 
performed variant validation and co-segregation analysis. Further, when possible, I used 
NGS data to identify novel CNVs.  
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1.7.2 Project hypothesis 
Given the evidence of a genetic basis for lipodystrophy, extreme early-onset obesity, 
brachydactyly, autosomal recessive cerebral atrophy, and past CARE4RARE/ FORGE 
Canada cases, I hypothesize that these aforementioned diseases are caused by rare genetic 
variants with functional relevance, following monogenic inheritance. Furthermore, I 
hypothesize that these variants will co-segregate with disease status in families, and be 
absent from unaffected family members and control populations. 
1.7.3 Project goal and aims 
Using LipidSeq™ and WES, the overall goal was to utilize these NGS technologies to 
identify a molecular basis for each patient/family disease of interest. In order to do this, 
my aims were as follows: 
1) To use NGS methods and bioinformatics processing, namely LipidSeq™ and 
WES, to detect genetic variants or CNVs.  
2) To identify rare or uncommon variants that are likely causative or associated with 
the disease phenotype of interest. 
3) To determine the functional relevance of these genetic variants using in silico 
tools and literature reviews.  
4) To perform variant validation studies to resolve whether these newly discovered 
variants are co-segregating with the disease phenotype in the family or an 
unaffected control population. 
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Chapter 2 – Materials and Methods 
2  Overview 
The following section provides an overview of all the Materials used and Methods 
performed in this study (Figure 2). Although the study relied on several external factors, 
including clinical diagnoses, the processing of the LipidSeq™ targeted gene panel and 
WES; I was involved in patient selection and developing eligibility criteria, and 
responsible for all sample preparation, bioinformatics processing and data analysis, 
variant validation and co-segregation analysis. Most importantly, I was responsible for all 
variant prioritization, consisting of literature review and analysis of hundreds-to-
thousands of variants per case. Furthermore, I was responsible for performing all 
analytics, reporting of the data, and manuscript preparation. For the CARE4RARE and 
FORGE Canada cases, I was significantly involved in the microcephaly-ichthyosis and 
widow’s peak cases (responsible for patient selection, bioinformatics processing and 
analysis, variant validation, and co-segregation analysis). For the remaining 
CARE4RARE and FORGE Canada cases, I was responsible for managing each case, 
organizing and chairing meetings with CARE4RARE/FORGE Canada collaborators, 
mentoring each student involved, and re-analyzing and confirming all results identified 
by students in these cases. 
2.1  Ethics approval 
Ethics approval was obtained for all projects in accordance with the Ethics Review Board 
at Western University (Certificate Number 07920E) in London, Ontario, Canada 
(Appendix I). For each study, informed consent and ethical approval was obtained from 
each participant, or in the event of a pediatric case, from a parent or guardian (the consent 
form can be found in Appendix II). 
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Figure 2. Flowchart of steps taken in order to identify the genetic bases of rare disorders. All steps shaded in blue represent steps 
where I was involved.
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2.2  Study subjects 
All study participants were recruited from Dr. Hegele’s Endocrinology Clinic (London 
Health Sciences Centre, University Hospital, London, ON, Canada), the Blackburn 
Cardiovascular Genetics Laboratory (Robarts Research Institute, London, ON, Canada), 
the Medical Genetics Program of Southwestern Ontario (London Health Sciences Centre, 
Victoria Hospital, London, ON, Canada), and the Children’s Hospital of Western Ontario 
(London Health Sciences Centre, Victoria Hospital, London, ON, Canada). For the 
CARE4RARE and FORGE Canada projects, patients were recruited from areas 
throughout Canada. 
2.2.1 Clinical information 
For each study subject, clinical information was provided from Dr. Hegele or the 
referring physician. For some CARE4RARE and FORGE Canada cases, clinical features 
were obtained from the CARE4RARE and FORGE Canada Consortiums. In the event 
that detailed clinical information was unavailable, the most common features and co-
morbidities of the diagnosed disease were assumed present. 
2.3  DNA extraction and quality control 
DNA was isolated from whole blood (3 mL) using the Puregene® Blood Extraction Kit 
(Cat. No. 158389, Gentra Systems, Qiagen Inc., Mississauga, ON, Canada). Both the 
quality and quantity of the DNA sample were measured using the NanoDrop 1000 
spectrophotometer with target ratios of 260:280 and 260:230 of approximately 1.8 
meeting the threshold for the study. DNA was purified and diluted to 5 ng/μL for both 
targeted and WES. 
2.4  SNP genotyping and autozygosity mapping 
For certain CARE4RARE and FORGE cases, namely CARE4RARE 907 (Heterotaxy) 
and FORGE 11 (Osteopetrosis), 122 (Dystonia, ataxia and intellectual disability) and 352 
(Microcephaly-ichthyosis), genomic DNA (gDNA) was extracted and genotyped for 
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SNPs using the Affymetrix® Genome-Wide Human SNP Array 6.0 (Santa Clara, 
California, United States). With the data as input, GeneSpring GT v2.0 (Agilent 
Technologies, Santa Clara, California, United States) software was used to identify areas 
of homozygosity that were identical-by-descent within family members. The SNP allele 
frequencies of healthy individuals were used to calculate a logarithm of the odds (LOD) 
score for each SNP. Homozygous regions in affected individuals with high LOD scores 
were prioritized when identifying candidate variants. 
2.5  Next-generation sequencing 
Two methods of NGS were used for the study. One technique used was targeted 
sequencing, namely LipidSeq™, and the second was WES, discussed in Sections 2.5.1 
and 2.5.2, respectively. 
2.5.1 Patient selection for LipidSeq™ 
One-hundred-and-fifty-three patients referred to the Blackburn Cardiovascular Genetics 
Laboratory with a clinical diagnosis of lipodystrophy were included in this portion of the 
study. Patients were prioritized based on two criteria: 1) the absence of mutations in 
known lipodystrophy-causing genes as previously determined from Sanger sequencing; 
and 2) disease severity, where those with severe phenotypic characteristics (i.e. the partial 
or complete absence of adipose tissue from the body) and metabolic comorbidities (i.e. 
insulin resistance, diabetes, hypertriglyceridemia) were selected. 
2.5.1.1 LipidSeq™ targeted sequencing 
After dilution and purification to 5 ng/μL, all DNA samples were indexed and pooled 
using the Nextera® Rapid Capture Custom Enrichment Kit, namely the “LipidSeq™” 
targeted sequencing design. Using LipidSeq™, 73 genes and >180 SNPs associated with 
lipid metabolism were sequenced for each sample. More specifically, all coding regions 
and a ~150-base pair (bp) pad at intron-exon boundaries were sequenced. Following 
indexing and pooling, library preparation was performed with the Nextera® Rapid 
Capture Custom Enrichment Kit, and enriched DNA samples were sequenced on an 
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Illumina MiSeq personal desktop sequencer (Illumina, San Diego, California, United 
States) using 2×150-bp paired-end chemistry in accordance to manufacturer instructions. 
DNA samples were sequenced in-house at the London Regional Genomics Centre 
(LRGC; http://lrgc.ca/) in London, Ontario with an average of approximately 300× depth-
of-coverage. 
Briefly, the extracted and purified DNA was first tagged with adapters. Reduced cycle 
amplification added additional motifs including unique primer binding sites, indices, and 
complementary regions to the oligonucleotides on the flow cell. The library was then 
quantified and measured using the Agilent® 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, California, United States) prior to being processed on the Illumina MiSeq. 
Once on the MiSeq, the DNA was immobilized onto a glass flow cell using the 
oligonucleotide complementary adapters. Bridge amplification occurred where all the 
strands were clonally amplified. This process occurred in parallel to millions of reactions, 
and resulted in cluster generation and amplification of all the fragments. After bridge 
amplification, sequencing was performed by way of sequencing-by-synthesis. More 
specifically, each nucleotide base possessed a unique fluorescence and competed for 
addition to the template strand, and the MiSeq instrument detected the fluorescent light 
emitted during synthesis. This resulted in complete sequencing of the DNA in a base-by-
base fashion109. 
2.5.2 Patient selection for whole-exome sequencing 
Twenty patients with lipodystrophy and five children with extreme early-onset obesity 
from Dr. Hegele’s Endocrinology Clinic were selected for this portion of the study. These 
patients were chosen based on the following criteria: 1) the absence of mutations in 
known disease-associated genes as determined from Sanger sequencing or LipidSeq™, 
and 2) disease severity, where those with severe characteristics (i.e. complete absence of 
adipose tissue or extreme excess of adiposity) and several confounding conditions (i.e. 
diabetes, insulin resistance or overgrowth) were prioritized. From the group of 
lipodystrophy patients deemed mutation negative from Sanger sequencing or LipidSeq™, 
patients of Dr. Hegele’s (rather than referrals from external physicians) were prioritized 
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for WES to ensure consistent clinical diagnoses and tests were performed. The parents of 
the children with extreme early-onset obesity were also approached for participation in 
the study. This resulted in the recruitment of two sets of parents, or two sets of trios 
(Mother, Father and proband) to the study. 
Families with rare genetic diseases (namely brachydactyly, type A1 and cerebral atrophy) 
referred to Dr. Hegele’s clinic or the Blackburn Cardiovascular Genetics Laboratory, and 
cases ascertained through the CARE4RARE and FORGE Canada projects were also 
selected for this portion of the study. These families were chosen based on similar 
criteria: lack of mutations in known disease-associated genes, disease severity, and rarity.   
2.5.2.1 Whole-exome sequencing 
After DNA extraction, quality control and dilution as described previously in Section 2.3, 
the DNA samples were indexed and pooled using the Illumina TruSeq Rapid Capture 
Exome Library Prep Kit in preparation for WES. The patient samples were sequenced in 
accordance to the WES protocol on the Illumina NextSeq 500 (Illumina, San Diego, 
California, United States) benchtop sequencer with 2×100-bp paired-end chemistry in 
accordance to the protocol used at the LRGC. Again, sequencing was performed using 
the sequencing-by-synthesis method, as described previously in Section 2.5.1.1. The 
average depth-of-coverage was approximately 100×.  
The lipodystrophy samples, all early-onset obesity samples, the autosomal recessive 
cerebral atrophy-like trio, and the brachydactyly proband were sequenced in-house at the 
LRGC. For the remaining cases, WES was generously funded by the FORGE Canada and 
CARE4RARE Research Programs, and performed at either the Genome Québec 
Innovation Centre (http://gqinnovationcenter.com/) in Montreal, Québec or The Centre of 
Applied Genomics (http://www.tcag.ca/) in Toronto, Ontario. At both locations, the 
samples were run on an Illumina HiSeq 2000 (Illumina, San Diego, California, United 
States) sequencer using an Agilent® SureSelect v5 Target Enrichment Kit.   
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2.6  Bioinformatics processing 
Following sequencing, both the LipidSeq™ and WES raw data were returned in the form 
of patient-specific, paired FASTQ files. FASTQ files contain FASTQ format, a text-
based format with nucleotide sequence and corresponding quality scores. The paired 
FASTQ files were input into CLC Bio Genomics Workbench v10 (CLC Bio, Aarhus, 
Denmark) to align the data to the human reference genome (build Hg19). Sequence 
alignment was performed using a custom automated workflow (Figure 2.6).  
Succinctly, the workflow began by mapping the reads to the reference genome. From 
there, the software performed local realignment, a “proofreading” step that used 
alignment information of other nearby reads in order to re-align each given read. A 
second “proofreading” step was then executed, where the tool effectively removed bias 
by discarding duplicate reads that may have arose from PCR amplification during sample 
preparation. Fixed ploidy variant detection was performed, using The Error Model 
estimation in order to estimate the probability of having a certain base in a read, but 
calling a different base. This tool allowed variants to be called or identified. The software 
then performed two steps: 1) filtered based on overlap, or kept the reads overlapping with 
the BED file (tab-delimited text file with information on the regions targeted using the 
LipidSeq™ or WES kit); and 2) created statistics for target regions, which provided a 
summary of the local and overall coverage. After the alignment and variant calling steps, 
variant data were exported in the form of a variant calling format or VCF (.vcf) file (a 
tab-delimited text file containing the variant information), and coverage statistics were 
exported in the form of a BAM file (.bam), a binary version of a SAM file (a tab-
delimited text file containing the sequence alignment data).  
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Figure 2.6. Next-generation sequencing bioinformatics workflow. Custom workflow 
designed in CLC Genomics Workbench v10. For each individual case, the workflow uses 
two batched FASTQ files and generates a VCF and BAM file as output. Note that the 
“Filter Based on Overlap” step utilizes the BED file for the LipidSeq™ or whole-exome 
sequencing kit. 
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2.7  Variant annotation 
After variant calling, the VCF files were utilized as input for variant annotation. For the 
LipidSeq™ data, ANNOVAR (http://annovar.openbioinformatics.org/), a software tool 
that functionally annotates genetic variants, was used to annotate the variants within the 
VCF files using a customized script. For the WES data, the Golden Helix VarSeq® 
software (Golden Helix Inc., Bozeman, Massachusetts, United States), a variant 
annotation and filtration software, was used to fully annotate the variants. ANNOVAR 
and VarSeq® both annotated each variant with predictions from in silico tools including: 
Polymorphism Phenotyping, v2 (PolyPhen-2; http://genetics.bwh.harvard.edu/pph2/)110, 
Sorting Intolerant From Tolerant (SIFT) predictor (http://sift.jcvi.org/)111, MutationTaster 
(http://www.mutationtaster.org/)112, and Combined Annotation Dependent Depletion 
(CADD; http://cadd.gs.washington.edu/score)113. For splicing mutations, concordance 
with in silico pathogenic predictions from the Human Splicing Finder 
(http://www.umd.be/HSF3/HSF.shtml)114 and the Splicing Based Analysis of Variants 
(SPANR; http://tools.genes.toronto.edu/)115 databases were used. For each variant, the 
minor allelic frequency (MAF) was also extracted from the following databases: 1000 
Genomes (http://www.internationalgenome.org/1000-genomes-browsers/)116, Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS/), Exome Aggregation 
Consortium (ExAC) browser (http://exac.broadinstitute.org/)117, and Genome 
Aggregation Database (gnomAD) (http://gnomad.broadinstitute.org/)117. Annotated 
variants harboured within genes associated with the disease of interest were prioritized. 
2.8  Variant prioritization 
Once annotated, variants were prioritized based on several criteria for causality. These 
stringent criteria were used to ensure the candidate variants identified for each case had a 
high likelihood of being disease-causing (Table 2.8). Note that given the complexities of, 
and differences between each case, some variant prioritization criteria varied between 
patient sample or family (i.e. autosomal dominant versus recessive mode of inheritance, 
minor allele frequency [MAF] of >1% versus 0%, etc.), and these criteria were 
customized for each case. 
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Table 2.8. Criteria used to prioritize candidate variants and infer them as disease 
causing. 
Criteria considered to predict a variant as disease-causing: 
I. The variant is predicted to be pathogenic by the following analyses: 
A. Multiple in silico prediction tools agree that the variant has a high likelihood of being 
disease-causing 
B. Gene function, expression, and pathway analyses are in line or associated with the phenotype 
of interest 
Using the following databases, but not limited to: GeneCards (http://www.genecards.org/)118, 
OMIM (https://www.omim.org/), NCBI Gene (https://www.ncbi.nlm.nih.gov/gene), UniProt 
(http://www.uniprot.org/)119, Reactome Pathway Database (http://reactome.org/)120, Human 
Protein Atlas (http://www.proteinatlas.org/)121, KEGG (http://www.genome.jp/kegg/)122 
C. Disease databases show a relation between the gene or variant and the disorder of interest  
Using the following databases, but not limited to: HGMD 
(http://www.hgmd.cf.ac.uk/ac/all.php)123, NCBI ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), Orphanet (http://www.orpha.net/consor/cgi-
bin/index.php)124, DECIPHER (https://decipher.sanger.ac.uk/)125 
D. Literature searches and guidelines suggest the variant has a high likelihood of being disease-
causing  
Using PubMed, Web of Science, and the ACMG standards and guidelines126 
II. Genotype analysis shows the mutation is rare (at least <1%) or absent from a large population* 
III. The mutation co-segregates in the family in accordance with the predetermined mode of inheritance, 
and can be validated through an independent method 
IV. Functional assessment – including ex vivo, in vitro and in vivo bench studies – show the mutant gene 
product is dysfunctional 
*Note that the control databases (1000 Genomes, ExAC, ESP, gnomAD) were first checked to ensure their control cohorts did not include the 
phenotype of interest. In the event that the phenotype of interest was part of the control cohort in the database, the frequency was used with 
caution.  
The database abbreviations are as follows: OMIM, Online Mendelian Inheritance in Man; KEGG, Kyoto Encyclopaedia of Genes and 
Genomes; HGMD, Human Gene Mutation Database; ACMG, The American College of Medical Genetics and Genomics. 
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2.8.1 Zygosity 
Given the predicted mode of inheritance of the disease from the family history, zygosity 
was used to prioritize specific variants. More specifically, if the disease was expected to 
follow an autosomal dominant mode of inheritance, heterozygous variants were 
prioritized; if the disease was expected to follow an autosomal recessive mode of 
inheritance, either homozygous variants or compound heterozygous variants were 
prioritized. In the event that there was no family history available, the predicted zygosity 
of the disease of interest was used (i.e. all known cases of congenital general 
lipodystrophy are associated with an autosomal recessive inheritance pattern, therefore 
homozygous variants were prioritized).   
2.8.2 Read depth 
The read depth represents the number of unique reads that include a given nucleotide in a 
sequence. In order to discard sequencing artifacts or Mendelian errors, variants are 
prioritized based on read depth. A read depth criterion of 30 was used for quality 
control. Note that the read depth is indicated as a quality control measurement and this 
step is capable of removing ~95% of Mendelian errors127. 
2.8.3 Sequence ontology  
Sequence ontology refers to the structured vocabulary used for genomic annotation. More 
specifically, it offers a common, universal set of terms and definitions for genomic data. 
In this project, the sequence ontology terms – disruptive inframe insertion/deletion, 
frameshift variant, inframe insertion/deletion, initiator codon variant, missense variant, 
splice acceptor/donor/region variant, stop gain/loss/retained variant – were prioritized. 
These non-synonymous and splicing variants were prioritized as they are more likely to 
be pathogenic, destabilize the protein structure, and result in dysfunctional interactions 
between interacting molecules128-131. 
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2.8.4 Minor allele frequency 
Minor allele frequency refers to the frequency at which the second most prevalent allele 
occurs in a population. In this case, the MAFs were extracted from 1000 Genomes, 
Exome Sequencing Project, ExAC and gnomAD, as mentioned in Section 2.7. A MAF of 
0.01 was used for all rare diseases with an autosomal recessive mode of inheritance, and 
a MAF of zero was used for rare diseases with a suspected autosomal dominant mode of 
inheritance. 
2.8.5 In silico analyses 
As specified in Section 2.7, in silico tools were used to predict the biological effect or 
functional relevance of the variants on protein function. Variants were prioritized if the 
tools predicted that the variant has a high-likelihood of being disease causing. 
2.8.6 Gene and protein analysis and literature review 
To narrow down the list of candidate variants, analysis into gene function, expression and 
pathway were performed, and disease databases were analyzed to determine a 
relationship between the variant and disease of interest. A comprehensive literature 
review was performed for each variant, and the American College of Medical Genetics 
(ACMG) standards and guidelines were implemented and considered. See Table 2.8 for 
more details on the prioritization method. 
2.8.7 Association with the disease phenotype 
In the event that a variant was identified in a known gene previously associated with the 
disorder, that variant was prioritized if it satisfied all aforementioned criteria. With regard 
to the LipidSeq™ data, the lipodystrophy-associated genes were selectively analyzed for 
potentially causative variants. 
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2.9  Copy-number variation detection  
All patients processed using LipidSeq™ or with WES performed in-house were subject 
to CNV detection. The CNV Caller tool, an application within the VarSeq® software, 
was used to call CNVs with sequencing depth-of-coverage data from the previously 
generated BAM file. The VCF file and BED file (tab-delimited text file with information 
on the targeted chromosomal regions) for either LipidSeq™ or WES were also input to 
VarSeq®, as the program uses a set of matched control samples prepared using the same 
library-preparation chemistry or sequencing method (i.e. LipidSeq™ or WES kit). The 
CNV Caller tool is capable of identifying four CNV states: 1) wild-type diploid state; 2) 
heterozygous deletion; 3) homozygous deletion; and 4) duplication. 
In short, the CNV calling algorithm relied on the coverage information computed from 
the BAM files. The algorithm inspected for a change in coverage compared to a set of 
reference samples as evidence of a CNV event. More specifically, the program selected 
the top 30 reference samples with the least percent-difference (<20%) in coverage data 
compared to the sample of interest. These reference samples were used to identify 
differences in coverage, and correct for GC-content bias and regions that were 
unamenable to mapping. Using the reference samples, the algorithm computed two 
evidence metrics: Z-score and ratio threshold value. The Z-score is a measurement 
referring to the number of standard deviations from the reference sample mean, whereas 
the ratio refers to the normalized mean for the sample divided by the average normalized 
mean of all the reference samples. Using these two metrics, the algorithm was able to 
assign a CNV state (deletion or duplication) to each target region. In addition to these 
metrics, a third metric, the Variant Allele Frequency (VAF), was calculated to be used as 
evidence for a CNV. Any VAF value other than zero or one were evidence against 
deletions, whereas VAF values of 1/3 and 2/3 represented supporting evidence for 
duplications. 
In addition to evidence metrics, quality control flagging was also performed by the 
software. These flags indicated whether a CNV event was unreliable, specifically if there 
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was a low reference sample read depth or high variation between reference samples in the 
region of interest. These flags were used to filter out unlikely CNV events. 
2.9.1 Copy-number variation prioritization 
After CNV calling in VarSeq®, CNV events were prioritized based on both ratio-
threshold value (≤0.7 for heterozygous deletions, ≥1.3 for duplications) and Z-score (≤-
3.0 for heterozygous deletions, ≥3.0 for duplications). The VAF value was considered as 
secondary validation of evidence. In the event that a CNV event was flagged with a 
quality control flag, the CNV was no longer considered a candidate CNV associated with 
the disease of interest. 
2.10  Variant validation and co-segregation analysis 
In the event that candidate variants were identified, validation and co-segregation 
analyses were performed using an independent method (i.e. Sanger sequencing or 
microarray analysis).  
2.10.1 PCR 
Genomic DNA was ascertained from the proband and all other family members (if 
available) and amplified using polymerase chain reaction (PCR) and a custom set of 
primers (see Appendix III for primer sequences). Unique primers were designed for each 
variant of interest. 
2.10.2 PCR imaging and purification 
After PCR, the PCR products were loaded onto a 1.5% agarose gel with RedSafe™ 
Nucleic Acid Staining Solution (iNtRON Biotechnology Inc., Gyeonggi Province, South 
Korea) and run with a 100-bp DNA Ladder (ThermoFisher Scientific, Waltham, 
Massachusetts, United States). The gel was run for 45 minutes at 145 volts using a Gibco 
BRL Horizontal 11-4 Gel Electrophoresis Apparatus (Life Technologies, Carlsbad, 
California, United States). The gel was subsequently imaged using the Azure Biosystems 
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c150 Gel Documentation Platform (ThermoFisher Scientific, Waltham, Massachusetts, 
United States). If the PCR products were of expected size when compared to the ladder 
fragment size, the PCR products were purified using calf intestinal alkaline phosphatase 
(CIAP) and exonuclease I (ThermoFisher Scientific, Waltham, Massachusetts, United 
States). 
2.10.3 Sanger sequencing and analysis 
After PCR, the cleaned and purified DNA product was sent for Sanger sequencing at the 
LRGC using an Applied Biosystems (ABI) 3730 Automated DNA Sequencer (Applied 
Biosystems, Foster City, California, United States). Electropherograms were generated 
and analyzed using the ABI SeqScape® Software v2.6 (Life Technologies, Carlsbad, 
California, United States) where it was aligned to the corresponding reference gene 
sequence from the National Centre for Biotechnology Information (NCBI) GenBank. If 
the variants were present in other clinically affected individuals in the family (when 
available) following the same mode of inheritance, they were considered to co-segregate 
with disease status in the family. In the event that the variant was absent from affected 
family members, the candidate variant was deemed not causative of the disease of 
interest. 
2.11  Validation of copy-number variation events 
For the validation of candidate CNVs, either Sanger sequencing as described or the 
CytoScan™ HD Array Kit and Reagent Kit Bundle (ThermoFisher Scientific, Waltham, 
Massachusetts, United States) were used. Briefly, the CytoScan™ HD Solution provides 
the broadest coverage for detecting human chromosomal aberrations; the CytoScan™ HD 
Array can reliably detect over 750,000 SNPs and 2.6 million copy-number probes (with 
25-50 kilo-base copy-number changes). Due to the high SNP coverage, the CytoScan™ 
HD Array allows a user to accurately estimate breakpoint locations, a necessary feat in 
validating CNV events. The CytoScan™ HD Array was performed according to 
manufacturer’s instructions at Victoria Hospital in London, Ontario (London Health 
Sciences Centre, Victoria Hospital, London, ON, Canada). Following sequencing, the 
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data were analyzed using the Chromosome Analysis Suite (ChAS) v3.2 (ThermoFisher 
Scientific, Waltham, Massachusetts, United States). The regions lying between probes 
differing in copy-number state were used to predict the approximate size of the copy-
number variant and were predicted to harbour the breakpoint of the candidate CNV. 
2.12  Gene enrichment analysis 
For patients with lipodystrophy or extreme early-onset obesity in which no candidate 
variant or multiple candidate variants were identified, PANTHER (protein annotation 
through evolutionary relationship) classification system (http://www.pantherdb.org/) was 
used to determine if any protein families (and their genes) were under-or-overrepresented 
using Fisher’s Exact Test in comparison to a reference database132. Put simply, 
PANTHER was used to determine whether certain genes or pathways were affected 
more-or-less often than expected by chance. For the cases in which PANTHER was run, 
the candidate variant list used as input was the list of variants remaining after filtering 
based on zygosity, ontology, and minor allele frequency. Note that proteins were 
classified according to family and subfamily, molecular function, biological process, and 
pathway.  
2.13  Statistical analysis: Brachydactyly case 
Statistical analysis and comparison of the anthropometric data between IHH mutation 
positive and IHH mutation negative individuals in the brachydactyly case was done using 
the Wilcoxon-Mann-Whitney test on SAS v.9.4 (SAS Institute, Cary, North Carolina, 
United States). The Wilcoxon-Mann-Whitney test is used when sample size is small, and 
data are not normally distributed133. For statistical analysis in the brachydactyly case, 
eighteen family members were assessed. Fourteen of these 18 family members were 
clinically affected, and four were clinically unaffected. 
2.14  Box plot generation: Brachydactyly case 
Box plots for the brachydactyly case were generated using R: The R Project for Statistical 
Computing software and the ggPlot2 package134. 
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Chapter 3 – Results 
3  Overview 
One-hundred-and-fifty-three patients with lipodystrophy, five children with extreme 
early-onset obesity, one family with a history of brachydactyly, one family with a history 
of cerebral atrophy, and 11 families with several rare diseases (as ascertained from 
FORGE Canada and CARE4RARE) participated in this study. Here, I discuss all the 
results and outcomes of NGS. 
3.1  Study subjects and clinical features 
For all cases studied – namely the lipodystrophy, early-onset obesity, brachydactyly, 
cerebral atrophy, CARE4RARE and FORGE Canada projects – patient files, clinical 
notes, and/or hospital records were thoroughly reviewed to develop accurate clinical 
descriptions and select appropriate patients for sequencing. All cases were chosen based 
on disease severity. In the event that limited information about the phenotype was 
available, the phenotype described in the OMIM database was used. 
3.2  LipidSeq™ variant detection 
After sequencing using the LipidSeq™ targeted gene panel, the data for all 153 patients 
with lipodystrophy were analyzed for potential disease-causing variants. These variants 
were prioritized based on zygosity, read depth, sequence ontology and minor allele 
frequency as discussed in Chapter 2, Section 2.8. Of the 153 total patients, 81 variants 
were identified within 14 lipodystrophy-associated genes: LMNA, PPARG, PLIN1, 
CIDEC, LIPE, LPIN1, AGPAT2, BSCL2, CAV1, AKT2, PTRF, DYRK1B, POLD1 and 
WRN (Figure 3.2). These variants explain the clinical phenotype or secondary 
complications of 58 patients (38% of the patient cohort) processed using the LipidSeq™ 
gene panel, as all genes are either associated with lipodystrophy or with common features 
often implicated in lipodystrophy (i.e. high triglycerides, high cholesterol). The 95 
patients classified as mutation negative after LipidSeq™ became candidates for the WES 
portion of the study. 
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Figure 3.2. Variant breakdown for patients with lipodystrophy sequenced using the 
LipidSeq™ targeted gene panel. The DNA samples of Dr. Hegele’s patients with 
lipodystrophy were ascertained and sequenced using LipidSeq™. Fifty-eight mutation-
positive patients were classified according to lipodystrophy-causing gene. Each region in 
the graph represents the gene implicated, and the number of patients with a variant in the 
gene. Note that some patients harboured multiple variants in more than one gene, which 
likely contributed to their phenotype. 
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3.3   Sanger sequencing of TMPRSS4 
For the proband featuring a cerebral atrophy-like phenotype, Sanger sequencing of the 
expected TMPRSS4 variant region using a custom set of primers (see Appendix III) was 
performed to determine whether the case shared the same molecular etiology as the 
previous case in the Blackburn Cardiovascular Genetics Laboratory (as described in 
Chapter 1, Section 1.5.4). From Sanger sequencing, no variants were identified in the 
TMPRSS4 region of interest designating the proband eligible for the WES part of the 
study. 
3.4  Whole-exome sequencing 
Twenty patients with lipodystrophy, five children with extreme early-onset obesity, one 
proband with brachydactyly, one proband with a cerebral atrophy-like phenotype, and 11 
CARE4RARE and FORGE Canada cases were selected for the whole-exome portion of 
the study. To start, patient data were collected in order to fully understand the patient 
phenotype. The clinical features of the lipodystrophy and extreme early-onset obesity 
cases are described in Table 3.4A and Table 3.4B, respectively. The clinical description 
of the brachydactyly, cerebral atrophy-like, CARE4RARE and FORGE Canada cases are 
listed in Chapter 1 (Sections 1.5.3.1.8, 1.5.4.1 and Table 1.2.5.3, sequentially). After 
WES, bioinformatics processing and in silico analyses were performed on the WES data 
to identify potential disease-causing variants. Variants were prioritized if they satisfied 
criteria I-III in Table 2.8 (Chapter 2).  
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Table 3.4A. Features of all patients with lipodystrophy in which whole-exome 
sequencing was performedA. 
Patient IDB Biological SexC Classification Additional Clinical Features (if present) 
1804 Female Total lipodystrophy T2D, insulin resistance, hyperlipidemia, exercise 
intolerance 
8615 Female Total lipodystrophy T2D, iron-deficient anemia, diabetic neuropathy, 
history of bronchitis, class 3 obesity, CAD 
1088 Female FPLD N/A 
3458 Female FPLD Hypothyroidism, diabetes 
3969 Female FPLD Peripheral neuropathy (motor/axonal), Charcot 
Marie Tooth, T2D, constant migraines, NASH 
4116 Female FPLD Hypertension, T2D, chronic renal failure, 
hypothyroidism 
4665 Female FPLD Neuropathy, T2D, Behçet syndrome, pyoderma 
gangrenosum, hidradenitis 
5662 Female FPLD N/A 
2025 Female FPLD Profound insulin resistance, decreased creatinine 
levels, proteinuria, dermatomyositis 
3011 Female FPLD Insulin resistance, dyslipidemia, hirsutism, high 
triglycerides 
11618 Female FPLD Hypertension, T2D, hypercholesterolemia, 
obesity 
14318 Female FPLD Severe insulin resistance 
794 Female FPLD Hepatosplenomegaly, cirrhosis and NASH, high 
triglycerides, high cholesterol, insulin-requiring 
T2D, liver failure 
14106 Female FPLD N/A 
1120 Male FPLD N/A 
4162 Female Acquired lipodystrophy Hypercholesterolemia, lower motor neuron 
weakness, hair loss, osteoarthritis 
4164 Female Acquired lipodystrophy Insulin-requiring T2D 
4194 Female Acquired lipodystrophy T2D, diabetic neuropathy, osteoarthritis 
4226 Female Acquired lipodystrophy N/A 
12395 Female PCOS/FPLD T2D, neuropathy, hypertension 
The abbreviations are as follows: ID, identification; N/A, not applicable; T2D, Diabetes mellitus, Type 2; CAD, coronary artery disease; FPLD, familial partial 
lipodystrophy; NASH, non-alcoholic steatohepatitis; PCOS, polycystic ovary syndrome. 
A Patients were selected based on their diagnosis with a rare metabolic disorder, poor lipid profile, and lack of mutations in known disease-related genes (as 
determined through Sanger sequencing). Patients of Dr. Hegele’s (London Health Sciences Centre) were prioritized to ensure consistent diagnosis, high sample 
quality, and detailed, accurate patient information. After whole-exome sequencing, the data were run through CLC Bio Genome Workbench v10 and annotated using 
the curation and annotation program, Golden Helix VarSeq®.  
B The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
C Referring to the biological sex assigned at birth. 
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Table 3.4B. Features of all patients with extreme early-onset obesity in which whole-
exome sequencing was performedA. 
Patient IDB Biological SexC Classification Additional Clinical Features (if present) 
12340 Male Early-onset obesity Insulin resistance, hyperphagia 
15544 Male Early-onset obesity Autism spectrum disorder and developmental 
delay, overgrowth 
15858D Female Early-onset obesity Hyperphagia, overgrowth, intellectual disability 
12424 Male Early-onset obesity N/A 
14504D Female Early-onset obesity N/A 
The abbreviations are as follows: ID, identification; N/A, not applicable. 
A Patients were selected based on their diagnosis with a rare metabolic disorder, poor lipid profile, and lack of mutations in known disease-related genes (as 
determined through Sanger sequencing). After whole-exome sequencing, the data was run through CLC Bio Genome Workbench v10 and annotated using the 
curation and annotation program, Golden Helix VarSeq®.  
B The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
C Referring to the biological sex assigned at birth. 
D Trio sequencing and analysis was performed with this patient and their unrelated parents. 
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3.4.1 Lipodystrophy 
From WES and bioinformatics analysis, over one-million variants were identified among 
the 20 patients with lipodystrophy. After variant prioritization, candidate variants were 
identified for 13 of the 20 patients with lipodystrophy within the following genes: ISCU, 
HSPG2, LDLR, PDRM16, ZMPSTE24, FLNC, GALC, ABCA4, WRN, ABCG8, FHL1, 
ANLN, LPL, FN1, PAPSS2, NEUROD1, BSCL2, APOB, PCSK9, and PYGM (Table 
3.4.1). These variants partially explain the lipodystrophy phenotype or associated 
comorbidities displayed by these patients. 
3.4.2 Extreme early-onset obesity 
After WES, data processing and bioinformatics analysis, over 100,000 variants were 
called in the exomes of five children with extreme early-onset obesity. After variant 
prioritization, candidate variants were identified in two of the probands (Table 3.4.2). 
These variants are predicted to explain the extreme early-onset obesity phenotype or the 
associated conditions (i.e. intellectual disability) described in these patients.  
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Table 3.4.1. Candidate variants identified in patients with lipodystrophy using 
whole-exome sequencingA. 
Patient 
IDB 
Gene 
Chromosome: 
Position 
DNA change 
Amino acid 
change 
Zygosity/Effect Frequency 
1804 
(CGL) 
ISCU 12:108956417 c.19_20delinsGG p.Phe7Gly Homo/Missense 0 
8615 
(CGL) 
HSPG2 1:22200454 c.3707C>A p.Ala1236Glu Homo/Missense 1×10-3 
1088 
(FPLD) 
LDLR 19:11221435 c.1048C>T p.Arg350Ter Het/Nonsense 8×10-6 
 PRDM16 1:3329229 c.2468G>C p.Arg823Pro Het/Missense 7×10-4 
3458 
(FPLD) 
ZMPSTE24 1:40756665 c.1199A>G p.Asn400Ser Het/Missense 0 
3969 
(FPLD) 
FLNC 7:128494727 c.6988G>A p.Gly2330Ser Het/Missense 7×10-4 
 GALC 14:88452941 c.334A>G p.Thr112Ala Het/Missense 2×10-3 
4116 
(FPLD) 
LDLR 19:11233961 c.2252G>A p.Arg751Gln Het/Missense 8×10-5 
  19:11233940 c.2231_2232delins
AG 
p.Arg744Gln Het/Missense 0 
4665 
(FPLD) 
ABCA4 1:94528818 c.1610G>A p.Arg537His Het/Missense 1×10-3 
  1:94510250 c.2969G>A p.Gly990Glu Het/Missense 0 
 WRN 8:30998961 c.2983G>A p.Ala995Thr Het/Missense 7×10-4 
  8:30938692 c.1149G>T p.Leu383Phe Het/Missense 4×10-4 
5662 
(FPLD) 
ABCG8 2:44101538 c.1412-8delinsTT N/A Homo/Splicing 0 
2025 
(FPLD) 
FHL1 X:135288637 c.46G>T p.Gly16Trp Het/Missense 0 
 ANLN 7:36450231 c.1205C>T p.Pro402Leu Het/Missense 0 
3011 
(FPLD) 
LPL 8:19811864 c.775G>A p.Asp259Asn Het/Missense 0 
 PAPSS2 10:89501019 c.1114G>T p.Val372Phe Het/Missense 8×10-6 
14318 
(FPLD) 
NEUROD1 2:182543418 c.170G>A p.Gly57Glu Het/Missense 0 
 BSCL2 11:62457948 c.1280T>C p.Leu427Pro Het/Missense 2×10-3 
 APOB 2:21232803 c.6936_6937delins
TG 
p.Ile2313Val Homo/Missense 0 
 PCSK9 1:55505647 c.137G>T p.Arg46Leu Het/Missense 8×10-3 
 PYGM 11:64527223 c.148C>T p.Arg50Ter Het/Nonsense 1×10-4 
4194 
(ALD) 
WRN 8:30921838 c.243T>G p.Phe81Leu Het/Missense 0 
Abbreviations are as follows: CGL, congenital generalized lipodystrophy; FPLD, familial partial lipodystrophy; ALD, acquired lipodystrophy; Het, heterozygous; 
Homo, homozygous. 
A The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype, 
and support from numerous papers in the literature. frequency listed for each candidate variant is the frequency from gnomAD, also confirmed from the databases: 
1000 Genomes, Exome Aggregation Consortium, and the Exome Sequencing Project. 
B The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
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Table 3.4.2. Candidate variants identified in patients with extreme early-onset 
obesity using whole-exome sequencingA. 
Patient IDB Gene 
Chromosome: 
Position 
DNA change 
Amino acid 
change 
Zygosity/Effect Frequency 
15544 BLK 8:11405609 c.244G>C p.Gly82Arg Het/Missense 1×10-5 
 MC4R 18:58038832 c.751A>C p.Ile251Leu Het/Missense 6×10-3 
15858 BBS10  c.424G>A p.Asp142Asn Het/Missense 0 
 SETD8  c.995T>C p.Leu332Pro Het/Missense 0 
   c.713G>C p.Arg238Pro Het/Missense 0 
 KMT2C  c.2645T>C p.Ile882Thr Het/Missense 0 
Abbreviations are as follows: Het, heterozygous; Homo, homozygous; Hemi, hemizygous. 
A The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype, 
and support from numerous papers in the literature. frequency listed for each candidate variant is the frequency from gnomAD, also confirmed from the databases: 
1000 Genomes, Exome Aggregation Consortium, and the Exome Sequencing Project. 
B The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
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A A version of this section has been submitted for publication83. 
3.4.3 BrachydactylyA 
From WES and bioinformatics processing of the DNA sample from the proband, over 
37,000 variants were identified in the proband’s exome. After a non-synonymous rare 
variant prioritization approach and literature review, I was left with one candidate variant 
correlating with the brachydactyly phenotype. This variant, a heterozygous disruptive 
inframe insertion (c.285_287dupGAA, p.Glu95_Asn96insLys), was detected in the 
Indian hedgehog gene (IHH). This IHH variant is predicted to exert a damaging effect on 
protein function from multiple in silico prediction tools, is considered novel in multiple 
control population databases, and has not been previously reported in the literature. 
Dominant variants in the IHH gene are associated with brachydactyly type A1, 
correlating with the phenotype and inheritance pattern seen in this family83. 
3.4.4 Cerebral atrophy-like 
Due to the absence of the expected variant in TMPRSS4, WES and bioinformatics 
analysis was performed on the DNA of the proband featuring a cerebral atrophy-like 
phenotype and his parents in order to perform trio analysis and identify causative genetic 
factors. From this analysis, one homozygous candidate variant (from 52,958 total 
variants) in the Kinetochore Scaffold 1 or CASC5 gene was identified (c.6485A>G, 
p.Glu2162Gly), associated with primary microcephaly-4. This gene variant is predicted 
to cause a pathogenic effect on protein function from in silico tools and is present at a 
minor allele frequency of 6×10-6 in control population databases. Note that the frequency 
in the normal population is associated with heterozygotes. 
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3.4.5 CARE for RARE and FORGE Canada 
From WES and bioinformatics processing on the exomes of the affected probands, 
candidate variants were identified in eight of the 11 CARE4RARE or FORGE Canada 
cases, namely microcephaly-ichthyosis, autosomal dominant isolated cryptophthalmos, 
widow’s peak syndrome, amyoplasia, metaphyseal chondrodysplasia, craniosynostosis, 
heterotaxy disorder, and craniorachischisis (Table 3.4.5).  
Here, I focus on the microcephaly-ichthyosis and widow’s peak cases. With the 
microcephaly-ichthyosis case, the DNA from two affected infants were subject to WES. 
From WES and data processing, a total of 121,280 variants were identified in both 
exomes. After prioritization, this was narrowed down to one candidate variant in the 
vacuolar protein sorting-52 gene (VPS52; c.57delG, p.Thr20fs). The VPS52 gene is 
associated with pluripotent differentiation for ectodermal cell interactions. Further, 
mutations in the VPS52 complex are associated with microcephaly, a clinical feature of 
the affected probands. 
For the widow’s peak case, two affected individuals had their DNA extracted and WES 
performed. From WES and bioinformatics analysis, a total of 1,873,928 variants were 
identified in the two exomes. After prioritizing based on variants on the X chromosome 
(due to the predicted X-linked dominant inheritance), frequency, read depth and sequence 
ontology, one candidate variant in the lysine-specific demethylase 6a gene (KDM6A) 
(c.2703-6_2703-5delTT) remained. Variation in the KDM6A gene is associated with 
Kabuki Syndrome-2, matching the phenotype of the proband. 
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Table 3.4.5. Status of all CARE for RARE and FORGE Canada cases. 
Case Status 
FORGE 214, Angelman-like syndrome  Nothing significant found with the functional studies 
 Input into MatchMaker Exchange 
FORGE 122, Dystonia, ataxia and 
intellectual disability* 
 Compound heterozygous variants previously found in the NudC 
Domain Containing 2 (NUDCD2) 
 Variants Sanger sequenced again, and are found to not co-
segregate in the family 
 Rainfall plots generated to determine mutational burden; gene 
enrichment analysis performed 
FORGE 11, Osteopetrosis  Exome analysis phase – looking for candidate variants 
 Waiting for DNA on an additional case 
FORGE 352, Microcephaly-ichthyosis*   Candidate variant (p.Thr20fs) found in the vacuolar protein 
sorting 52 (VPS52) gene co-segregates in the pedigree 
 Waiting on DNA for additional affected family members 
C4R 572, Autosomal dominant isolated 
cryptophthalmos  
 Investigating a candidate variant in the Diacylglycerol Kinase 
Delta (DGKD) gene 
C4R 573, Widow’s peak syndrome*  Candidate variant (c.2703-6_2703-5delTT) identified in Lysine 
Demethylase 6A (KDM6A) 
 RNA extraction performed on the samples of both affected 
individuals 
 RT-PCR to be performed to confirm the variant 
C4R 575, Amyoplasia  New mutations identified in affected patients and not in parents: 
heparin sulfate proteoglycan 2 (HSPG2; p.Val3507Leu) in 
affected male, TEA Domain Transcription Factor 4 (TEAD4; 
p.Val212Met) in affected female  
 Currently looking to recruit additional patients 
C4R 592, Metaphyseal chondrodysplasia  Candidate variant identified in the Dishevelled Segment Polarity 
Protein 3 (DVL3) gene (p.Gln301Ter) 
 Currently investigating other variants and considering functional 
studies 
C4R 664, Craniosynostosis*  Candidate variant identified in the  TNF Receptor Associated 
Factor 7 (TRAF7) gene (c.1673C>T, p.S558F) 
C4R 907, Heterotaxy disorder  Candidate variant identified in the  Interferon Related 
Developmental Regulator 1 (IFRD1) gene (c.568-4_568-3delTT) 
 Waiting on DNA to confirm the variant of interest 
C4R 924, Craniorachischisis*  Variants of interest identified in the Zinc Finger And BTB 
Domain Containing 33 (ZBTB33; p.Asp189_Asp190insAla) and 
the LFNG O-Fucosylpeptide 3-Beta-N-
Acetylglucosaminyltransferase (LFNG; p.Trp49Argfs) genes 
 Confirmed to co-segregate with disease status in the pedigree 
Abbreviations are as follows: FORGE, Finding of Rare Disease Genes Canada project. 
Results listed are those up until July 1, 2018. 
*The red asterisk represents the projects I was directly involved in or working with undergraduate students on. The remaining cases without an asterisk were those in 
which I assumed an administrative role. 
75 
 
 
3.5  Shared sequence variation 
From over one million total variants across the 25 rare metabolic disease (lipodystrophy 
and early-onset obesity) exomes, six ultra-rare androgen receptor (AR) variants were 
identified in four patients with partial lipodystrophy and one with extreme early-onset 
obesity (Table 3.5). Of these six identified variants, three have never been reported in the 
literature or in any database. For the variants that are not novel, note that a frequency 
greater than zero-percent was prioritized to account for heterozygotes in the normal 
control population.  
The markedly high prevalence of rare AR variants in this small patient cohort is 
unexpected; furthermore, AR variants have never been described in either of these two 
disorders characterized by abnormal tissue distribution. All variants detected were 
harboured within the N-terminal domain of the AR protein product (Figure 3.5) 
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Table 3.5. Candidate variants identified in the androgen receptor gene. 
Patient ID 
(Phenotype)A 
Amino Acid Change Sequence Ontology Zygosity/Effect Frequency 
2025 (FPLD) Gly470_Gly473del In-frame deletion Homozygous 5 × 10-3 
3011 (FPLD) Gln80_Glu81insGlnGlnGln In-frame insertion Heterozygous 0 
4116 (FPLD) His384Gln Missense Heterozygous 0 
14318 (FPLD) Gly470_Gly473del In-frame deletion Homozygous 5 × 10-3 
 Gln62Leu Missense Heterozygous 4 × 10-5 
15544 (Obesity) Gln69fs Frameshift Hemizygous 0 
The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype, 
and support from numerous papers in the literature. 
The frequencies listed for each candidate variant were extracted from gnomAD and verified using independent databases, ExAC, 1000 Genomes and ESP. 
Abbreviations are as follows: FPLD, familial partial lipodystrophy.  
A The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
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Figure 3.5. Androgen receptor gene and protein structure. Amino acid changes of interest in the androgen receptor (AR) protein 
structure are represented by the yellow stars. 
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3.6  Copy-number variation discovery 
All patients processed using LipidSeq™ (individuals with lipodystrophy) or with WES 
performed in-house (lipodystrophy and obesity cases) were subject to CNV detection. To 
call CNVs, the CNV Caller tool within the VarSeq® software was used. CNVs were 
called using sequencing depth-of-coverage data from each BAM file. As discussed in 
Chapter 2, CNVs were prioritized based on both ratio-threshold value (≤0.7 for 
heterozygous deletions, ≥1.3 for duplications) and Z-score (≤-3.0 for heterozygous 
deletions, ≥3.0 for duplications). 
3.6.1 LipidSeq™ copy-number variation detection 
For each patient with lipodystrophy processed on the LipidSeq™, the CNV Caller tool 
within VarSeq™ was used to call CNVs. After CNV calling and prioritization, seven 
candidate CNVs were identified within seven patients and predicted to be causative of the 
lipodystrophy phenotypes (Table 3.6.1).  
In total, three heterozygous deletions and four duplications were detected and prioritized 
as causative. The deletions were present in AGPAT2, PLIN1 and CIDEC, where AGPAT2 
is associated with CGL1, and both PLIN1 and CIDEC are associated with FPLD5. Each 
deletion is expected to cause or be associated with the lipodystrophy phenotype of these 
patients. The duplications identified in four patients were present in PLIN1, MFN2, 
APOA5/APOA4 and CREB3L3 associated with FPLD5, neuropathy, high triglycerides, 
and hyperlipidemia/hypertriglyceridemia, respectively. While the PLIN1 variant is 
expected to cause the lipodystrophy phenotype, the MFN2, APOA5/APOA4 and 
CREB3L3 duplication CNVs are thought to be associated with the secondary 
complications of lipodystrophy (i.e. high triglycerides). 
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Table 3.6.1. Candidate copy-number variants identified in patients with 
lipodystrophy using the LipidSeq™ targeted gene panel. 
Patient IDA Region (affected probes) Gene(s), Exon(s)B  CNV State 
1120C  19:4153347-4173301 CREB3L3, 5’UTR – 3’UTR Duplication 
4192 11:116659835-116694261 APOA5, APOA4, 5’UTR – 3’UTR Duplication 
14557 1:12052361-12057728 MFN2, exons 4 – 6 Duplication 
15678 15:90207349-90216895 PLIN1, exon 3 – 3’UTR Duplication 
1099D 15:90220425-90220484 PLIN1, exon 2 Deletion/Heterozygous 
15529 3:9921657-9922188 CIDEC, alternative non-coding exon 1  Deletion/Heterozygous 
2108 9:139581377-139582161 AGPAT2, 5’UTR – exon 1 Deletion/Heterozygous 
After sequencing using the LipidSeq™ panel, the data was run through CLC Bio Genome Workbench v10 and annotated using the curation and annotation program, 
Golden Helix VarSeq®. Copy-number variation was called using the depth of coverage and the CNV caller algorithm embedded in the Golden Helix VarSeq® 
software. 
Abbreviations are as follows: ID, identification; CNV, copy-number variation; UTR, untranslated region. 
A The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the 
patient. 
B All known genes and exons/regions affected. 
C Copy-number alteration confirmed using the independent method, CytoScan™ HD.  
D Copy-number alteration confirmed using Sanger sequencing. 
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A A version of this section has been submitted for publication83. 
3.6.2 Exome copy-number variation detection 
For the 25 lipodystrophy and obesity exomes, the CNV Caller tool in VarSeq® was 
utilized to call CNVs. After prioritization based on ratio threshold value and Z-score, no 
CNVs were predicted to be causative from WES data. 
3.7  Validation of candidate variants and copy-number 
variations 
When a candidate variant or CNV is discovered, it is imperative to ensure the variant or 
CNV is not a sequencing artifact, and to determine whether the variant or CNV co-
segregates with disease status in the family (if available). For select cases, variants were 
confirmed through Sanger sequencing, and CNVs were confirmed through Sanger 
sequencing, WES, or the CytoScan™ HD microarray. 
3.7.1 IHH validation (brachydactyly)A 
The IHH p.Glu95_Asp96insLys variant was validated using PCR and Sanger sequencing. 
Primers were designed (see Appendix III) for the region of interest (c.285_287dupGAA, 
p.Glu95_Asn96insLys) and genomic DNA from the family was genotyped to confirm the 
presence of the mutation. Seventeen family members were genotyped for the mutation 
using direct Sanger sequencing, and the variant was determined to co-segregate with 
disease status in the family. Figure 3.7.1A shows the same family pedigree as Chapter 1, 
Figure 1.5.3.1.8 with additional genotyping information, Figure 3.7.1B illustrates the 
results from Sanger sequencing. 
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Figure 3.7.1A. Pedigree and IHH genotype information for a Canadian autosomal dominant brachydactyly type A1-affected 
family.  
The proband, as indicated by the black arrow, was the first patient ascertained. All red and blue shaded individuals represent those 
whose DNA samples were Sanger sequenced for the IHH variant (exon 1, c.285_287dupGAA, p.Glu95_Asn96insLys). The reddened 
squares (males) and circles (females) represent affected individuals with brachydactyly type A1 who carry the IHH variant. The blue 
coloured squares and circles indicate those who are unaffected by brachydactyly and do not carry the IHH variant. The green coloured 
squares and circles represent the individuals clinically diagnosed with brachydactyly whose DNA was not obtained or sequenced. 
Diagonal lines indicate deceased individuals.
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Figure 3.7.1B. Chromosome location, gene structure, sequence analysis and protein structure of Indian Hedgehog. A shows 
chromosome 2 and the location of the IHH gene drawn to scale. B shows the genomic DNA for the IHH gene. C shows the mRNA for 
IHH with the mutation indicated. Electrophoretic tracings for the IHH variant for both unaffected and affected family members are 
also shown. D shows the IHH protein structure with key domains, regions, and the mutation indicated.
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3.7.2 VPS52 validation (microcephaly-ichthyosis) 
Using PCR followed by Sanger sequencing, the VPS52 (c.57delG, p.Thr20fs) variant was 
validated in the two affected individuals. Additionally, the DNA of an available, 
unaffected sibling was Sanger sequenced to confirm the absence of the variant. The 
VPS52 variant was found to co-segregate with disease status in the pedigree (Figure 
3.7.2). 
3.7.3 KDM6A validation (widow’s peak) 
The KDM6A variant (c.2703-6_2703-5delTT) was subjected to PCR and Sanger 
sequencing to confirm the validity of the candidate variant. The variant was present in 
both affected individuals, and absent in an unaffected family member, confirming co-
segregation with disease status in the family (Figure 3.7.3).  
3.7.4 AR validation (lipodystrophy and obesity) 
All six AR gene variants (p.Gly470_Gly473del, p.Gln80_Glu81insGlnGlnGln, 
p.His384Gln, p.Gly470_Gly473del, p.Gln62Leu, p.Gln69fs) were subject to PCR and 
Sanger sequencing for validation. Due to the high GC-content of the AR gene, the 
sequencing results were inconclusive and validation of the AR variants is ongoing. 
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Figure 3.7.2. Sanger sequencing confirmation of the VPS52 gene variant in a family with a history of microcephaly-ichthyosis. 
From whole-exome sequencing, one candidate variant (c.57delG) in the vacuolar protein sorting-52 gene (VPS52) was predicted to be 
causative of the microcephaly-ichthyosis phenotype in the family. The arrows indicate the probands. After whole-exome sequencing, 
Sanger sequencing was utilized to confirm the variant in the two affected probands and confirm the absence of the variant in an 
available unaffected family member. Squares indicate biological males, circles indicate biological females, and diagonal lines 
represent individuals who are deceased.
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Figure 3.7.3. Sanger sequencing confirmation of the KDM6A gene variant in a 
family with a history of widow’s peak syndrome. From whole-exome sequencing, one 
candidate variant (c.2703-6_2705-5delTT) in the lysine-specific demethylase 6a gene 
(KDM6A) was predicted to be causative of the widow’s peak syndrome phenotype in the 
family. After whole-exome sequencing, Sanger sequencing was utilized to confirm the 
variant in the two affected probands and confirm the absence of the variant in an 
available unaffected family member. Squares indicate biological males, and circles 
indicate biological females. Horizontal lines over the squares represent the samples 
subjected to whole-exome sequencing.  
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3.7.5 Copy-number variation validation 
After CNV detection, validation was necessary to ensure that the CNV events called were 
not artifacts or false positives. In order to validate the CNVs, three independent methods 
were used, namely Sanger sequencing, WES and the CytoScan™ HD array. To date, two 
CNVs in patients 1099 and 1120 have been confirmed while five are ongoing.  
3.7.5.1 Patient 1099: PLIN1 exon 2 deletion 
From the VarSeq® CNV Caller tool and LipidSeq™ data, an exon 2 deletion was 
identified in the PLIN1 gene. This CNV event was validated using PCR, gel 
electrophoresis and Sanger sequencing on the patient and normal control samples (no 
lipodystrophy) with primers flanking exons 1 and 3 (Figure 3.7.5.1; see Appendix III for 
primer details).  
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Figure 3.7.5.1. Validation of a PLIN1 exon 2 deletion in a patient with familial partial lipodystrophy. Panel A: Sanger 
sequencing results showing the deletion of exon 2. Panel B: PCR and agarose gel electrophoresis across the breakpoints to confirm a 
PLIN1 exon 2 deletion in a patient with familial partial lipodystrophy. Lane 1 shows a 1-kb ladder, lane 2 shows a normal control, and 
lane 3 shows the patient sample. The patient is heterozygous for both the wild type sequence and a 1646-bp deletion. 
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3.7.5.2 Patient 1120: CREB3L3 duplication 
From the VarSeq® CNV Caller tool and LipidSeq™ data, a full gene deletion of 
CREB3L3 was detected. To confirm this CNV event and determine whether the 
neighbouring genes were affected, WES was performed. From WES, it was determined 
that several neighbouring genes were also duplicated (Figure 3.7.5.2). More specifically, 
the PIAS4, ZBTB7A, MAP2K2, CREB3L3, SIRT6, and ANKRD24 genes were fully 
duplicated (5’UTR–3’UTR). Notably, the SIRT6 gene encodes the sirtuin-6 protein, a 
nuclear protein that catalyzes deacylation and mono-ADP ribosylation. Deficiency of 
SIRT6 results in accelerated aging, suggesting a link between lamin A and SIRT6, as 
lamin A defects are associated with progeroid features and lipodystrophy. Lamin A 
deficiency is the main cause of FPLD2, matching the phenotype of the patient.  
To further validate the CNV event detected from WES, the DNA of the patient was 
subjected to genotyping using the CytoScan™ HD array. The microarray demonstrated 
the same results as the WES data, confirming the validity of the multi-gene duplication. 
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Figure 3.7.5.2. Detection of a duplication event from LipidSeq™ versus whole-exome sequencing data. Panel A shows the CNV 
event called by the VarSeq® CNV Caller tool using LipidSeq™ data. Panel B illustrates the CNV event called by the VarSeq® CNV 
Caller tool using exome data. In each panel, the top region shows the CNV state as determined from both ratio and Z-score metrics, 
and the bottom region shows the exon map of the affected gene(s). The regions highlighted in blue as “duplicate” are the regions 
where a duplication event occurred. 
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3.8 Gene enrichment analysis 
In the event that multiple candidate variants, no candidate variants or no candidate CNVs 
were identified, PANTHER was used to analyze gene lists and determine whether there 
was overrepresentation of certain protein families, molecular functions, biological 
processes, or cellular components and pathways. The list of genes remaining after initial 
rare non-synonymous filtering (non-synonymous sequence ontology, Read Depth ≥ 30, 
Minor Allele Frequency ≤ 1%) were used as input. From analysis on the gene lists of 
patients with lipodystrophy and early-onset obesity, two partial lipodystrophy patients 
were found to harbour variants with significant overrepresentation in specific biological 
pathways. More specifically, for patient 14318, gene overrepresentation was identified in 
the biological pathways of O-glycan processing and tissue homeostasis. For patient 
11618, overrepresentation was significant in the interferon-gamma-mediated signaling 
pathway. 
3.9  Statistical analysis: Brachydactyly case 
To strengthen the association of the IHH variant with the brachydactyly phenotype 
displayed in the family, family-based association analyses were performed using the 
Wilcoxon-Mann-Whitney test and anthropometric measurements. From these tests, the 
IHH variant was associated with shortened length of middle phalanges by 21.1% 
(P<0.001), of palms by 13.8% (P<0.01), of middle digit to palm ratio by 6.8% (P<0.03) 
and of stature by 9.5% (P<0.001), consistent with the relative mild clinical phenotype 
displayed by the patient (Figure 3.9). 
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Figure 3.9. Comparison of anthropometric measures between those positive for the 
IHH mutation and those negative for the IHH mutation. Physical measurements were 
taken for all available family members with brachydactyly. Validation of the IHH 
mutation was performed using Sanger sequencing. Statistical analysis was performed 
using the Wilcoxon-Mann-Whitney test on SAS v9.4. Box plots were generated using the 
ggPlot2 package in R project v3.4.3. Panel A represents the digit length (cm) for IHH 
mutation positive and mutation negative individuals taken from the base of the third 
finger to the tip. B shows the palm length (cm) for IHH mutation positive and negative 
individuals taken from the base of the palm to the top of the palm. C displays the height 
in inches for mutation positive and negative individuals. D shows the digit-palm ratio for 
mutation positive and negative individuals, where the digit and palm lengths were taken 
as described previously. 
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Chapter 4 – Discussion 
4  Summary of findings 
In this MSc Thesis, I have identified genetic variants underlying several rare diseases 
using NGS technologies. More specifically, each case was subjected to either LipidSeq™ 
targeted sequencing or WES. Bioinformatics processing and in silico analyses were then 
utilized to identify potential disease-causing variants from the LipidSeq™ and WES data.  
From LipidSeq™ targeted sequencing of 153 patients clinically diagnosed with 
lipodystrophy, 58 patients were found to harbour 81 variants within 14 lipodystrophy-
associated genes. Furthermore, seven patients were found to harbour CNVs in 
lipodystrophy-associated genes. This is the first report of systematically screening for 
CNVs in patients with lipodystrophy, and these are the first CNVs reported in 
lipodystrophy patients in the literature. 
From WES and bioinformatics analysis, candidate variants were identified in 13 of the 20 
patients with lipodystrophy, and two of the five patients with extreme early-onset obesity. 
For the rare disease cases ascertained through the Blackburn Cardiovascular Genetics 
Laboratory, namely the brachydactyly and autosomal recessive cerebral atrophy-like, 
candidate variants were identified in both cases. Last, for the rare disease cases 
ascertained through the CARE4RARE and FORGE Canada Consortiums, eight out of the 
11 cases had candidate variants identified. 
Of the candidate variants found, several were validated using Sanger sequencing and 
many were found to co-segregate with disease status in the pedigrees. These variants 
have been prioritized and will be considered for future functional studies. Of the 
candidate CNVs identified, the CNV in patient 1120 (CREB3L3 and surrounding genes) 
was confirmed using the independent methods of WES and CytoScan™ HD. Secondary 
validation (through Sanger sequencing) of the PLIN1 CNV was also performed using 
Sanger sequencing. 
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The context of these findings are discussed within the subsequent sections in this 
Chapter. Additionally, I discuss the implications, limitations, and future directions for 
this study, and the benefits and caveats of using NGS for identifying the genetic basis of 
rare diseases.  
4.1   LipidSeq™  
LipidSeq™, the custom-designed targeted NGS panel, was utilized for the sequencing of 
lipodystrophy-associated genes in patients with various forms of lipodystrophy. From the 
DNA of 153 patients with lipodystrophy, LipidSeq™ targeted sequencing, bioinformatics 
processing and variant curation were performed, and 81 variants harboured within 14 
genes were identified among the 58 patients. Furthermore, from CNV calling and 
prioritization, seven novel CNVs were identified within seven patients. 
4.1.1 Unexpected variation in POLD1 
From the LipidSeq™ data, despite the fact that many of the causative genetic variants 
were harboured within common lipodystrophy-associated genes (i.e. LMNA, PPARG, 
PLIN1, etc.); an unexpected 14 variants were detected within POLD1. The POLD1 gene, 
encoding polymerase (DNA-directed), 1, is a catalytic and proofreading subunit of DNA 
polymerase  (Pol), involved in lagging strand DNA synthesis during replication135,136. 
In order to aid in high fidelity DNA replication, synthesis and repair, POLD1 works with 
accessory proteins POLD2, POLD3 and POLD4. Together with these subunits, the 
heterotetramer interacts with Proliferating Nuclear Cell Antigen (PCNA) and the clamp 
loader, Replication Factor C (RFC) to form the polymerase holoenzyme. In addition to its 
role in lagging strand synthesis, Pol plays a role in proofreading (through exonuclease 
activity), and lesion repair resulting from mutagenic exposure. Furthermore, Pol is 
important in DNA repair mechanisms including base excision repair, mismatch repair, 
double strand break repair, and nucleotide excision repair. Mutations in Pol have been 
associated with genomic instability and tumourigenesis. Variants have also been 
identified in the developmental disorders mandibular hypoplasia, deafness, progeroid 
features and lipodystrophy (MDPL), and Werner’s syndrome137. 
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MDPL is an extremely rare, heterogeneous, multi-system disorder featuring premature 
aging of the tissues and organs. Most importantly, MDPL features variable lipodystrophy. 
In 2013, Weedon et al. reported POLD1 variants in four individuals featuring a 
prominent, atypical lipodystrophy phenotype136. Using deletion mutants, they showed 
that POLD1 variants abolished polymerase activity while maintaining exonuclease 
activity.  
Due to the similar adipose tissue distribution of MDPL and the lipodystrophy seen in our 
patient cohort, I encourage LipidSeq™ targeted sequencing to differentiate lipodystrophy 
associated with POLD1 versus lipodystrophy caused by genes such as LMNA, PPARG 
and PLIN1. Differentiation may change treatment, thereby altering patient prognosis. 
Moreover, due to the higher than expected prevalence of POLD1 variants in our cohort, I 
suggest that lipodystrophy associated with POLD1 variants may be underestimated, 
further encouraging investigation of POLD1 in addition to classic lipodystrophy-
associated genes in the future.  
4.1.2  Copy-number variation findings 
The advent of LipidSeq™ targeted sequencing has shown numerous benefits for patients 
with metabolic disease and clinical medicine, notably for the clarification of disease 
phenotypes caused by pathogenic variants. Understudied however, was the contribution 
of CNVs to lipodystrophy phenotypes. Using LipidSeq™ data and the CNV Caller Tool 
in VarSeq®, I detected CNVs by analysing depth of coverage readings from next-
generation sequencing results. From the 153 uncharacterized lipodystrophy patients who 
were evaluated for potential CNVs, I identified seven novel CNVs that have never been 
reported in the literature or in any control database. Three individuals carried 
heterozygous deletions (patients 1099, 2108 and 15529), while four carried heterozygous 
duplications (patients 1120, 4192, 14557 and 15678). 
4.1.2.1 Patient 1099 
In a biological male with FPLD, a PLIN1 heterozygous deletion of exon 2 was identified. 
Using Sanger sequencing, this PLIN1 deletion was confirmed to be a 1646-bp deletion. 
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Perilipin-1, encoded by the PLIN1 gene, is a lipid droplet coat protein expressed in 
adipocytes, involved in the facilitation of lipolysis. Loss-of-function variants in PLIN1 
are associated with autosomal dominant FPLD4, a subtype of partial lipodystrophy 
featuring variable loss of adipose tissue from the extremities138. As mutant PLIN1 
proteins have an increased propensity for degradation and heterozygous knockout mice 
display significantly reduced fat mass, I suggest that the PLIN1 exon 2 deletion is causing 
the lipodystrophy in this patient139.   
4.1.2.2 Patient 2108 
In patient 2108 – a biological female clinically diagnosed with autosomal dominant 
Dunnigan-Köbberling syndrome – a heterozygous deletion of the 5’UTR–exon 1 region 
of AGPAT2 was identified. Dunnigan-Köbberling syndrome is a form of lipodystrophy 
characterized by the loss of adipose tissue from the body, sparing the face140. As 
homozygous variants of AGPAT2 are associated with CGL (a more severe, recessive 
form of complete lipodystrophy), I suggest that this heterozygous CNV event may be 
causing the milder, partial lipodystrophy phenotype in this patient. 
4.1.2.3 Patient 15529 
In a biological female featuring FPLD, a heterozygous deletion of alternative non-coding 
exon 1 in CIDEC was detected. Generally, recessive variants in CIDEC are associated 
with FPLD5. As this is a heterozygous deletion, it is predicted that this CIDEC CNV is 
contributing to the FPLD phenotype rather than causing it. As alternative non-coding 
exons play a large role in alternative splicing, I suggest that this CNV affects the splicing 
of the CIDEC gene. Further, as a candidate variant (c.T53G, p.V18G) was identified in 
the AGPAT2 gene through LipidSeq™ sequencing, I propose that the CIDEC CNV and 
AGPAT2 variant are acting synergistically to cause the partial lipodystrophy phenotype. 
4.1.2.4  Patient 4192 
In another biological female with FPLD, I detected a duplication of the entire APOA5 and 
APOA4 genes. APOA5 encodes apolipoprotein A-V, a low abundance plasma protein that 
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plays a role in triacylglycerol homeostasis141. APOA4 encodes apolipoprotein A-IV, a 
component of chylomicrons and high-density lipoproteins that plays a protective role in 
reverse-cholesterol transport142. GWASs have identified multiple SNPs in APOA5 that 
are associated with elevated TGs. Furthermore, studies on mutant Apoa5-/- mice 
demonstrate aberrant lipoprotein binding and TG modulation functions143. Due to the 
duplication of the entire APOA5 coding gene, I suggest that the duplication may be 
contributing towards the lipodystrophy phenotype in this patient. Furthermore, I suggest 
the duplication may be synergistically working with the APOA4 duplication and an 
additional aberrant gene product in order to cause the lipodystrophy present in this 
patient. In the future, I suggest WES to determine added genetic factors causing the 
lipodystrophy phenotype. 
4.1.2.5 Patient 14557 
In a patient (14557) with FPLD, I identified a novel duplication event in the MFN2 gene. 
The MFN2 gene encodes the mitofusin 2 protein, involved in the morphology of 
mitochondria. As the mitochondria require flexibility in morphology to maintain 
mitochondrial function, the mitofusin 2 protein is generated in many tissues and cells 
including muscle, the spinal cord, nerves, and peripheral nerves. Variants in MFN2 are 
the primary cause of autosomal dominant Charcot-Marie-Tooth (CMT) disease, type 
2A144. CMT is a heterogeneous disorder, characterized by peripheral neuropathy145. An 
additional clinical disease associated with MFN2 mutations is multiple symmetric 
lipomatosis (MSL), a mitochondrial disorder associated with abnormal brown fat 
metabolism. Patients with MSL feature lipomatosis (multiple lipomas or benign fat tissue 
tumours on the body) as well as lipodystrophy. MSL has been attributed to a p.R707W 
(c.2119C>T) mutation146. As our patient was found to carry a heterozygous p.R707W 
mutation in MFN2 in addition to a heterozygous duplication, I suggest this variant and 
CNV are cooperatively contributing to the lipodystrophy phenotype. Additionally, due to 
the overlap between FPLD and MSL in terms of lipoatrophy, I suggest that the CNV 
duplication and variant in MFN2 are causing an atypical form of lipodystrophy. Follow-
up studies are required to confirm the pathogenicity of the CNV event and the effects of 
the CNV combined with the p.R707W variant. 
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4.1.2.6 Patient 15678 
From CNV detection, a biological female with FPLD was found to harbour a 
heterozygous duplication of PLIN1 (exon 3 – 3’UTR). As in the case with patient 1099, I 
propose that the FPLD phenotype in this patient can be explained by the PLIN1 
duplication. As both excess and insufficient lipid storage in white adipose tissue lipid 
droplets can result in dyslipidemia, insulin resistance and diabetes, I suggest the PLIN1 
duplication is contributing to the lipodystrophic phenotype of this patient147. Furthermore, 
as a novel heterozygous AGPAT2 variant (c.T53G, p.V168G) was also detected in this 
patient’s genome from LipidSeq™, I suggest this AGPAT2 variant and PLIN1 duplication 
are both contributing to the patient’s lipodystrophy.  
4.1.2.7  Patient 1120 
In a biological male clinically diagnosed with FPLD, a duplication of the CREB3L3 gene 
was identified. The cyclic AMP-responsive element-binding protein 3-like protein 3 
(CREB3L3) gene encodes a transcription factor that activates unfolded protein response 
target genes during endoplasmic reticulum stress. Activated by cAMP stimulation, 
CREB3L3 binds the cAMP response element (CRE) and box-B element to activate 
transcription. In addition, CREB3L3 is involved in fatty acid oxidation and ketogenesis, 
and induced during fasted or insulin-resistant states148. Variations in CREB3L3 cause 
hypertriglyceridemia, where Creb3l3-/- mice have elucidated the mechanism as due to 
inefficient catalysis of triglyceride clearance149. As the entire CREB3L3 gene was 
duplicated, I speculated that neighbouring genes (such as the SIRT6 gene associated with 
lipid metabolism) were also affected. To confirm this prediction, I pursued WES. The 
results of the CNV detection from WES data are further discussed in Section 4.2.13. 
In addition to the CREB3L3 CNV, patient 1120 also harbours two missense mutations, 
each in PLIN1 (c.G814A, p.V272M) and PTRF (c.C168A, p.S56R) predicted as 
deleterious from in silico prediction tools. Moreover, PLIN1 and PTRF are associated 
with FPLD5 and CGL4, respectively, each associated with lipodystrophy. All together, I 
suggest that the CREB3L3 duplication, along with the variants in PLIN1 and PTRF, are 
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modulating or causing the lipodystrophy phenotype and abnormal lipid profile present in 
this patient. 
4.1.3 Benefits of LipidSeq™ 
The use of LipidSeq™ targeted sequencing offers several benefits. First, LipidSeq™ is a 
targeted panel, with the flexibility to adapt with the growing body of literature. As novel 
lipodystrophy genes are continually being discovered (i.e. adrenoceptor alpha 2A 
[ADRA2A] mutations in FPLD150), the LipidSeq™ has the ability to stay current and 
include all known genes associated with dyslipidemia. Second, as LipidSeq™ is 
restricted to specific genes, it lessens the probability of incidental findings associated 
with other disorders. With concerns regarding the proper disclosure of incidental 
findings, the use of LipidSeq™ decreases the possibility of these findings and the 
potential for genetic discrimination in the workplace or from insurers. Third, in 
comparison to Sanger sequencing, LipidSeq™ can rapidly provide a higher diagnostic 
yield at a cost-effective rate. With LipidSeq™ data generation taking less than a week, 
LipidSeq™ offers a quick turnaround from bench-to-bedside. Last and most importantly, 
LipidSeq™ allows for the genetic diagnosis of several metabolic disorders. Notably in 
the 153-person lipodystrophy cohort, LipidSeq™ sequencing led to the genetic diagnosis 
of 40% of patients through variants or CNVs, speaking to the utility of LipidSeq™ in the 
clinic. For these patients, the results may have actionable consequences in the realms of 
treatment, management or predictive recurrence risks, altogether improving patient 
outcome and prognosis. 
4.1.4  Limitations of LipidSeq™ 
Although I was able to use the LipidSeq™ targeted gene panel to identify the genetic 
basis (variants and CNVs) of 40% of patients with lipodystrophy, 60% of cases remain 
genetically unexplained, speaking to the limitations of LipidSeq™. This gap in variant 
and/or CNV discovery is due to the inherited constraints of LipidSeq™ targeted 
sequencing. First, with LipidSeq™ there is low-to-no coverage of the untranslated and 
non-coding regions, making the identification of candidate variants in those regions 
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impossible. This is a drawback of LipidSeq™ as disease-associated variants have been 
known to be harboured in the UTR. For example, in 2017 Wang et al. identified a TBX5 
3’UTR variant driving congenital heart disease in a Han Chinese population151. Second, 
with targeted NGS-based approaches, although there can be identification of CNV 
events, many CNVs can be missed depending on the location of the event. More 
specifically, numerous CNV events occur in highly repetitive regions through genomic 
instability, non-allelic HR or NHEJ152. Due to these areas being relatively unamenable to 
mapping (i.e. due to guanine-cytosine rich regions), these areas are either missed or not 
targeted through LipidSeq™ sequencing. Last, despite the fact that the LipidSeq™ is 
flexible and can be modified to incorporate any gene of interest, variant discovery from 
LipidSeq™ is restricted to a priori knowledge. Therefore, it is impossible for LipidSeq™ 
sequencing to allow for the identification of novel disease-associated genes. Albeit the 
utility of LipidSeq™ in identifying variants in known lipodystrophy-associated genes, it 
is necessary to use broader methods such as WES in order to identify novel pathogenic 
genes and variants, not previously implicated in lipodystrophy. 
4.2  Whole-exome sequencing of patients with rare 
metabolic diseases 
In patients with prior Sanger sequencing or LipidSeq™ sequencing in which no candidate 
variants were found, WES was pursued in order to identify novel disease-causing 
variants. Rare metabolic disease patients – namely 20 patients with lipodystrophy and 
five with extreme early-onset obesity – were subjected to the WES process. Following 
WES, data processing and bioinformatics analysis were performed to identify and 
prioritize putative disease-causing variants. After individual analysis, the exomes of 
individuals with lipodystrophy and extreme early-onset obesity were evaluated for shared 
variation. From these analyses, 13 of the 20 patients with lipodystrophy and two of five 
patients with extreme early-onset obesity had candidate variants identified. Furthermore, 
variation in the AR gene was detected in four patients with partial lipodystrophy and one 
patient with extreme early-onset obesity, creating a connection between the two opposite 
phenotypes. 
100 
 
 
 
4.2.1 Lipodystrophy 
WES was performed for 20 patients with variable forms of lipodystrophy. WES 
identified variants within 13 patients discussed herein. 
4.2.1.1 Patient 1804 
In a biological female clinically diagnosed with CGL, a homozygous variant in the iron-
sulfur cluster assembly enzyme (ISCU, c.19_20delinsGG, p.Phe7Gly) was identified. The 
ISCU protein is a scaffold protein required for the de novo synthesis of iron-sulfur 
clusters (Fe-S) in mitochondria. Specifically, ISCU is responsible for the maturation of 
mitochondrial and cytoplasmic proteins153. These Fe-S clusters are required for the 
function of numerous proteins, including those required for iron regulation and DNA 
repair. Proteins with these Fe-S clusters are also required for energy production in the 
mitochondria154. As Fe-S clusters are required cofactors for proteins involved in several 
biological processes, it is likely that dysfunction of the iron-sulfur cluster biogenesis 
pathway underlies several human diseases. 
Mutations in ISCU are causative of iron-sulfur deficiency myopathy, or myopathy with 
exercise intolerance. This disease features severe, progressive muscle weakness, severe 
exercise intolerance and cardiomyopathy155,156. As patient 1804 exhibits exercise 
intolerance, specifically exertion-related chest complications, I suggest that this novel 
ISCU variant is contributing towards the phenotype present in this patient.  As a 
candidate variant has not been identified as causative of her lipodystrophy, I suggest 
further analysis of the exome data using less stringent criteria (i.e. lower read depth) to 
determine the genetic basis of the lipodystrophy in this patient. I also suggest considering 
other genetic factors (discussed in Section 4.8) as causing the lipodystrophy in this 
patient. 
4.2.1.2 Patient 8615 
From WES, patient 8615 – a biological female featuring general lipodystrophy, diabetes, 
iron-deficient anemia, diabetic neuropathy, central obesity and coronary artery disease – 
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was found to harbour a homozygous variant in the heparin sulfate proteoglycan 2 gene or 
HSPG2 (c.3707C>A, p.Ala1236Glu) encoding for the perlecan protein. The perlecan 
protein belongs to the extracellular matrix basement membrane, where it supports cells in 
many tissues. Additionally, perlecan is found in cartilage and plays a role in cell 
signaling, angiogenesis and muscle contraction157. Perlecan also plays a large role in the 
cardiovascular system, where it plays a role in lipid metabolism by interacting with 
lipoprotein lipase and apolipoprotein B. Variants in HSPG2 have been linked to coronary 
artery disease, insulin sensitivity, adipose tissue defects and metabolic syndrome, all 
secondary features of the proband158,159. Therefore, I predict that the HSPG2 variants are 
contributing towards the lipodystrophy phenotype of this patient. As the definitive cause 
of the lipodystrophy present in this patient has not been elucidated, I suggest further 
analysis of the exome of this patient using less stringent criteria, as discussed prior. 
4.2.1.3  Patient 1088 
In patient 1088, a biological female featuring FPLD, high cholesterol, diabetes and high 
blood pressure, two candidate variants were detected and are predicted to cause the 
phenotype of the patient. The first is a missense variant (c.2468G>C, p.Arg823Pro) in 
PRDM16 encoding the PR domain containing 16 protein, a transcription co-regulator that 
binds and activates PPARɣ to develop brown adipocytes from brown adipose tissue 
(BAT). When functioning normally, BAT oxidizes chemical energy to produce heat in 
protection against obesity. An association between PRDM16 variants and a metabolic 
syndrome phenotype in a Uygur Chinese population has been reported, which suggests it 
may be involved in the development of lipodystrophy, as lipodystrophy is classified as a 
metabolic disorder160. The second candidate variant (c.1048C>T, p.Arg250Ter) is a 
classified pathogenic variant within LDLR, encoding the low-density lipoprotein receptor. 
LDL receptors are cell surface proteins involved in the receptor-mediated endocytosis of 
LDL cholesterol. Under normal circumstances, LDL is transported into the cell through 
receptor binding, and carried to the lysosome where it is subsequently degraded. 
Mutations in LDLR cause familial hypercholesterolemia (FH), an autosomal dominant 
disorder characterized by elevation of serum cholesterol bound to LDL, promoting the 
deposit of cholesterol in the arteries, tendons, and skin161.  
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In sum, these findings suggest that patient 1088 is not only affected with FPLD but may 
also have FH, explaining the high cholesterol levels. Considering the chance of 
developing familial partial lipodystrophy is approximately one in 50,000 and the 
prevalence of FH is one in 300, this makes the phenotype of patient 1088 one in 15 
million. This illustrates the power of WES in the clinic, as it would be difficult for a 
clinician to diagnose a disorder with such low and improbable statistical odds. 
4.2.1.4 Patient 3458 
In patient 3458, a female clinically diagnosed with FPLD, a novel, heterozygous variant 
in the ZMPSTE24 gene was detected (c.1199A>G, p.Asn400Ser). The ZMPSTE24 
protein is a zinc metalloproteinase STE24 with a role in processing farnesylated 
proteins162. ZMPSTE24 also ensures the correct processing and maturation of lamin A. 
Mutations in ZMPSTE24 are known to cause mandibuloacral dysplasia with type B 
lipodystrophy (MADB). This condition features bone abnormalities, patchy skin 
colouring, and loss of fat tissue across the body163. Mutations in ZMPSTE24 are also 
associated with severe progeria and restrictive dermopathy (thin, easily eroded skin and 
joint contracture). Complete loss-of-function alleles are associated with restrictive 
dermopathy, whereas residual or partial activity of ZMPSTE24 correlates with increased 
disease severity and MADB or progeroid features164. We suggest that this ZMPSTE24 
variant is contributing towards the lipodystrophy phenotype of this patient. As a note, 
Sanger sequencing performed 12 years ago missed the variant in ZMPSTE24. The recent 
identification of this variant using WES highlights the power of NGS in variant 
identification. 
4.2.1.5 Patient 3969 
In patient 3969, a biological female featuring FPLD, candidate variants were identified in 
FLNC (c.6988G>A, p.Gly2330Ser) and GALC (c.334A>G, p.Thr112Ala). FLNC encodes 
gamma filamin, a protein that aids in the crosslinking of actin filaments in the cortical 
cytoplasm, involved in the anchoring of membrane proteins for the actin cytoskeleton. As 
gamma filamin is muscle-specific, dominant mutations in FLNC cause myofibrillar 
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myopathy, a myopathy characterized by muscle weakness and the atrophy of the upper 
and lower extremities165. GALC encodes galacosylceramidase, an enzyme involved in 
breaking down galactolipid fats in the nervous system, epithelial cells of the small 
intestine and colon, and kidneys166. Defects in GALC are associated with Krabbe disease, 
a disease featuring mobility restrictions due to damage to myelin-forming cells in the 
nervous system. Due to the loss of myelin, nerves in the brain cannot properly transmit 
signals, leading to Krabbe disease167,168. As the primary health concern of patient 3969 is 
peripheral neuropathy, I suggest that the variants in FLNC and GALC are contributing 
towards the neuropathy phenotype. Additional analysis should be done to determine 
whether these genetic variants interact to amplify the neuropathy in this patient. 
Furthermore, future directions for this patient should include continued analysis of her 
exome data using less stringent criteria to determine the genetic basis of her 
lipodystrophy. 
4.2.1.6 Patient 4116 
After WES and bioinformatics analysis, patient 4116 – a biological female clinically 
diagnosed with FPLD – had two LDLR candidate variants (c.2252G>A, p.Arg751Gln; 
c.2231_2232delinsAG, p.Arg744Gln) identified in her exome. Similar to patient 1088 as 
discussed in Section 4.2.1.3, the LDLR variants are likely contributing to the high 
cholesterol levels in this patient. In addition to the LDLR variants, a novel variant in the 
AR gene was also detected (c.1152C>G, p.His384Gln) in the patient’s exome (discussed 
in Section 4.2.3). Together, the LDLR and AR variants are likely contributing to the 
abnormal lipid profile of the patient. Future work should focus on identifying the genetic 
basis of the lipodystrophy phenotype of the patient. This can be done by using less 
stringent criteria when analysing the exome data or considering alternative genetic factors 
(as discussed in Section 4.8).  
4.2.1.7 Patient 4665 
In a biological female with FPLD (patient 4665), four candidate variants were identified 
from WES. Two variants were detected in ABCA4 (c.1610G>A, p.Arg537His; 
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c.2969G>A, p.Gly990Glu) and two in WRN (c.2983G>A, p.Ala995Thr; c.1149G<T, 
p.Leu383Phe). ABCA4 encodes a member of the ATP binding cassette transporters. 
Involved in lipid transport, ABCA4 is associated with the import of lipid substrates such 
as vitamins, phospholipids, glycolipids, fatty acids, cholesterol and bile salts169. On the 
other hand, WRN encodes the Werner protein, where variants in WRN cause an aging 
disease known as Werner syndrome, featuring abnormal fat deposition including the loss 
of adipose from the distal limbs170. As Werner syndrome is caused by pathogenic 
recessive variants in the WRN gene and this patient harbours two heterozygous variants in 
WRN, I suggest that patient 4665 may feature an atypical form of Werner syndrome. I 
also propose that the ABCA4 gene variants are contributing to the lipodystrophy 
phenotype of the patient. Additional studies should be done to confirm the pathogenicity 
of the variants and their role in the lipodystrophy phenotype (see Section 4.8 for details). 
4.2.1.8 Patient 5662 
The DNA of patient 5662, a female featuring FPLD was subjected to WES and 
bioinformatics processing. After analysis, a homozygous splicing variant was identified 
in ABCG8 (c.1412-8delinsTT). This ABCG8 splicing variant is predicted to alter the wild 
type splice acceptor site from multiple in silico splicing prediction tools, is considered 
novel in multiple control databases, and has not been previously reported in the literature. 
The ABCG8 gene encodes sterolin-2, half of the protein, sterolin. In the body, sterolin is 
involved in eliminating fatty components of plant-based foods that cannot be used in 
human cells171. Mutations in ABCG8 have been identified in individuals with 
sitosterolemia, a condition characterized by the accumulation of plant sterols and the 
impaired ability to remove cholesterol from the body. Furthermore, individuals with 
sitosterolemia feature atherosclerosis, xanthomas, and blood abnormalities172. I propose 
that the ABCG8 gene is contributing to the abnormal lipid profile of the patient; however, 
further analysis of the exome data is required to determine the genetic cause of the 
patient’s lipodystrophy. 
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4.2.1.9 Patient 2025 
Patient 2025 is a biological female that was clinically diagnosed with lipodystrophy. 
Upon review of the patient’s clinical data, it was discovered that the patient also has 
dermatomyositis – a rare genetic inflammatory disease causing severe myopathy, painful 
skin rashes, sensitivity to light and calcinosis (calcium deposits in the muscle). 
Furthermore, the patient suffers from severe insulin resistance and proteinuria. Due to the 
fact that this patient has dermatomyositis in addition to lipodystrophy, variants associated 
with dermatomyositis were also prioritized during exome analysis. 
In this patient, three candidate variants were identified within three candidate genes: 
FHL1 (c.46G>T, p.Gly16Trp), ANLN (c.1205C>T, p.Pro402Leu) and AR 
(c.1369_1380delGGCGGCGGCGGC, p.Gly470_Gly473del). The FHL1 gene (four and a 
half LIM domains 1) encodes three isoforms that play critical roles in skeletal muscle and 
cardiac muscle movement. More specifically, FHL1A plays a key role in sarcomere 
assembly, FHL1B plays a role in the nuclear envelope, and FLH1C is thought to play a 
role in the function of skeletal and cardiac muscles173. Dominant mutations in FHL1 have 
been linked to reducing-body myopathy (RBM), a rare myopathy featuring the 
progressive weakness of the muscles, a rigid spine, and a progressive disease course174. 
The ANLN gene encodes anillin, an actin binding protein with a role in cell growth and 
migration. Variants in ANLN are causative of focal segmental glomerulosclerosis-8, a 
renal disease featuring proteinuria and the progressive decline in renal function175. The 
AR variant is discussed in Section 4.2.3. 
Due to the association with myopathy, proteinuria and renal function and the severe 
myopathy and renal dysfunction in the patient, I suggest that the novel FHL1 and ANLN 
variants are contributing towards the disease phenotype of the patient. Furthermore, I 
suggest that the AR gene variant is contributing to the metabolic profile of patient 2025. 
4.2.1.10 Patient 3011 
Patient 3011 is a biological female featuring FPLD, insulin resistance, dyslipidemia, 
hirsutism (overgrowth of hair) and hypertriglyceridemia. From WES, I identified three 
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candidate gene variants contributing to the phenotype of the patient: LPL (c.775G>A, 
p.Asp259Asn), PAPSS2 (c.1114G>T, p.Val372Phe), and AR 
(c.170_171insGCAGCAGCA, p.Gln80_Glu81insGlnGlnGln). The LPL gene encodes 
lipoprotein lipase, an enzyme found within cells that line capillaries in muscles and 
adipose tissue. LPL plays a key role in breaking down fat into triglycerides, which are 
then transferred from organs to the blood through lipoproteins. Mutations in LPL have 
been associated with many conditions, including atherosclerosis, insulin resistance, and 
dyslipidemia associated with diabetes176. The PAPSS2 gene encodes 3'-phosphoadenosine 
5'-phosphosulfate synthase 2, a sulfate donor co-substrate required for sulfotransferase 
(SULT) enzymes. These SULT enzymes catalyze many endogenous and exogenous 
compounds, such as drugs and xenobiotics177. Mutations in PAPSS2 are associated with 
brachyolmia type 4 with mild epiphyseal changes (BCYM4). Furthermore, variants in 
PAPSS4 have been associated with hirsutism, androgen excess and polycystic ovary 
syndrome, all clinical features of patient 3011178. The AR variant is discussed in detail in 
Section 4.2.3. 
All together, I predict that the LPL, PAPPS2 and AR gene variants are all contributing to 
the patient’s phenotype. More specifically, it is likely that the LPL variant is contributing 
to the insulin resistance, dyslipidemia and hypertriglyceridemia, whereas the PAPSS2 
variant is contributing to the polycystic ovary syndrome and hirsutism. The AR variant is 
likely also contributing to the hirsutism and involved in the metabolic profile of the 
patient. Further analysis is required to confirm the pathogenicity of the novel variants and 
identify the genetic basis of the patient’s lipodystrophy (as discussed in Section 4.8). 
4.2.1.11 Patient 14318 
Patient 14318 is a biological female in her teens, clinically diagnosed with FPLD. From 
WES and bioinformatics analysis, several candidate variants were detected. These 
include variants in NEUROD1 (c.170G>A, p.Gly57Glu), BSCL2 (c.1280T>C, 
p.Leu427Pro), APOB (c.6936_6937delinsTG, p.Ile2313Val), PCSK9 (c.137G>T, 
p.Arg46Leu), and PYGM (c.148C>T, p.Arg50Ter) and AR (c.185A>T, p.Gln62Leu; 
c.1369_1380delGGCGGCGGCGGC, p.Gly470_Gly473del).  
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NEUROD1, encoding the neurogenic differentiation 1 protein, is a transcription factor 
involved in cell type determination during development. NEUROD1 is also important in 
the regulating insulin gene expression. Mutations in NEUROD1 are associated with 
mature-onset diabetes of the young 6 (MODY6) and autosomal dominant diabetes 
mellitus179. The BSCL2 gene encodes seipin, an endoplasmic reticulum protein involved 
in late pre-adipocyte differentiation and lipid droplet formation180. Mutations in BSCL2 
are associated with CGL2, as discussed in Chapter 1. APOB encodes apolipoprotein B, 
the main apolipoprotein on low density lipoproteins (LDLs) and chylomicrons181. Defects 
in APOB are associated with autosomal dominant hypercholesterolemia. The prohormone 
convertase 9 (PCSK9) gene encodes a serine protease involved in the elevation of plasma 
LDL cholesterol and reduction of hepatic and extrahepatic LDL receptor levels182. 
Mutations in PCSK9 are causative of autosomal dominant hypercholesterolemia, 3, 
featuring significantly high cholesterol levels. The glycogen phosphorylase, muscle 
associated (PYGM) gene or the muscle isoform of glycogen phosphorylase is involved in 
the breakdown of glycogen during glycogenolysis183. Mutations in PYGM are associated 
with glycogen storage disease type V (GSDV), a disease caused by the impaired 
breakdown of glycogen. Due to this defective enzyme being unable to break down 
glycogen, muscle cells cannot produce energy and become easily fatigued184. The AR 
variant is further discussed in Section 4.2.3. 
Together, I suggest that the variants within NEUROD1, BSCL2, APOB, PCSK9, PYGM 
and AR are all contributing to the severe lipodystrophy phenotype of this young patient. 
Further research is required to determine the pathogenicity of the novel variants and 
determine whether these variants work synergistically (see Section 4.8 for details). 
4.2.1.12 Patient 4194 
In patient 4194, a female clinically diagnosed with acquired lipodystrophy, a variant in 
the WRN gene (c.243T>G, p.Phe81Leu) was detected from WES. Variants in the WRN 
gene are associated with Werner syndrome or adult progeria, characterized by dramatic 
aging, abnormal fat deposition, diabetes mellitus, diminished infertility and 
atherosclerosis185. More specifically, patients with Werner syndrome experience fat loss 
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from the extremities with excess fat in the truncal region, similar to patients with 
FPLD170. As Werner syndrome is generally caused by homozygous variants, I suggest 
that this heterozygous variant is causing the milder phenotype seen in this patient.  
As patient 4194 has a form of acquired lipodystrophy generally caused by environmental 
effects, I also propose the possibility that this heterozygous variant in WRN could have 
been activated by environmental factors, leading to the onset of lipodystrophy in this 
patient. Note that this patient was not processed on the LipidSeq™ gene panel prior to 
WES. 
4.2.1.13 Patient 1120 
After identifying a CREB3L3 duplication from LipidSeq™ targeted sequencing, the DNA 
of patient 1120 was subjected to WES to investigate whether additional neighbouring 
genes were also duplicated. From WES data and CNV analysis, the duplication in patient 
1120 was found to span six genes: protein inhibitor of activated STAT 4 (PIAS4), zinc 
finger and BTB domain containing 7A (ZBTB7A), mitogen-activated protein kinase 
kinase 2 (MAP2K2), CREB3L3, SIRT6, and ankyrin repeat domain 24 (ANKRD24). 
Interestingly, one of the duplicated genes is the SIRT6 gene, encoding the sirtuin-6 
protein. 
The sirtuin-6 or SIRT6 protein is a protein deacetylase and mono-ADP ribosyltransferase 
enzyme activated under stress conditions186. SIRT6 is a major player in many pathways 
associated with aging, such as glycolysis, lipid metabolism, inflammation and DNA 
repair187. Mutations in SIRT6 are a major cause of progeroid diseases, which feature 
lipodystrophy, kyphosis (excessive convex curvature of the spine), neurodegeneration, 
immune deficiency, and metabolic defects188. Specific to metabolism, the SIRT6 protein 
is considered the epigenetic gatekeeper of glucose metabolism, playing a key role in 
glucose homeostasis. This role was demonstrated in SIRT6 knockout mice, where the 
complete loss of subcutaneous fat and insulin hypersensitivity led to early mortality189,190. 
As our patient harbours a duplication of SIRT6 in addition to CREB3L3, I propose that 
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the lipodystrophy phenotype and metabolic abnormalities featured by this patient are 
caused by this large CNV event.  
4.2.2 Extreme early-onset obesity 
The DNA of five children with extreme early-onset obesity were subjected to WES. 
Candidate variants were identified in two patients from WES and bioinformatics 
processing. 
4.2.2.1 Patient 15544 
In a male child with early-onset obesity, features of autism spectrum disorder, 
developmental delay and overgrowth, candidate variants were detected in three genes: 
BLK (c.244G>C, p.Gly82Arg), MC4R (c.751A>C) and AR (c.204_205insA, p.Gln69fs). 
Further discussion on the AR gene is in Section 4.2.3. 
The BLK gene encodes a non-receptor tyrosine kinase involved in cell proliferation and 
differentiation. Playing a role in B-cell receptor signaling and development, this protein is 
also known to stimulate insulin synthesis and secretion191. Mutations in BLK are 
associated with mature-onset diabetes of the young (MODY11), characterized by 
autosomal dominant diabetes and insulin-dependence192. As discussed in Chapter 1, the 
MC4R gene is a member of the melanocortin receptor family that interacts with 
adrenocorticotrophic hormones. Defects in this gene are known to cause autosomal 
dominant obesity. The AR variant is discussed further in Section 4.2.3. Together, I 
suggest that the defects in BLK, MC4R and AR are contributing to the extreme early-onset 
obesity phenotype of this patient by modulating normal lipid metabolism.  
4.2.2.2 Patient 15858 
In a female child featuring extreme early-onset obesity, hyperphagia and intellectual 
disability, a novel heterozygous missense variant (c.2645T>C, p.Ile882Thr) was 
identified within the KMT2C gene. KMT2C encodes the lysine-specific methyltransferase 
2C, a histone methyltransferase that regulates gene transcription through modification of 
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chromatin structure. Particularly, KMT2C mediates the mono- and tri-methylation of 
histone H3 at lysine 4193. In 2012, Kleefstra et al. discovered a dominant mutation in 
KMT2C as causative for Kleefstra syndrome-2, a neurodevelopmental disease 
characterized by delayed development, intellectual disability, childhood obesity, and 
prominent facial features194. As the description of intellectual disability, obesity, and 
facial features (hypertelorism, synophrys, carp mouth with macroglossia) of Kleefstra 
syndrome matches the phenotype of the patient, I suggest that this child has a form of 
Kleefstra syndrome-2195. 
In addition to the dominant KMT2C variant, additional variants were identified in the 
Bardet-Biedl Syndrome 10 (BBS10) and SET domain containing (lysine 
methyltransferase) 8 (SETD8) gene. As variants in BBS10 are associated with Bardet-
Biedl syndrome and variants in SETD8 are associated with adipogenesis and rodent 
obesity, I suggest that these gene variants are also modulating the phenotype and causing 
the extreme overgrowth and obesity features of this patient196,197. Further studies (such as 
those outlined in Section 4.8) are necessary to confirm the pathogenicity of the KMT2C 
variant and determine whether the SETD8 or BBS10 variants are involved in the disease 
phenotype of this patient. 
4.2.3  Lipodystrophy-obesity connection 
With lipodystrophy and obesity, despite the fact that they sit on opposite ends of the 
spectrum (excess versus absent adiposity), they share many metabolic complications 
including diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Furthermore, 
although both disorders are widely heterogeneous in terms of underlying genes and 
pathways, the diseases both feature severe insulin resistance, suggesting a commonality 
between the two disorders and the potential for shared genetic variation198. To determine 
whether there was a connection between lipodystrophy and obesity, I analyzed all 
exomes for shared variation. 
Altogether, over one million variants were identified in the 25 rare metabolic disease 
exomes of interest. From the 25 exomes, ultra-rare androgen receptor gene (AR) 
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mutations were detected in 20%. These variants include missense mutations in two 
familial partial lipodystrophy females, small deletions in three insulin resistant partial 
lipodystrophy females, and a frameshift in a male child with extreme early-onset obesity. 
Of these identified variants, four have never been recorded in the literature. Due to the 
burden of ultra-rare AR mutations in these rare metabolic phenotypes, I suggest that the 
AR gene may be the common link between lipodystrophy and extreme early-onset 
obesity. 
The AR gene encodes a DNA-binding transcription factor involved in the regulation of 
gene expression. Activated by androgens, these androgen receptors allow the body to 
appropriately respond to these hormones, playing critical roles in the reproductive, 
muscular, skeletal, cardiovascular and central nervous systems. In the literature, 
dysfunctional androgen levels have been known to predispose individuals to metabolic 
abnormalities. More specifically, hyperandrogenism in women has shown to predispose 
to T2D, and hypoandrogenism in men has been linked to insulin resistance and metabolic 
syndrome199,200. Furthermore, androgen receptor-deficient mice have been shown to 
develop obesity and metabolic dysfunction, further demonstrating the association 
between aberrant AR and metabolic disease features201. Due to the high frequency of AR 
variants in this cohort, I suggest that AR mutations are contributing to these metabolic 
phenotypes by modulating the metabolic dysfunction in these patients. 
Although these effects on metabolic syndrome are well established, our study is the first 
to suggest a direct association between AR mutations, lipodystrophy and obesity. In 
addition, because the burden of ultra-rare AR variants is specific to the N-terminal 
domain (NTD), I suggest an important role of the NTD in metabolic function. Identifying 
a common genetic factor for both lipodystrophy and extreme early-onset obesity can 
allow for the understanding of the pathways controlling insulin sensitivity and glucose 
uptake and allow for the development of therapeutic interventions for adipose tissue 
disorders. In the future, I suggest assessing all lipodystrophy and obesity patients for AR 
gene variation, and functional studies on the AR protein (additional details in Section 
4.8).
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A A version of this section has been submitted for publication83. 
4.3   Whole-exome sequencing of rare disease families 
For families with a history of rare disease referred to the Blackburn Cardiovascular 
Genetics Laboratory (namely, BDA1 and cerebral atrophy-like), WES was performed on 
the DNA of the proband followed by bioinformatics processing and variant curation. 
From thousands of variants, one candidate variant was identified for each case. The 
successful identification of candidate variants for both cases highlights the capability of 
WES in identifying novel variants. Notably, the BDA1 case demonstrates the ability of 
WES to clarify the genetic basis of “cold cases”.  
4.3.1  Brachydactyly type A1A 
Fifteen years ago, a 31-year-old female from Ontario was referred for medical 
consultation at Dr. Hegele’s clinic for a lifelong history of short stature and shortening of 
all digits of the upper and lower extremities. After discussion regarding her family 
history, it was discovered that the brachydactyly phenotype co-segregated in her family. 
After Sanger sequencing of all known brachydactyly-associated genes was performed at 
the Blackburn Cardiovascular Laboratory, the family remained genetically unexplained 
and the case was left untouched for 15 years. One patient sample was recently processed 
using WES and analyzed for variants of interest. In this family, we report autosomal 
dominant BDA1, characterized by short stature and shortened digits. Affected family 
members carry a heterozygous in-frame insertion in IHH, designated c.285_287dupGAA, 
p.Glu95_Asn96insLys, explaining their brachydactyly phenotype. This IHH variant is 
predicted to exert a damaging effect on protein function from multiple in silico prediction 
tools, co-segregates with disease status in the family, is considered novel in multiple 
control population databases, and has not been previously reported in the literature. 
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4.3.1.1  IHH and brachydactyly type A1 
Previously, a genetic basis of BDA1 had been identified, with causative mutations 
harboured in IHH77,202. Located at the chromosomal position 2q35-36, IHH encodes the 
IHH protein, a member of the hedgehog family of proteins. Along with sonic and desert 
hedgehog, IHH acts as a signaling molecule that regulates patterning processes in both 
vertebrate and invertebrate development203. In vertebrates, the family is involved in limb 
polarity and chondrogenesis, with IHH playing a critical role in human skeletal 
development. IHH mutants show decreased chondrocyte maturation and proliferation, 
and the failure of osteoblast development in endochondral bones, highlighting the role 
that IHH plays in bone formation and cartilage differentiation204. The connection between 
skeletogenesis and BDA1 has been solidified in Ihh-/- mice studies, where the loss of IHH 
signaling leads to reduction defects in the forelimbs and digits205.  
Several mutations have been identified in the IHH gene. Dominant mutations in IHH are 
causative of BDA1, whereas recessive mutations in IHH have been linked to an extended 
phenotype, acrocapitofemoral dysplasia, which features short stature, short limbs and 
cone-shaped epiphyses206. All mutations responsible for BDA1 have been limited to the 
N-terminal active fragment of IHH79. These mutations have been restricted to codon 
positions 95, 100, 131 and 154, with ours as no exception. The prevalence of BDA1 
mutations at these codon positions suggests they are mutation hotspots, with high 
conservation of these amino acid positions existing between humans and species 
including mice, chicken, frog and zebrafish207. This feature solidifies the importance of 
the N-terminal region in bone development and differentiation, especially since mutations 
causing acrocapitofemoral dysplasia differ and are exclusively at the distal N and C 
terminal regions.  
The IHH protein works through a feedback control mechanism. IHH binds to the 
PTC1/patched receptor, which in turn, binds to SMO/smoothened to activate the Gli 
complex of transcription factors. From there, these transcription factors continue to signal 
and regulate downstream genes affecting patterning. Because IHH acts later in 
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endochondral bone formation, mutations in IHH lead to the delay in bone growth and 
subsequent digit abnormality. Studies on IHH-null mice uncovered the association 
between IHH mutations and BDA1, as loss of IHH signaling leads to shortened forelimbs 
and abnormal digits. We propose that our novel variant is acting in the same manner, 
leading to digit reduction and shortened stature. More specifically, although our variant is 
the first insertion identified in BDA1, we suggest that our variant acts similar to the 
p.Glu95Lys missense mutation identified by Ma et al., where the mutation results in the 
conversion of a negatively charged area to a positive area in a critical calcium-binding 
groove207. In turn, this leads to instability of the N-terminal fragment, and the potential 
increased intracellular degradation through the lysosome.               
4.3.2  Cerebral atrophy-like 
In 2013, our laboratory used homozygosity mapping and WES to identify the genetic 
basis of a novel pediatric neurodegenerative disorder, autosomal recessive cerebral 
atrophy. This phenotype is caused by a missense variant (c.995C>T, p.Thr332Met) in the 
TMPRSS4 gene. Recently, our laboratory was referred a second case from India with a 
high resemblance to the initial autosomal recessive cerebral atrophy case. More 
specifically, the patient displayed microcephaly and cerebral atrophy. Using Sanger 
sequencing of the region containing the previously identified TMPRSS4 variant, I sought 
to determine whether this phenotype shared the same genetic basis. When no variants 
were identified from Sanger sequencing, I pursued WES to identify novel disease-
associated variants. From WES and bioinformatics processing of the proband’s exome, I 
identified a variant in the kinetochore scaffold 1 gene (CASC5; c.6485A>G, 
p.Glu2162Gly) matching the phenotype of the proband. 
4.3.2.1  CASC5 and primary microcephaly-4 
During cell division, genetic material must be accurately transmitted from parent to 
daughter cells. To ensure this, eukaryotes couple the movement of spindle microtubules 
to replicated chromosomes through a multi-protein attachment complex termed the 
kinetochore. The kinetochore is a disc-shaped protein that holds the sister chromatids 
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together during cell division. In total, kinetochores perform four functions: 1) create a 
sturdy interface with centromeric chromatin, 2) contribute a microtubule-binding 
interface, 3) generate the spindle assembly checkpoint, and 4) correct improper 
attachments208. Even the simplest kinetochores consist of over 19 proteins, with all 
proteins highly conserved among eukaryotes. One such protein that localizes to the 
kinetochore is the kinetochore scaffold 1 protein, encoded by the CASC5 gene. This 
protein is pertinent for two events: the accurate attachment of centromeres to the 
microtubules, and spindle-assembly checkpoint signaling209.  
Microcephaly, Primary Hereditary (MCPH) is a neurodevelopmental disorder featuring 
intellectual disability coupled with microcephaly from birth, where the microcephaly is 
caused by the reduction of the cerebral cortex. To date, several causative genes have been 
identified, including: microcephalin, CDK5 Regulatory Subunit Associated Protein 2 
(CDK5RAP2), Abnormal Spindle Microtubule Assembly (ASPM), Centrosomal Protein 
135 (CEP135), Centrosomal Protein 152 (CEP152) and CASC5210. Although each of 
these genes play a unique role in the pathogenesis of MCPH, each is predicted to cause 
MCPH by disturbing mitotic spindle orientation, causing premature chromosomal 
condensation, or affecting microtubule dynamics211. 
Specifically, variants in the CASC5 gene cause microcephaly 4, primary, autosomal 
recessive – a form of MCPH featuring brain reduction and mental handicap209. Although 
the pathophysiological mechanism has not been resolved, it is thought that variants in 
CASC5 affect the ability for CASC5 to bind the mitotic spindle checkpoint protein, 
BUBR1, an essential component of the mitotic checkpoint212. Variants in BUBR1 are 
associated with Mosaic Variegated Aneuploidy (MVA) Syndrome 1, a phenotype 
attributed to a mitotic chromosomal segregation defect leading to aneuploidy213. Due to 
the required direct interaction between CASC5 and BUBR1, it is suggested that defects in 
CASC5 are pathogenic by way of a common mechanism involving chromosome 
missegregation. As our variant is in the same exon as known, classified microcephaly-4 
variants, I suggest that our variant acts in a similar fashion, causing chromosome 
missegregation, and allowing premature entry into mitosis.  
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4.4  Whole-exome sequencing for CARE for RARE 
and FORGE Canada projects 
For families ascertained through clinicians as part of the CARE4RARE and FORGE 
Canada projects, WES was performed on the DNA of the probands followed by 
bioinformatics processing and variant curation. From thousands of variants, candidate 
variants were narrowed down for eight of the 11 total cases. The successful identification 
of candidate variants for these rare disease cases demonstrates the utility of WES in 
identifying novel variants. Furthermore, as this was the effort of numerous clinicians and 
scientists, it emphasizes the importance of collaboration in the discovery of the genetic 
basis of rare diseases. Herein, I discuss two cases, microcephaly-ichthyosis and widow’s 
peak syndrome, and briefly summarize the project. 
4.4.1 Microcephaly-ichthyosis in the Old Order Amish 
The Old Order Amish are a North American religious group from Anabaptist origins. In 
Canada, the majority of the Old Order settlements are within Ontario, mainly in the 
Norfolk and Bruce counties. Due to social isolation, the founder effect (loss of genetic 
variation in an area established by a small number of individuals), and the many genetic 
bottleneck events in Amish history, there is a high incidence of particular genetic 
disorders among the Old Order Amish214. This is due to the autozygosity – chromosomal 
segments or alleles that are identical-by-descent due to consanguineous mating – often 
present in the Old Order Amish population. 
In an Old Order Amish family with a history of microcephaly and ichthyosis, WES, 
bioinformatics processing and variant detection was performed. From WES on the DNA 
of the proband, a novel frameshift insertion was identified in the VPS52 gene (c.57delG, 
p.Thr20fs). This variant results in a premature stop codon 30 amino acids from the start 
site, ultimately leading to deletion of 90% of the protein. Furthermore, this frameshift 
variant co-segregates with disease status in the pedigree, is predicted to be pathogenic 
from in silico prediction tools, is not present in any disease database, and has not been 
reported previously in the literature. This variant is also harboured within an autozygous 
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block in the family, 6p22.2p21.2. Due to the severity of the frameshift and the association 
of the gene defects with the phenotype, I propose that the VPS52 variant is causing the 
recurring microcephaly-ichthyosis phenotype in this family. 
The VPS52 gene encodes the vacuolar protein sorting-52 protein, a component of the 
Golgi associated retrograde protein (GARP) complex. The GARP complex is a large 
complex involved in the retrograde transport of proteins from endosomes to the trans-
Golgi network215. Moreover, the GARP complex is a tetrameric complex consisting of 
four proteins, VPS51, VPS52, VPS53 and VPS54. These four proteins tether together to 
fulfil retrograde vesicle trafficking.  
Vps52 acts to support the growth and pluripotent differentiation of the embryonic 
ectoderm through cell-cell interactions in extraembryonic tissues. Null mutations in 
Vps52 have been shown to cause early embryonic lethality, ectoderm death, and 
gastrulation defects in murine models216. Furthermore, Vps52 knockouts result in the 
complete loss of GARP function215. Due to the similarity between the consequences of 
null Vps52 and the microcephaly-ichthyosis phenotype in this family, I predict that the 
variants in VPS52 are causative of the disease. More specifically, as the ectoderm is 
responsible for skin formation and there is embryonic lethality in the affected individuals, 
I suggest that the VPS52 frameshift variant is causative of the microcephaly-ichthyosis 
lethal phenotype. Functional studies are required to confirm that the variant is indeed 
causing the microcephaly-ichthyosis phenotype in this family.  
4.4.2 Widow’s peak syndrome 
Widow’s peak syndrome is an ultra-rare X-linked dominant disease featuring a prominent 
widow’s peak (pointed frontal hairline), facial abnormalities and skeletal anomalies. 
Described by Kapur et al. in 1989, widow’s peak syndrome has only been reported once 
previously in the literature217. Through CARE4RARE, we report a second case of 
widow’s peak syndrome with matching features, namely, a pointed frontal hairline, 
epiphyseal dysplasia (disorder of bone and cartilage development affecting the long 
bones or epiphyses in the arms and legs), rotated ears, bilateral ptosis (drooping of both 
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eyelids) and knee joint issues. From WES, bioinformatics processing and variant 
detection, I report a novel splicing variant in KDM6A (c.2703-6_2703-5delTT), predicted 
to be pathogenic from in silico prediction tools. Using Sanger sequencing, this variant 
was found to co-segregate with disease status in the family. 
Mutations in KDM6A are causative of Kabuki syndrome-2, a congenital syndrome 
featuring intellectual disability, facial anomalies (long palpebral fissures and eversion of 
the eyelids), prominent ears, scoliosis, and radiographic abnormalities218,219. Due to the 
overlapping clinical features of widow’s peak syndrome and Kabuki syndrome-2, I 
suggest that this family features a novel disease overlapping with these syndromes. 
Furthermore, I propose a potential link between these exclusive disorders. Due to the 
presence of the variant in a polyT region, it is necessary to quantitatively confirm the 
KDM6A variant. SNaPshot Multiplex sequencing was unsuccessful in confirming the 
variant, therefore, it is necessary to perform reverse transcription polymerase chain 
reaction (RT-PCR) in the future. To date, RNA extraction has been done and RT-PCR is 
ongoing. 
4.4.3 CARE for RARE and FORGE summary 
In summary, eight of 11 CARE4RARE and FORGE Canada Cases in the Blackburn 
Cardiovascular Genetics Laboratory were solved using WES and bioinformatics analysis, 
highlighting the utility of WES in gene discovery. The cases with candidate variants 
identified are microcephaly-ichthyosis, autosomal dominant isolated cryptophthalmos, 
widow’s peak syndrome, amyoplasia, metaphyseal chondrodysplasia, craniosynostosis, 
heterotaxy disorder, and craniorachischisis. Each aforementioned case requires functional 
assessment in order to confirm the pathogenicity of the variants of interest. For the 
remaining cases, namely, Angelman-like syndrome, dystonia, ataxia and intellectual 
disability, and osteopetrosis, it is necessary to consider factors beyond the exome. 
4.5   Gene enrichment analysis 
From PANTHER computing and analysis on data from patients with lipodystrophy and 
extreme early-onset obesity, two patients with partial lipodystrophy were found to 
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harbour variants with significant overrepresentation in specific biological pathways. 
Namely, patient 14318 had overrepresentation of genes involved in O-glycan processing 
and tissue homeostasis, and patient 11618 had overrepresentation of genes involved in 
interferon-gamma-mediated signaling (PANTHER outputs in Appendix IV). 
The O-glycan processing pathway is involved in adding a carbohydrate or carbohydrate 
derivative to an O-linked residue to form a core O-glycan structure. As these genes are 
fundamental, defects in this pathway often result in severe metabolic perturbations or 
embryonic lethality220. For patient 14318, there was a 5.11-fold enrichment of genes 
involved in this biological process. Therefore, variants in genes involved in O-glycan 
processing were considered for association with lipodystrophy. From this gene list 
associated with O-glycan processing, most of the genes involved were those belonging to 
the mucin gene family. As mucin genes are highly polymorphic with variable number 
tandem repeat (VNTR) length polymorphisms, these variants were excluded as they are 
likely unassociated with the lipodystrophy in this patient221,222.  
Genes involved in maintaining tissue homeostasis are those that regulate somatic stem 
cell activity223. In patient 14318 there was a 3.35-fold enrichment of genes involved in 
this biological process. For the list of overrepresented genes in patient 14318 involved in 
tissue homeostasis, each gene was examined for association with lipodystrophy. As there 
was no literature supporting an association between each gene and/or variant with 
lipodystrophy, these genes were not prioritized as candidates. Although there is no 
available literature supporting these genes now, future work should continue to 
investigate the variants within these genes for their potential contribution to 
lipodystrophy. 
For patient 11618, genes involved in interferon-gamma mediated signaling were 
overrepresented. More specifically, there was 6.54-fold enrichment of the genes in this 
pathway. As most of these genes were human leukocyte antigen (HLA) genes with a high 
degree of polymorphism, they were deemed unassociated with the lipodystrophy in this 
patient.  
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In sum, although PANTHER was helpful in identifying overrepresented biological 
processes in these patients, no gene lists generated from PANTHER are predicted to 
contribute to the partial lipodystrophy phenotypes of these patients. 
4.6   Clinical utility of LipidSeq™ and whole-exome 
sequencing 
From the utilization of the LipidSeq™ resequencing gene panel, 40% of a 153-person 
lipodystrophy cohort was, at least partially, genetically explained. From WES, 65% of 
lipodystrophy patients, 40% of extreme early-onset obesity patients, two rare disease 
cases (brachydactyly type A1 and cerebral atrophy-like), and 73% of 
CARE4RARE/FORGE Canada cases had candidate variants identified. Together, these 
statistics indicate the clinical utility of NGS, especially in the context of variant discovery 
in rare disease research. 
4.6.1 Comparison of LipidSeq™ and whole-exome 
sequencing to whole-genome sequencing  
As some cases remained genetically unexplained following the implementation of 
LipidSeq™ and WES, it begs the question whether WGS would have been preferred. 
Here, I argue that although WGS is capable of sequencing almost all three-billion base 
pairs of the human genome, compared to 2% with WES and even less with targeted 
sequencing, LipidSeq™ and WES are still superior to WGS for rare disease research. 
With WGS, there are several implications affecting clinicians, researchers and patients. 
These implications refer to data yield, interpretation and ethics. 
Although the diagnostic yield is greater with WGS, there are several issues concerning 
amassing such a wealth of data. In terms of computational storage, it is impractical for 
most laboratories to store such data. Furthermore, the processing of the data require high 
computational and statistical power, often unavailable at a cost-efficient rate. As large 
cohorts would need to be processed and screened to result in a clinical outcome, it is 
unfeasible for most laboratories to advance towards the sole use of WGS. In addition, the 
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body of literature regarding intergenic regions and their role in disease is sparse. Without 
an abundance of information on these regions or a universal standard for their 
interpretation, it is difficult for providers to assess risk without creating false reassurance 
or needless worry. Last, there are several ethical implications regarding the availability of 
such data. Without distinct laws in place on genetic discrimination, issues may arise 
when patients with WES data try to obtain insurance. Additionally, with an almost 
guaranteed likelihood of incidental findings, there is apprehension to progress towards 
WGS. As WGS has shown to only offer limited clinical utility compared to WES (only 
3% increased detection in a recent study), WES is recommended over WGS224.  
4.7  Limitations of the project 
Although I demonstrated the clinical utility of NGS in solving or clarifying the molecular 
basis of rare disorders, there are limitations and study caveats to consider. These caveats 
are divided to those specific to this project, and those specific to the use of targeted 
panels and WES technology. 
4.7.1 Study considerations 
1)  Acquired lipodystrophy cases 
In this study, I relied on an assumption that all the lipodystrophy cases were genetic. For 
many patients in our lipodystrophy cohort, it is likely that some of these lipodystrophy 
cases are acquired with no inherited component. The presence of acquired lipodystrophy 
cases was demonstrated when it was determined that four patients subjected to WES had 
acquired lipodystrophy. Acquired lipodystrophy refers to lipodystrophy that sporadically 
appears during a random point in life. As up to 70% of human immunodeficiency virus 
(HIV)-infected individuals on highly active antiretroviral therapy (HAART) therapy 
report to have HIV-associated lipodystrophy, it is likely that some forms of lipodystrophy 
are drug-related or environmental225. The study of these cases may have caused an 
underestimation of the clinical utility of LipidSeq™ and WES. In the future, it is 
necessary to consider these cases separately in order to refrain from any bias in the 
results. 
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2)  Limited clinical information 
For some of the cases listed in this MSc Thesis, clinical information was limited. 
Moreover, some of the cases were referred from external physicians to the laboratory 
leading to inconsistencies in clinical diagnosis. As additional clinical information would 
have streamlined the variant prioritization process (i.e. if information was available on 
mode of inheritance, secondary complications, etc.) and potentially changed the outcome 
of cases, this was an inherent limitation of the study. 
3)  Lack of trios and families 
For many of the pediatric cases and those affecting multiple members in a family, one 
frequent challenge was the inaccessibility of patient samples. Regardless of whether it 
was due to lack of proximity of the patients or lack of willingness to participate in genetic 
research, the inaccessibility of patient samples made it difficult to confirm variants, co-
segregation and pathogenicity. To account for the unavailable DNA samples, I used 
numerous databases; however, it would have been beneficial to ascertain these samples to 
perform trio and family analysis.  
Furthermore, as rare diseases are so uncommon it can often be more challenging to study 
these diseases due to small sample size. In this study, some cases were limited to a single 
affected individual. This n-of-1 problem also contributed to the difficulty in confirming 
variants and pathogenicity.  
4.7.2 General methodological limitations 
In general, there are numerous limitations with targeted sequencing and WES. With these 
methods, several genetic factors are not considered. These include large rearrangements, 
mitochondrial gene mutations, epigenetic factors, uniparental disomy, environmental 
effects, and mutations in repetitive and GC-rich regions. As these were not investigated, I 
may be lacking all the information necessary to genetically explain each patient or rare 
disease case. 
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4.8   Future directions  
From this MSc Thesis, there are several considerations in terms of future directions. 
These include those specific to this project and those necessary for the rare disease 
research field. These are separated into their respective categories below. 
Future work for the project 
From here, future work for this project will require focus on confirming the WES results 
and ensuring the disease-causing criteria for candidate variants are fulfilled. For cases 
with a candidate variant or multiple variants identified, validation and co-segregation 
analyses should be performed if not done so already. For all candidate CNVs identified, 
secondary validation using an independent method (i.e. Sanger sequencing or 
CytoScan™ HD) should be done. Ultimately, functional studies are required to confirm 
the pathogenicity of each CNV in causing the disease of interest. These studies are 
recommended for all novel variants, particularly the CARE4RARE and FORGE Canada 
cases, and are listed in the following sub-section. For those cases in which a candidate 
variant (or multiple candidate variants) was not identified, the exome data should be 
revisited and re-evaluated using less stringent criteria (i.e. higher minor allele frequencies 
and lower read depth stringency) and other factors, as discussed in the following section, 
should be considered. 
Functional assessments to be considered for this project 
For those cases in which a candidate variant was identified using NGS – namely the 
lipodystrophy, extreme early-onset obesity, brachydactyly, cerebral atrophy-like and 
solved CARE4RARE/FORGE Canada cases – it is suggested that functional assessments 
be undertaken to confirm the validity and pathogenicity of the candidate variants. These 
experiments may include, but are not limited to the following: 
1) Western blotting 
A Western blot is an analytic method used in molecular biology to identify specific 
protein molecules from a mixture of proteins extracted from cells. By separating based on 
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size, transferring to a solid support, and using a primary and secondary antibody to 
visualize a target protein, Western blotting can elucidate the molecular weight of a 
protein of interest226.  
For this project, Western blotting can be used as a first tier assessment of whether a 
protein product is present or absent. More specifically, Western blotting can allude to 
whether the defective gene results in abnormal protein expression. If Western blotting 
demonstrates a change in expression, additional studies may be pursued to determine if 
the protein product is dysfunctional. 
2) mRNA quantification (RT-qPCR) 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) is a technology 
used to analyze RNA expression. By converting labile RNA to more stable 
complementary DNA (cDNA) using a reverse transcriptase and using real-time 
fluorescence to quantify the quantity of DNA present at each cycle during PCR, RT-
qPCR can be used for measuring gene expression and copy-number variation227. In this 
study, RT-qPCR can be used to determine differences in mRNA expression between 
patients with genetic variants and control samples. Additionally, this technique can allow 
for independent confirmation of NGS results228. 
3) Co-immunoprecipitation 
In a cell, two or more proteins can interact and lead to biological effects. Co-
immunoprecipitation (co-IP) is a common method used to analyze protein-protein 
interactions. Briefly, in co-IP the protein of interest is isolated using a specific antibody, 
and interacting partners are identified by subsequent Western blotting229. In this project, 
co-IP may be a useful technique in determining AR protein interactions. Furthermore, 
with the lipodystrophy patients harbouring variants in multiple genes, co-IP may be 
useful in elucidating protein interactions. 
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4) Molecular studies 
In molecular biology, molecular studies and model systems are common methods used to 
study the biological consequences of the genetic variation underlying human diseases. 
These studies may include in vitro assays, ex vivo studies, or in vivo models. 
In vitro assays are those used to determine whether gene products are defective and/or 
disrupt downstream pathways. These assays typically introduce the variant into the DNA 
of an artificial system to assess the biological effects on protein function and connecting 
pathways. Ex vivo studies are those that are generally performed on extracted patient 
tissues. Experiments to determine gene expression or protein interactions are pursued 
with patient-derived cells to investigate the pathogenicity of a candidate variant. In vivo 
experiments are those done within a model system. Common model organisms include 
Drosophila melanogaster (fruit flies), Caenorhabditis elegans (roundworms), Danio 
rerio (zebrafish) and mus musculus (mice). Model organisms are an efficient and 
effective strategy, as you can manipulate the genome of the animal and investigate the 
resultant phenotype. 
In this project, molecular studies would be useful to confirm that the novel candidate 
variants discovered are indeed pathogenic.  
Further considerations for the project 
For those cases in which a candidate variant was not identified – namely Angelman-like 
syndrome; osteopetrosis; dystonia, ataxia and intellectual disability; remaining 
lipodystrophy cases; and the remaining extreme early-onset obesity cases – it is necessary 
to consider other genetic factors or determinants of disease. Here I list some avenues that 
are being pursued, and others that are options for the future: 
1) Mosaicism 
Mosaicism describes a situation where different cells in an individual carry a distinct 
number of chromosomes or chromosomal arrangements. This is demonstrated as the 
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presence of two genotypes in a single individual from a single egg230. Mosaicism is often 
the cause of sporadic disease in affected individuals with unaffected parents231. 
In one study, I took mosaicism into account when analysing the LipidSeq™ results of a 
child with prenatal hypoglycemia. This child could not be explained solely by a 
heterozygous mutation in KCNJ11. After consideration of mosaicism, it was determined 
through surgery and DNA testing that the child harboured somatic ABCC8 mutations in 
her pancreas. Together, the KCNJ11 and ABCC8 variants explained her phenotype. 
2) Splicing 
Splice variants play a central role in the diversification of genomes and in cellular 
function. Furthermore, splice sites are associated with disease states and may drive 
disease phenotypes232. As exonic regions were prioritized more in this study, it is 
necessary to retroactively consider splicing variants, especially those more distal to the 
exons.  
Recently, my laboratory began a collaboration with Dr. Brendan Frey of the University of 
Toronto in order to classify splice variants and use algorithms to predict the pathogenicity 
of each splice variant. Continued work on understanding these splice region variants and 
their contribution to disease will be pursued in the future. 
3) Chromosomal rearrangements 
Chromosomal rearrangements involve large structural changes including deletions, 
duplications, inversions and translocations. As the DNA is sheared prior to WES and the 
WES kit only captures ~150-bp reads, it is necessary to consider cytogenetic techniques 
to determine whether chromosomal rearrangements may be involved.  
4) Regulatory regions 
Regulatory regions are one of the mechanisms through which protein levels are 
controlled. Regulatory regions include promoters, enhancers, silencers and insulators233. 
As much of the regulatory content is harboured within intergenic DNA not sequenced 
through WES, it is imperative that the sequence of these regions be considered. 
127 
 
 
5) Digenic disorders 
Digenic disorders refer to those diseases where mutations on two genes interact to cause 
the phenotype234. In this MSc Thesis, I consistently use knowledge of candidate genes 
and protein-protein interactions in order to consider the possibility of digenic inheritance. 
Future work will continue to explore the prospect of digenic inheritance by keeping up 
with current literature and continually checking for newly elucidated interactions between 
candidate genes. 
6) Polygenic disorders 
Polygenic diseases are those caused by the contribution of numerous distinct or 
interacting genes53. Generally, in these disorders each variant contributes a small-to-
moderate effect on the phenotype, cumulatively causing the disease. To determine 
whether the genetic basis of any of the unsolved cases are polygenic, it would be 
necessary to perform a GWAS to identify genetic loci associated with the disease. From 
there, it would be possible to develop a polygenic risk score – a metric that summarizes 
all genome-wide genotype data to predict the genetic risk of a disorder – to determine 
risk for disease235.  
7) Matchmaker Exchange  
Due to the scarcity of rare diseases and the small datasets in each laboratory for each rare 
disease case, it is necessary for data sharing in the research community. The Matchmaker 
Exchange (MME) platform was designed to provide a robust approach to gene discovery 
through the creation of a network connecting databases of rare phenotypes and genotypes 
using a programming interface236. Put simply, MME is a platform allowing clinicians, 
physicians and patients to connect with the hope for serendipitous occasions where two 
investigators learn that they share similar rare disease cases (i.e. cases with similar 
features or symptoms). So far, the Angelman-like syndrome case has been input into 
MME, with other CARE4RARE and FORGE Canada cases to follow if necessary. 
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8) Epigenetics 
The term “epigenetics” refers to a change in gene expression without a change in DNA 
sequence. These modifications in gene expression may be through changes in 
methylation or acetylation. As epigenetics has been shown to play a large role in 
phenotypic traits and disease, it is necessary to consider epigenetic mechanisms of 
disease. In the future, it may be necessary to explore epigenetic changes. For example, 
future work could include the use of bisulfite genomic sequencing – a method to detect 
changes in DNA methylation through the conversion of genomic DNA with sodium 
bisulfite – to evaluate the epigenetic landscape of each unsolved disease. 
Future directions for the rare disease research field 
For the rare disease research field, there is an ample amount of work that needs to be 
done. Three main points that should be focused on are: 1) the standardization of variant 
interpretation and analysis; 2) the conversion of all data to open-source; and 3) the 
increase in awareness of rare diseases. With candidate variant interpretation, it is 
necessary for all clinicians and researchers to conform to a standard set of guidelines to 
ease communication and promote collaboration. In this study, I considered the ACMG 
standards and guidelines for variant interpretation126. I suggest the adoption of these 
guidelines across the field to 1) promote a universal standard of variant interpretation and 
2) reduce any possible contradictions regarding variant interpretation. I also encourage 
that all data be open-source and accessible. As rare diseases are extremely difficult to 
study due to small sample sizes and low statistical power, it is necessary that all 
investigators make their data publically available to allow for further and faster 
advancements within the field. Last, I advocate for increased awareness of rare diseases. 
As individuals with rare diseases face a diagnostic odyssey, it is necessary to increase the 
awareness of these diseases to pave the way towards the end of the diagnostic odyssey for 
these patients. By raising awareness with policy makers, researchers, physicians and the 
public, it may translate to greater research funding and research interest, more robust 
diagnoses in the clinic, and ultimately, the elucidation of molecular mechanisms and 
potentially, novel treatments or cures in the future. 
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4.9   Conclusions 
NGS technologies, including targeted resequencing panels and WES, are highly robust, 
efficient and cost-effective approaches in the diagnosis of rare disorders. In this MSc 
Thesis, I have effectively achieved my goal: to demonstrate the utility of NGS in rare 
disease research, the laboratory and the clinic, and identify a molecular basis for rare 
disease patients and families of interest. More specifically, I have fulfilled my aims to 
apply NGS technologies to detect genetic variants and CNVs, identify rare variants 
underlying disease phenotypes, determine the functional relevance of these variants using 
in silico tools, and perform variant validation studies to determine whether the variants 
co-segregate with disease status in families.  
More specifically, by processing 153 patients clinically diagnosed with lipodystrophy 
through the LipidSeq™, a custom gene panel used for the clinical diagnosis of 
monogenic dyslipidemias, 81 variants in 14 lipodystrophy-associated genes (LMNA, 
PPARG, PLIN1, CIDEC, LIPE, LPIN1, AGPAT2, BSCL2, CAV1, AKT2, PTRF, 
DYRK1B, POLD1 and WRN) were identified within 58 patients. Furthermore, an 
additional seven CNV events were detected in seven patients with lipodystrophy, namely 
duplications in PLIN1, MFN2, APOA5/APOA4, CREB3L3 and deletions in AGPAT2, 
PLIN1 and CIDEC. This is the first report of systematically screening for CNV events, 
and these represent the first CNVs identified in patients with lipodystrophy. 
Twenty patients with lipodystrophy and five patients with extreme early-onset obesity 
were subjected to WES and bioinformatics analysis. From WES, candidate variants were 
discovered in 13 patients with lipodystrophy and two with extreme early-onset obesity in 
the following genes: ISCU, HSPG2, LDLR, PDRM16, ZMPSTE24, FLNC, GALC, AR, 
ABCA4, WRN, ABCG8, FHL1, ANLN, LPL, FN1, PAPSS2, NEUROD1, BSCL2, APOB, 
PCSK9, PYGM, BLK, MC4R, BBS10, SETD8, and KMT2C. Furthermore, two of two rare 
disease cases (brachydactyly type A1, IHH; cerebral atrophy-like, CASC5) and eight of 
11 CARE4RARE/FORGE Canada had candidate variants identified from WES data and 
bioinformatics processing. The successful identification of candidate genes and the 
clarification of the genetic determinants underlying many of these rare disease cases 
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demonstrate the power of WES in rare disease research. Additionally, as many of these 
genetic variants have never been reported, these results highlight the effectiveness of 
NGS in detecting novel genetic variation. 
In sum, in my MSc Thesis project I have identified novel disease-associated genes, 
characterized novel variants, and demonstrated the utility of targeted sequencing and 
WES in clarifying the genetic basis of rare genetic diseases. Furthermore, I have provided 
instructions on how to perform NGS and bioinformatics in a robust, efficient manner, and 
effectively ended the diagnostic odyssey for some patients through the identification of 
candidate variants. Understanding these genetic variants and their association with each 
will lead to many positive implications, most importantly, benefits to families, changes in 
treatment options for genetically explained patients, and added knowledge for the field. 
4.10  Project significance 
Broadly, many significant outcomes may result from this MSc Thesis. These outcomes 
take three forms: benefits to the family, therapeutic benefits, and scientific benefits. On 
the family level, identifying the molecular basis of these rare diseases can allow for 
several positive outcomes. First, it can allow the physician to assign a definitive name of 
the condition. Although this may not lead to altered management, this may allow the 
individual or the family to find support in community groups or the scientific literature. 
Second, it marks the end of the diagnostic odyssey. As a tumultuous journey for 
individuals, the end of the diagnostic odyssey may prevent unnecessary tests, 
prescriptions or consultations. Third, it may open the door for preventative medicine. For 
example, one clinical story describes a lipodystrophy patient whose LMNA mutation 
discovery encouraged physicians to approach her case differently. This enabled the 
detection of a severe cardiac rhythm disorder, and allowed subsequent life-saving 
treatment237. Last, it may provide recurrence risk for future pregnancies. The 
understanding of recurrence may allow for advanced family planning and preparation on 
the psychosocial level.  
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The second significant outcome of this research is the effect that these results have on 
treatment options for an affected individual. Through a genetic diagnosis, a physician 
may be able to offer a change in surveillance, or modification in medication. These 
alterations may provide an improved prognosis for an individual.  
The third outcome of genetic variant discovery are the benefits that these results have on 
the rare disease research field. By identifying a genetic basis of a rare disorder, the results 
may provide insight on both normal and disease pathways and pave the way towards the 
development of novel therapeutic interventions. 
In addition to the positive implications on rare disease research, the application of NGS 
technologies in rare disease research also has significant implications on the field. More 
specifically, by demonstrating the clinical utility of LipidSeq™ and WES for rare disease 
cases, we can encourage other researchers or clinicians to use these methods when 
investigating the genetic basis of rare disease phenotypes.  
In sum, identifying the molecular bases of rare disorders using NGS technologies 
demonstrated the power of NGS as a clinical diagnostic tool, and contributed the first 
step towards the long-term goal – to develop novel treatments and end the diagnostic 
odyssey for these rare disease patients. 
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Appendix III: Primer List 
Gene  Primer Names Primer Sequence (5’-3’) 
IHH Forward 
Reverse 
CTCGCCTACAAGCAGTTCAGC 
AAAATGTGCCAGGGGGTGGGTAG 
TMPRSS4 Forward 
Reverse 
CCGGGAAAGGCTGAGTAACAAAAC 
GATAGTCTTAGCCCAGGTTTCTC 
AR* AR1-F1 
AR1-F2 
AR1-R5 
AR1-F3 
AR1-R4 
AR1-F4 
AR1-R3 
AR1-F5 
AR1-R2 
AR1-R1 
AR2-FWD 
AR2-REV 
AR3-FWD 
AR3-REV 
AR4-FWD 
AR4-REV 
AR5-FWD 
AR5-REV 
AR6-FWD 
AR6-REV 
AR7-FWD 
AR7-REV 
AR8-FWD 
AR8-REV 
GTTGAACTCTTCTGAGCAAGAG 
GGATGAGGAACAGCAACCTTCAC 
GTGAAGGTTGCTGTTCCTCATCC 
CCAAGGACAATTACTTAGGGG 
CCCCTAAGTAATTGTCCTTGG 
CAAAGGGCTAGAAGGCGAGAGCC 
GGCTCTCGCCTTCTAGCCCTTTG 
GAAGAAGGCCAGTTGTATGG 
CCATACAACTGGCCTTCTTC 
GAACACAGAGTGACTCTGCCCTG 
GACCTGAGACTTCACTTGCC 
CCCTGAAAGGTTAGTGTCTCTC 
CCCGAAGAAAGAGACTCTGGAAAC 
GACTAGAAAATGAGGGAGAAGGGG 
CTATGTCACCCAGGCTAGAGC 
GGATTTCACCAGGCAAAGGTG 
CTCAACCCGTCAGTACCCAG 
CCATCACCACCAACCAGGTCTG 
GAGGGATGGCAATCAGAGAC 
GTCCTCTCTGAATCTCTGTGC 
CTAATGCTCCTTCGTGGGCATG 
CATTGGCTCTATCAGGCTGTTC 
GAAGAGGCTAGCAGAGGCCAC 
CAGGCAGAAGACATCTGAAAGG 
PLIN1 Forward 
Reverse 
CTTCAGCTCTGCCACCTACC 
AAGAGGAGCCTGTTGTGTGG 
VPS52 Forward 
Reverse 
GCTAAGAGAACAGCGAAGGTTCCG 
CAGCTCAGGTCTTTCTGAAGCTAGG 
KDM6A Forward 
Reverse 
CATCTCATGGACTTGTGCAAATGCC 
GTGGTCTTGGAGGTGGACATTTATC 
*AR primer naming method: geneexon-Forward/Reverse(number if necessary) 
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Appendix IV: PANTHER gene lists 
Patient 14318, O-glycan processing 
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Patient 14318, tissue homeostasis 
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Patient 11618, interferon-gamma-mediated signaling 
 
 
160 
 
 
Curriculum Vitae 
Rosettia Ho 
EDUCATION 
Master of Science                       2018 
Supervisor: Dr. Robert A. Hegele 
Department of Biochemistry, Schulich School of Medicine and Dentistry 
Robarts Research Institute, Western University, London ON, Canada 
 
Bachelor of Science, Honours Specialization Genetics and Biochemistry      2016 
Western University, London ON 
 
 
EMPLOYMENT 
Graduate Teaching Assistant                   January – April 2018 
Biochemistry 4455G: Translation in Cancer Biology, Western University, London ON 
 
Graduate Teaching Assistant            September – December 2016 and 2017 
Biochemistry 4450A: Molecular Genetics of Human Cancer, Western University, 
London ON 
 
Graduate Teaching Assistant                   January – April 2017 
Biochemistry 3380G: Biochemistry Laboratory, Western University, London ON  
 
Research Assistant (Part-time)                                             September 2014 – July 2016 
Dr. Kwok and Dr. Tam, Department of Social Work, King’s University College, London 
ON                  
 Involved in the following research studies: Chinese Youth in Conflict with the 
Law, Violence Against Women in China, and Examining Gatekeeping and 
Assessment of Professional Suitability in Canadian Social Work Education 
 Responsible for transcribing qualitative interviews, attending workshops, 
attending qualitative interviews, and generating bibliographies for grant proposals 
 
Research Assistant (Full-time Summer)                                       May – September 2014 
Dr. Hegele, Blackburn Cardiovascular Genetics Lab, Robarts Research Institute, London 
ON                            
 Projects included: Identifying the Molecular Basis of Lipodystrophy Through 
Next-Generation Sequencing, Absence of Protective APOC3 Mutations in 
Dyslipidemic Patients, DYRK1B R102C Mutations in Uncharacterized 
Lipodystrophy Patients, and assisting with Provisional Patent Application – 
LipidSeq™ and ONDRISeq™ 
 
161 
 
 
LABORATORY EXPERIENCE: TECHNIQUES/SKILLS 
 Primer design 
 Gel electrophoresis 
 Protein purification 
 Whole-exome sequencing preparation 
 DNA gel isolation 
 Polymerase chain reaction 
 Sanger sequencing 
 DNA/RNA extraction 
 Sequence alignment and analysis (DNA, RNA, protein) 
 Bioinformatics processing 
 Bioinformatics and statistical tools 
 
 
ADDITIONAL SKILLS 
 
Languages – English, Cantonese  
 
Computer Software – Microsoft Excel, Publisher, Access, PowerPoint; CLC Bio 
Genomics Workbench; ANNOVAR; SeqScape; SAS; Golden Helix VarSeq® 
 
 
HONOURS, AWARDS AND ACHIEVEMENTS 
CIHR International Symposium on Atherosclerosis Travel Award      2018 
Canadian Institutes of Health Research (CIHR) 
Institute of Circulatory and Respiratory Health (ICHR) 
Funding Amount: $1000 
 
Dean’s Honor List                                     2012 – 2016  
Western University, London ON 
 
Western Scholarship of Excellence                                                                             2011 
Western University, London ON 
 
 
TRAINING AND CERTIFICATION 
Teaching Assistant Training Program                        September 2017 
Western University, London ON 
 
 
 
 
162 
 
 
PUBLICATIONS  
Ho, R. and Hegele, R.A. (2018). Complex effects of laminopathy mutations on nuclear 
structure and function. Clinical Genetics Submitted: CGE-00672-2018. 
 
Ho, R., Wang, J. Cao, H., and Hegele, R.A. The identification of novel CNVs in patients 
with inherited lipodystrophy. In: Atherosclerosis Supplements. June 9–12, 2018; 
International Symposium on Atherosclerosis, Toronto, ON. Abstract C2-2.06 
 
Ho, R., Wang, J. McIntyre, A.D., and Hegele, R.A. Connecting extreme ends of the 
spectrum: ultra-rare androgen receptor mutations in metabolic phenotypes. In: 
Atherosclerosis Supplements. June 9–12, 2018; International Symposium on 
Atherosclerosis, Toronto, ON. Abstract P2.043. 
 
Ho, R., McIntyre, A.D., Kennedy, B.A., and Hegele, R.A. (2018). Whole-exome 
sequencing identifies a novel IHH insertion in an Ontario family with brachydactyly type 
A1. SAGE Open Medical Case Reports Submitted: SOMCR-18-0068. 
 
Berberich A.J., Ho, R., and Hegele, R.A. (2018). Whole-genome sequencing in the 
clinic: empowerment or too much information? Canadian Medical Association Journal 
190. 
 
Ho, R.*, Dron, J.S.* and Hegele, R.A. (2017). Recent Advances in the Genetics of 
Atherothrombotic Disease and Its Determinants. Arteriosclerosis, Thrombosis, and 
Vascular Biology 37(10), e158-e166. 
*These authors contributed equally to this article. 
 
 
POSTERS 
Connecting Extreme Ends of the Spectrum: Ultra-rare Androgen Receptor 
Mutations in Metabolic Phenotypes (June 9–12, 2018)  Presented at the International 
Symposium on Atherosclerosis at the Toronto Metro Convention Centre, Toronto ON 
 
Identification of a novel IHH insertion causative of brachydactyly type A1 (May 11, 
2018)  Presented at Schulich School of Medicine and Dentistry Department of 
Medicine Resident Research Day at the Lamplighter, Best Western, London ON 
 
Identification of a novel IHH insertion causative of brachydactyly type A1 (May 10, 
2018)  Presented at London Health Research Day 2018 at the Convention Centre, 
London ON 
 
163 
 
 
Determining the genetic basis of rare diseases using whole-exome sequencing: 
Brachydactyly type A1 (November 16, 2017)  Presented at the Western University 
Health and Research Conference at Western University, London ON 
 
Dual genetic diagnoses identified in a large family with brachydactyly type A1 and 
insulin resistance using whole-exome sequencing (October 20, 2017)  Presented at 
the American Society of Human Genetics 2017 Annual Meeting at the Orange County 
Convention Center, Orlando USA 
 
Determining the genetic basis of rare diseases using whole-exome sequencing: 
Brachydactyly type A1 (June 20, 2017)  Presented at the Robarts Research Retreat at 
Kings University College, London ON 
*Won the “Best Poster Award” at the conference 
 
Ultra rare androgen receptor mutations in metabolic phenotypes (June 20, 2017)  
Presented at the Robarts Research Retreat at Kings University College, London ON 
 
Determining the genetic basis of rare diseases using whole-exome sequencing: 
Brachydactyly type A1 (April 23, 2017)  Presented at the Canadian Human and 
Statistical Genetics Meeting at Le Chateau Frontenac, Quebec City QC 
 
Ultra rare androgen receptor mutations in metabolic phenotypes (March 28, 2017) 
 Presented at London Health Research Day 2017 at the Convention Centre, London 
ON 
 
Determining the molecular basis of rare disorders using whole-exome sequencing 
(January 20, 2017)  Presented at the Harold B. Stewart Memorial Lecture at Western 
University, London ON 
 
Absence of Protective APOC3 Mutations in Dyslipidemic Patients (August 2014)  
Presented at Western University’s Biochemistry Undergraduate Summer Research 
Program (BUSRP) Presentation Day 
 
 
 
 
 
 
 
164 
 
 
ORAL PRESENTATIONS 
Novel CNVs in patients with inherited lipodystrophy (June 13, 2018)  Presented at 
the Department of Biochemistry Graduate Student Spring Symposium at Western 
University, London ON 
 
The identification of novel CNVs in patients with inherited lipodystrophy (June 11, 
2018)  Presented at the International Symposium on Atherosclerosis at the Toronto 
Metro Convention Centre, Toronto ON 
 
The identification of novel CNVs in patients with inherited lipodystrophy (June 1, 
2018)  Presented at the Robarts Research Retreat at King’s University College, London 
ON 
* Won a monetary award ($100) and my name engraved on a plaque 
 
Connecting extreme ends of the spectrum: obesity and lipodystrophy (January 10, 
2018)  Presented at the Molecular Data Club at Robarts Research Institute, London ON 
 
Genetic testing: finding the needle in a haystack (September 29, 2017)  Presented 
with Strong Brains, Strong Minds, Strong Muscles at the Kiwanis Senior’s Centre, 
London ON 
 
Determining the genetic basis of rare diseases using whole-exome sequencing: 
Brachydactyly type A1 (June 20, 2017)  Presented at the Robarts Research Retreat at 
King’s University College, London ON 
 
Determining the genetic basis of rare diseases using whole-exome sequencing (May 
31, 2017)  Presented at the Molecular Data Club at Robarts Research Institute, London 
ON 
 
Determining the genetic basis of rare diseases using whole-exome sequencing: 
Brachydactyly type A1 (April 22-25, 2017)  Selected to present at the Canadian 
Human and Statistical Genetics Meeting at Le Chateau Frontenac, Quebec City QC 
 
Gene hunting: determining the molecular basis of lipodystrophy using whole-exome 
sequencing (March 21-22, 2015)  Presented at Ontario Biology Day at Carleton 
University, Ottawa ON  
 
 
 
 
165 
 
 
CONFERENCES/EDUCATIONAL EVENTS  
American Society of Human Genetics 2017 Annual Conference (presented)       
October 2017 
Hosted by the American Society of Human Genetics at the Orange County Convention 
Centre, Orlando USA 
 
Robarts Research Retreat (presented)                   
June 2017 
Hosted by Robarts Research Institute at King’s University College, London ON 
 
Sixth Annual Canadian Human and Statistical Genetics Meeting (presented)       
April 2017 
Hosted by the Canadian Institute of Health Research, Le Chateau Frontenac, Quebec City 
QC 
 
London Health Research Day (presented)          
March 2017 
Hosted by Schulich School of Medicine and Dentistry, at the Convention Centre, London 
ON 
 
Harold B. Stewart Memorial Lecture (presented)       
January 2017 
Schulich School of Medicine and Dentistry, Western University, London ON 
 
Genetics in Your Practice Education Day (participated)            
November 2016 
Hosted by the Medical Genetics Program of Southwestern Ontario, at the Sheraton, 
London ON 
 
Ontario Biology Day (presented)                                
March 2015 
Carleton University, Ottawa ON 
 
Biology and Environmental Sciences Research Day (presented)                             
March 2015 
Department of Biology, Western University, London ON 
 
 
 
 
166 
 
 
VOLUNTEERING 
Schulich Graduate Student Council Representative       July 2017 – present 
LHSC University Hospital, London ON 
 Representative for the Biochemistry Department in the council 
 The council is responsible for meeting every month, informing every department 
of the changes happening within Schulich School of Medicine and Dentistry, and 
representing all departmental graduate students during voting and decision-
making 
 The Representative is responsible for relaying all information to the Department 
and responding to student inquires 
 
Crisis and Support Line (Counselling)                                     September 2014 – present 
ANOVA, formerly known as the Sexual Assault Centre London and Women’s 
Community House, London ON 
 Volunteer on the Crisis and Support Line providing non-directive, non-
judgmental support and information to anyone who has been directly or indirectly 
impacted by sexual violence or domestic violence 
 
Big Bike Participant/Volunteer                                              June 20, 2017 
Western University, London ON 
 Raised funds and participated in the annual Big Bike event, where all proceeds go 
to the Heart and Stroke Foundation 
 Also assisted at the Waffle Breakfast event hosted by Robarts Research Institute 
to raise additional funds  
 
Discovery Day 2018 Host                                           May 4, 2018 
Western University, London ON 
 Helped run the Biochemistry Laboratory Workshop for high school students at 
Discovery Day at Western University 
 
Medical Genetics Sponsored Studentship              November 2017 – April 2018 
Medical Genetics, LHSC Victoria Hospital, London ON 
 Responsibilities include: assisting genetic counsellors with generating pedigrees, 
assessing lifetime risks of cancer using IBIS and BOADICEA, and prioritizing 
patients for appointments 
 Opportunities also include shadowing the Genetic Counsellors during new clinic 
appointments and follow-ups 
 Currently involved in updating the website content 
 
Food Services: Menu Pick Up/Patient Visiting              January 2017 – November 2017 
LHSC University Hospital, London ON 
 Duties included: picking up menus from all inpatient floors in the hospital, going 
room-to-room to visit patients and pick up outstanding menus, delivering cards, 
and helping patients complete their daily menus 
 
167 
 
 
Panel Interviewee                                                June 19, 2017 
London Central Secondary School, London ON 
 Attended Grade 12 English classes to answer any questions about life beyond 
high school 
 Sat on a panel with other volunteers and provided guidance and support 
 
Big Bike Participant/Volunteer                                              June 14, 2017 
Western University, London ON 
 Raised funds and participated in the annual Big Bike event, where all proceeds go 
to the Heart and Stroke Foundation 
 Also assisted at the Waffle Breakfast event hosted by Robarts Research Institute 
to raise additional funds  
 
Magic Wand Planning Committee                     January 2017 – June 2017 
Ronald McDonald House of Southwestern Ontario, London ON 
 On the organizing committee for the 2nd biennial Storybook Ball, a night of dinner 
and dancing and magical fun to raise money for the Ronald McDonald House 
 Responsibilities included: obtaining sponsorships and donations, planning and 
setting up the event, and running the event 
 
Discovery Day 2017 Host                                         May 12, 2017 
Western University, London ON 
 Helped run the Biochemistry Laboratory Workshop for high school students at 
Discovery Day at Western University 
 
President                   September 2016 – April 2017 
Western Aikido Club, Western University, London ON      
 As the Sport Western Aikido Club’s President, I planned, organized and carried 
out daily presidential responsibilities such as financial accounting, email 
communication to other executive members, and weekly communication with the 
Western Rec Centre 
 I also assisted in planning club events, and attended Rec Centre Presidential 
Meetings 
 
Unit Support (Surgical Outpatients)                                          April 2012 – January 2017 
LHSC University Hospital, London ON 
 As a unit support volunteer in surgical outpatients, I assisted with greeting and 
welcoming patients, visitors and staff 
 I also provided assistance to surgeons, residents, nurses, and occupational 
therapists by putting together operation room kits, wound kits and breast surgery 
care kits 
 
LAMP Presenter (Graduate Student Meet and Greet)                          November 2016 
Western University, London ON 
 For the LAMP meet and greet, I sat on the panel and answered questions from 
undergraduate students pertaining to research and graduate school 
168 
 
 
Registration Volunteer (Genetics in Your Practice Education Day)         November 2016 
Hosted by the Medical Genetics Program of Southwestern Ontario, at the Sheraton, 
London ON 
 For the Medical Genetics Education Day, I was in charge of registration for all 
health care professionals and attendees, and organizing event handouts and CME 
certificates 
 
Vice President/Communications     September 2015 – April 2016 
Western Aikido Club, Western University, London ON 
 As the Vice President, I was responsible for planning, organizing and carrying out 
daily club responsibilities, and maintaining club communications 
 
Research Assistant       September 2015 – April 2016 
Dr. Hegele, Blackburn Cardiovascular Genetics Lab, Robarts Research Institute, London 
ON 
 I helped run various scientific experiments, assisted in the writing of a provisional 
patent, and assisted the Medical Administrator with clerical duties 
 
 
Child Mentor (Stand by Me Program)                           September – April 2013 and 2014 
Thames Valley District School Board, London ON  
 Acted as a caring adult mentor for at-risk children under the age of 12 
 Committed two hours a week to my mentee for one-on-one meetings, and 
provided friendship, reinforcement, academic support and encouragement 
 
Daffodil Sales                                                                                  April 2011, 2012, 2013 
Canadian Cancer Society, London ON 
 Involved in the Daffodil Month sales to raise money for the Canadian Cancer 
Society 
 
 
